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 Ubiquitination is the most versatile and is certainly one of the most difficult 
post-translation modifications to understand in eukaryotic life.  In the process of 
ubiquitination the C-terminus of ubiquitin (Ub), a small 8.65 kDa protein is 
covalently attached to εNH2 groups of lysine side chains on target proteins.  Once 
attached, additional Ubs can be added to the original Ub at eight unique linkage sites 
(M1, K6, K11, K27, K29, K33, K48, or K63) to form polyUb chains.  This internal 
Ub-Ub linkage dictates the structural conformation of the polyUb chain, which in turn 
governs the receptors that can recognize a given chain.  PolyUb chains were thought 
to be homogeneously linked until very recently when mixed linkage polyUb chains 
were detected on several cellular pathways.  This observation implied that instead of 
having just eight distinct polyUb signals, there were now potentially quadrillions of 
  
unique chains.  The results presented within represent the first in depth studies of 
mixed linkage polyUb chains, focusing on the structural impact of linkage mixing.  
For mixed K48 and K63 linked chains the findings support that their individual 
linkage properties are preserved regardless of linkage mixing.  However, simulations 
for mixed linkage chains containing different linkages imply that many novel polyUb 
signals are possible.     
 The ubiquitin-proteasome pathway is the primary mechanism to degrade short 
lived proteins in the cell and has also emerged as a top therapeutic target.  Ubistatins, 
a class of small molecules bring about the same effects as existing proteasome 
inhibitor drugs by directly binding the polyUb chain.  However, virtually nothing is 
known about the structural properties for any ubistatin/Ub complex.  Here is provided 
the first structure of a ubistatin/Ub complex along with data that overwhelmingly 
validates the structure.  Other important factors regarding the ubistatin/Ub interaction 
including the stoichiometry and dual hydrophobic / electrostatic binding mechanism 
are also uncovered.    
 Proteomic analysis of polyUb conjugates has been limited to determining 
which linkage types are present.  A novel method for K63 linked polyUb conjugates, 
which can measure consecutive K63 linkages is described here.  This method allows 
the proteomics community to gain unprecedented information on cellular pathways 
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The expanding field of ubiquitin biology has passed many milestones since its 
discoverers conducted their first experiments in the late 1970’s.  Decades later, at this 
present time, the significance of the ubiquitin-proteasome system and other ubiquitin 
mediated signaling pathways have been noted by researchers the world over.  The 
sheer number of cellular pathways and processes that utilize ubiquitin are simply 
astounding, however this has triggered many more researchers to enter the field and 
blaze trails to new frontiers.  Moreover, basic research focused on understanding the 
molecular details of how different components on ubiquitin signaling pathways 
function has led to numerous therapeutic targets for an array of human diseases.  
Specifically, Velcade and subsequent second-generation small molecule proteasome 
inhibitors have turned the tide in several different malignancies.   Therapeutics for 
many other targets on ubiquitin pathways are currently in testing and expected to 
have a great impact across a range of diseases.  Many others outside of the scientific 
community, such as investors of all stripes have also recognized the potential 
ubiquitin signaling holds.  As a result much capital has poured into small 
pharmaceutical companies focused on therapeutics targeting ubiquitin pathways and 
larger companies are creating whole divisions for development of similar therapeutics 
or simply placing high bids to buy up smaller companies that hold promising 
technologies (e.g. the 2009 acquisition of Proteolix, Inc by Onyx Pharmaceuticals).   
Despite the high profile of ubiquitin research, the most significant outcome is 
not the large amount of money invested, jobs created, the ever increasing number of 
iii 
 
research grants, or even the therapeutics, it is the intellectual revolution which has led 
to an exponential increase in publications spanning across many disciplines for the 
past decades.  Since the initial discovery of ubiquitin there have been around 37,000 
published research articles and 2,200 structures and models deposited in the Protein 
Data Bank (roughly 14% of all known biomolecular structures) pertaining to some 
aspect of ubiquitin biology.  Each year brings more publications than the last, a trend 
that has continued exponentially for over three decades with 2012 yielding 3,511 
publications on ubiquitin biology, compared to 3,167 in 2011, 982 in 2000, and just 
35 in 1985.  It is an undeniable fact that ubiquitin biology is an established field, 
however there is an argument as to whether the field has matured.  Given the 
increasing number of publications and consistent stream of new methodology, most 
would conclude that there is still much more room for growth.  On the other hand, the 
large number of researchers and technical experts that have entered the field can 
make publishing on certain areas extremely competitive.  Yet, overall this is not a 
drawback for conducting research in the ubiquitin field since there are more than 
enough areas that remain undiscovered or which are poorly understood for anyone, 
veteran or newcomer to explore.  More and more is being discovered about the 
importance and versatility of ubiquitin signaling every day and the future seems 








Figure 0.1 – Number of publications on ubiquitin vs. time.  
Since the discovery of ubiquitin, there have been over 37,000 publications relating to 
it.  The above plots the number of publications on ubiquitin for each year since 1975.  
The data were obtained by using “ubiquitin” as keyword search in the PubMed, a 
service from the National Library of Medicine (NLM), a division of the National 
Institutes of Health (NIH). 
                                                                                                                                                                                                                         
Although cell biologists with basic biochemical skills initially set the ubiquitin 
field in motion, other more sophisticated methods have at times eclipsed some of the 
more traditional biochemical methods in respect to the excitement they spark.  Most 
notable are the advances in structural biology, synthetic chemistry, and proteomics.  
Solution NMR has always used monomeric ubiquitin as a model protein, due to its 
favorable spectral properties and extremely long shelf life, however NMR methods 
have leaped up a few steps.  Lewis Kay and Vitali Tugarinov previously recorded 
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NMR spectra for malate synthase G (MSG), an 82-kDa protein giving them the 
distinction of largest molecule every approached with NMR.  Shortly after in 2008, 
Lewis Kay attempted the 20S proteasome core with a similar NMR approach used for 
MSG.  This not only allowed him to surpass his previous record of studying the 
largest molecule by NMR, but also allowed him to use the method to determine how 
substrates enter the proteasome core and how small molecule drugs interact with 
individual subunits of the proteasome.  Several leading labs specializing in cryoEM 
then approached the whole 26S proteasome and independently reported near atomic 
resolution models for the whole 2.5 MDa proteasome in late 2012.  This finding 
attracted much attention and although it was not the largest structure solved with 
cryoEM it was a great advance towards determining the structure of the 26S 
proteasome, which is also known as “the most complicated protease in nature.”  
Aside from the structural biologists, many other leading experts from around the 
world have devoted their efforts to ubiquitin research.  The bioorganic and synthetic 
chemists are relatively new to the field, but the reagents available through their 
expertise have allowed others to make unprecedented advances in characterizing 
ubiquitin-signaling pathways.  One of the leading synthetic chemists, Ashraf Brik 
holds the distinction of synthesizing the longest peptide in addition to all of the other 
technologies he has developed for the ubiquitin field.  Many other synthetic chemists 
are entering the field and their unique technologies will ultimately benefit many 
researchers in addition to bringing notoriety to their methods.  Several mass 
spectrometry leaders studying the ubiquitin modification have arguably conducted 
many landmark studies in proteomics over the last decade.  Utilizing experts from 
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bioinformatics, researchers specializing in mass spectrometry have been able to report 
the details of ubiquitin modification in many systems and reveal that ubiquitin 
modification is in fact ubiquitous for a majority of proteins in eukaryotic cells.  This 
has induced other world-class proteomics labs to enter the ubiquitin field, a trend that 
is welcome given the complexity of ubiquitin modification.   
In 1993 I had my first laboratory experience at the University of Maryland in 
the lab of Prof. Scott Angle.  Over a decade later, in 2007 I returned to the University 
of Maryland as a doctoral student in biochemistry.  After several laboratory rotations, 
I selected the laboratory of Prof. David Fushman to conduct my doctoral research.  
When I first started, 2D NMR spectra were confusing dots I could not interpret, I was 
completely dependent on others to perform basic laboratory functions, and I 
understood virtually nothing about ubiquitin biology let alone its structural properties.  
Over my doctoral career with the careful guidance of Prof. David Fushman I 
developed to a point where I could independently carry out NMR experiments, design 
my own projects, and where I was frequently consulted as an expert on various 
aspects of ubiquitin biology.  Now in the present year, 2013 my doctoral career at the 
University of Maryland is concluding and I am leaving behind a body of work in the 
shadow of ~37,000 ubiquitin focused publications.  The field has become 
increasingly more technical and at times I have been dazed by the sheer amount of 
information.  However, through much effort I was able to design and carry out 
experiments that answered many pressing questions and opened new insights to 
ubiquitin biology.      
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 During my doctoral career I was constantly advancing many diverse projects 
simultaneously and was fortunate to learn from them all.  My main projects included 
the first structural studies of mixed linkage polyubiquitin chains, determining the 
structural properties of ubiquitin/ubistatin (a class of small molecules) interactions, 
and the characterization of proteasomal deubiquitinases. In addition to these projects I 
created a NMR method to measure the activity of deubiquitinases, used the F45W 
ubiquitin mutant for several fluorescence assays, and developed new methods to 
make novel polyubiquitin chains.  In collaboration with Prof. Catherine Fenselau and 
her graduate student Joseph R. Cannon, I was able to demonstrate a technique to 
measure the number of consecutive K63-linkages in polyubiquitin chains, a feat that 
has never been accomplished before, but provides critical information for 
understanding several signaling pathways.  My collaboration with Prof. TingTing 
Yao and Prof. Robert E. Cohen allowed me to determine the structural properties of 
ubiquitin modified histones.  Work with Ming-Yih Lai on H68 ubiquitin mutants and 
Carlos A. Castaneda on K11-linked polyubiquitin allowed me to establish how 
deubiquitinases select catalytically favorable conformations of polyubiquitin chains.  
A study carried out with Prof. Michael Glickman and Dasha Krutauz where I 
provided polyubiquitinated Ubb(+1) established that inhibiting the activity of 
deubiquitinases contributes to neurodegenerative diseases.  With the work of my 
collaborators and myself, I present my dissertation, which details how my doctoral 
work expands our understanding of ubiquitin biology and the true significance our 






The dissertation herein is the culmination of my major findings since I joined 
the lab of Prof. David Fushman in January of 2008.  The writing requirements for this 
work strictly constrain me to discuss technical scientific topics, however some of my 
most important findings were the experiences and professional relationships I had 
with members of David Fushman’s lab, the University of Maryland community, 
researchers outside of our institution, and also those of late.  In this section I will 
briefly describe how many individuals from diverse scientific backgrounds facilitated 
the path to this dissertation and also how they helped me survive as a researcher.       
My greatest acknowledgment is to my advisor, Prof. David Fushman who 
trained me as an NMR spectroscopist, mentored me through five years of intense 
research, and who has routinely made extraordinary efforts to ensure my scientific 
development.  Utilizing his talents as a world-class NMR spectroscopist and as an 
authority on ubiquitin signaling, Prof. Fushman created the perfect environment for 
conducting cutting edge research in several interdisciplinary fields.  Over my career 
Prof. Fushman’s lab continued to grow and I was honored to provide data for our 
grants and also help shape the lab with my input as we evolved to accommodate 
larger projects.  The diversity of the technical skills perfected in Prof. Fushman’s lab 
is simply astounding and spans biomolecular NMR, quantum physics, high 
performance computing, solution scattering, organic synthesis, X-ray crystallography, 
and traditional biochemical methods.  My only regret is that I did not have enough 
time to master all of the skills and I am still in awe of Prof. Fushman’s seemingly 
superhuman ability to acquire so many advanced technical skills.  I am also grateful 
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that Prof. Fushman spent the time to carefully edit and comment my written work, 
which dramatically improved my scientific writing, but cost him many hours of his 
time over the years.  Aside from the research training Prof. Fushman has also aided 
me greatly in developing networking skills and generously sent me to four 
international conferences to present my findings, allowing me to create a web of 
collaborators from around the world in the process.  Outside of the lab, Prof. 
Fushman also encouraged me to take on leadership roles and to organize events for 
the CBSO and biochemistry, which exposed me to other biochemical techniques and 
experts in different subfields of biochemistry.  One of the major reasons I am in Prof. 
Fushman’s debt is that he took a major gamble and allowed me to pursue my own 
original projects simply based on my own scientific curiosity.  These projects include 
the structural characterization of mixed-linkage ubiquitin chains, a method to 
determine deubiquitinase kinetics by NMR, fluorescence assays with the F45W 
ubiquitin mutant, decoding the activity of proteasomal deubiquitinases, and designing 
model substrates for deubiquitinases.  Without Prof. Fushman taking a major risk and 
granting me free rein to independently carry out my projects I would have never 
developed my critical thinking skills.          
Since my 2007 rotation in the Fushman lab as a first year graduate student I 
had the opportunity to interact with over twenty lab members.  Ming-Yih Lai was 
officially the first lab member I would work with and he helped guide me through my 
rotation focused on ubiquitin/ubistatin interactions.  Ming-Yih and I have worked 
alongside each other since 2008 and he is also a collaborator on one publication.  
Daoning Zhang has been with me every step of the way, guiding me in the lab, 
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working as a collaborator, and most importantly his great help with the acquisition 
and analysis of NMR data.  Without the expertise of Daoning, I would not be the 
researcher I am today.  Tony Chen and Shirley Lee were two very talented 
undergraduate students in the lab before I joined.  Together they aided me in 
designing assays, preparing reagents, optimizing protocols, and ultimately helped me 
get my start in the lab.  Although never formal collaborators Adithya Sundar and Dr. 
Rajesh Singh who shared similar projects offered me some of the most stimulating 
scientific discussion and were also extremely helpful for obtaining many reagents.  
Over the years Raquel Godoy-Ruiz and Tanuja R. Kashyap would also help me 
acquire reagents and equipment even though we never shared any related projects.  I 
had the opportunity to mentor Andrew Timmons, an undergraduate who used his new 
skills to help me prepare important reagents and pioneer pull down assays with 
polyubiquitin chains.  Working with Dr. Carlos A. Castaneda as a collaborator for the 
K11-linked ubiquitin project was a rewarding experience and exposed me to new 
techniques.  Urszula K. Nowicka, who joined the lab at the same time as me, helped 
me analyze NMR experiments and always was open to discuss topics regarding our 
research.  Konstantin Berlin or just “Dr. Berlin” as he is known, is a computer 
scientist that taught me the value of scientific computing, the best ways to implement 
my own programs, and the importance of selecting the proper methods for error 
analysis.  Overall, the personnel Prof. Fushman selected for his lab complemented 
each other well and created a productive environment with satisfying day-to-day 
experiences.  We are all in debt to each other for our combined efforts to advance our 
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research and I acknowledge all lab members past and current for aiding me all of 
these years.  
    The University of Maryland has proven to be an excellent place to conduct 
collaborative interdisciplinary research and I have been very fortunate to work with 
Prof. Catherine Fenselau’s lab on several projects.  In 2011 Prof. Catherine Fenselau 
and her graduate student Joseph R. Cannon, also a personal friend suggested we 
attempt microwave assisted acid cleavage of polyubiquitin chains.  I recognized that 
this method or any ASP specific cleavage could be used to measure consecutive K63 
linkages and we were able to publish this exciting result in 2012.  In addition, I was 
also able to learn much about several mass spectrometry methods and how to analyze 
the data.  The two resident biomolecular crystallographers Prof. Nicole LaRonde-
LeBlanc and Prof. Paul J. Paukstelis have been extremely helpful in my X-ray 
crystallography pursuits, lending their time and also their resources.  Prof. Paukstelis 
kindly mentored me through every step of my attempts to crystallize 
ubiquitin/ubistatin complexes and Ub mutants, which took up a significant amount of 
his valuable time and I am very grateful for everything I got to learn from him.  Prof. 
Dorothy Beckett also opened her lab to me and allowed me to investigate binding 
interactions in early stages of some of my projects.  Prof. Beckett was also extremely 
supportive in graduate student initiatives and excellent for discussing topics in 
biophysics.  Prof. George H. Lorimer generously opened his lab to me and allowed to 
explore fluorescence assays, specifically for the F45W ubiquitin project.  Inside of 
biochemistry all of the faculty were extremely supportive of graduate students and 
always willing to provide their advice on conducting experiments and how to 
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interrupt data.  Our biomolecular NMR program has expanded greatly since I joined 
and I was fortunate to have Prof. Vitali Tugarinov who provided me with much 
advice for NMR experiments, in particular 13C based experiments.  Teaching faculty 
like Dr. Daniel Steffek did their best to facilitate the TA assignments of graduate 
students and I am very grateful for his efforts during my tenure as a TA.                        
I would also like to acknowledge my former biochemistry instructor Prof. 
Melanie R. Nilsson at McDaniel College for her rigorous course work and mentoring 
my undergraduate research, which prepared me for graduate school.  If my late 
undergraduate advisor Prof. David W. Herlocker were still alive to see me graduate I 
would thank him for guiding me to graduate school and all of his helpful advice.  
Additionally, I’d also like to acknowledge Prof. Michael Rosenthal, a former physical 
chemistry instructor for introducing me to his friend Prof. Michael P. Doyle who was 
kind enough to take the time and recruit me on his visit to McDaniel College in 2007.   
The collaborations I have had with other institutions have been invaluable and 
greatly increased the significance of my research.  Collaborators Prof. Robert E. 
Cohen (Colorado State) and Prof. Tingting Yao (Colorado State) aided me greatly 
with the study of mixed linkage ubiquitin chains.  They also sent me key plasmids 
and we also carried out a small project focused on the properties of ubiquitinated 
histones.  I am in a great debt to Prof. Olivier Walker (Université Claude Bernard 
Lyon 1, France) who took some of his vacation time during the summers of 2010 and 
2011 to teach me how to perform molecular docking, convert PREs to distances, and 
teach me computational methods for protein/small molecule interactions.  Prof. 
Walker is also a major collaborator for the ubistatin project and without him we 
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would not have our structural data. Medicinal chemist Dr. Tim Lewis (Broad Institute 
of Harvard and MIT) was vital for synthesizing ubistatin compounds and kindly 
distributing the compounds to other collaborators.  Prof. Raymond Deshaies 
(California Institute of Technology) and Prof. Jeffery Brodsky (University of 
Pittsburgh) carried out the critical structural activity relation and in vivo assays for 
ubistatin compounds on the project.  Prof. Cynthia Wolberger (Johns Hopkins) with 
her postdoctoral fellows Reuven Wiener and Christopher Berndsen were extremely 
helpful in optimizing the enzymatic synthesis of our polyubiquitin chains, providing 
reagents, and also in discussions we had at conferences.  Prof. Brenda Schulman (St. 
Jude Children’s Research Hospital) and Michael J. Eddins (Progenra, Inc) allowed 
me to advance in my early attempts to enzymatically synthesize polyubiquitin chains.  
A major competitor, Prof. David Komander (MRC Cambridge, UK) was always open 
to technical discussion at conferences and useful for exchanging ideas.  Additionally, 
Prof. Gai Prag (Tel Aviv University, Israel) and Prof. Aaron Ciechanover (Technion, 
Israel) generously made their reagents available to the research community.  
   Prof. Fushman’s internationally renowned research has indeed attracted many 
collaborators.  Perhaps the most productive collaboration over the past years has been 
with the lab of Prof. Michael H. Glickman (Technion, Israel).  Prof. Glickman has 
become a trusted friend and was instrumental for many of my studies regarding the 
ubiquitin-proteasome pathway.  There were several collaborations with Prof. 
Glickman’s lab and I would like to acknowledge Nurit Livnat-Levanon for her role in 
the mixed linkage ubiquitin chain project and Dasha Krutauz for allowing me to be 
involved with the Ubb(+1) project.  Noa Reis, the lab manager was always helpful in 
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sending plasmids and writing concise protocols.  Out of all of the lab members, I 
spent the most time with Wissam Mansour working on polyubiquitin processing by 
the proteasome.  Through much adversity, Wissam visited the Fushman lab in the 
summer of 2012 were we discovered a new deubiquitinase in the proteasome and 
developed novel assays to decrypt the function of isolated proteasomal 
deubiquitinases.  On my visit to the Technion in November of 2012, we expanded our 
assay to the whole proteasome and are on track to have several publications from this 
collaboration.              
After extensively reviewing the literature and also the reagents in our lab I 
have come to realize that the late Prof. Cecile M. Pickart (Johns Hopkins) deserves a 
very special acknowledgment.  Without the plasmids she created and early 
collaborations with Prof. Fushman, our lab would not be able to synthesize 
polyubiquitin chains, let alone monomeric ubiquitin.  However, just mentioning Prof. 
Pickart’s contribution to my projects is a bit demeaning.  In 1982 Prof. Pickart was 
working under Irwin Rose at the Fox Chase Cancer Center, at the same time 
Ciechanover, Hershko, and Rose were credited with discovering the ubiquitin 
proteasome pathway.  By any standard she is considered the mother of the ubiquitin 
field and Prof.  Pickart’s seminal work, which established that different ubiquitin 
linkages initiate distinct signaling outcomes has provided the foundation for much of 
my own work.  In addition, many critical reagents used for my projects were 
personally prepared by Prof. Pickart herself and I am truly grateful she was able to 
share them with Prof. Fushman, before she passed away at the age of 51 on April 5, 
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2006.  Without the decades of work from Prof. Pickart and her generosity in 
providing materials none of my projects would have been possible.     
In February of 2013 the presidentially appointed Foreign Scholarship Board 
selected me for the prestigious J. William Fulbright post-doctoral research grant for 
study in Israel.  This highly competitive award was the most significant honor of my 
doctoral career and I could not have achieved this without the efforts of Prof. 
Lorimer, Prof. Glickman, and my advisor Prof. Fushman.  I would like to 
acknowledge them for persuading me to apply, writing excellent letters of support, 
and carefully reviewing my proposal.   
Last, I would like to acknowledge my friends and family.  Although they did 
absolutely nothing to contribute to my research and at times kept me from research 
with events such as vacations and Christmas, their moral support impacted me 
greatly.  I never was able fully explain my research to them, but my friends and 
family certainly improved the quality of my life and my character.                   
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Chapter 1: Introduction to polyubiquitin signaling 
1.1 Introduction to ubiquitin biology 
Early studies in the biological sciences focused on understanding how proteins 
were created in the cell and there was little attention directed at determining how 
proteins were removed at the end of their lifetimes.  Decades later, studies of protein 
turnover would fill this void in knowledge, when the issue was starting to be 
addressed in the mid 1950’s.  Although protein turnover was probed with a range of 
techniques and in a variety of different organisms, seemingly unrelated studies 
reported the presence of a highly conserved polypeptide (1-3).  The universal 
presence of this polypeptide in eukaryotes led to its name, “ubiquitin” (Ub).  In a 
series of papers Ciechanover, Hershko and Rose established the foundation for a 
degradation pathway of cellular proteins that was dependent on both ATP and the Ub 
molecule (originally called APF-1) (1, 3-11).  This work was the first to clearly layout 
what would later be named the ubiquitin-proteasome pathway (UPP), but more 
importantly provided a mechanism for explaining protein turnover in the cell (12).  
For this contribution Ciechanover, Hershko and Rose were awarded the 2004 Nobel 
Prize in chemistry, “discovery of ubiquitin-mediated protein degradation.”  Evidently, 
the philosophy of Hershko and Ciechanover, “to work where no one else was 
working” paid off.  Since the initial discovery of the UPP, Ub mediated signaling has 
also been found to be involved with regulating many other diverse cellular processes.                               
In the cell Ub is present in a multitude of oligomeric forms and is commonly 
post-translationally added to other proteins as a monomeric unit or as a polyUb chain.  
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Although the same unit (Ub) is added in the case of polyubiquitination, the signaling 
outcomes that result from modification with polyUb are extremely broad due to the 
number of distinct signals that can be created by specific Ub-Ub linkages in a given 
polyUb chain.  Typically the E1, E3, E3 enzyme cascade catalyzes the formation of 
an isopeptide bond between the C-terminus of an Ub and the ε-amino group of a 
lysine on a target protein, a process known as ubiquitination.  Once the first Ub is 
added to a target protein, subsequent Ubs can be added to the previously ligated Ub at 
eight different positions; K6, K11, K27, K29, K33, K48, K63 or the N-terminus 
“M1.” The general principle of how Ub is linked to create isopeptide bonds is 
represented in (Figure 1.1).  It is thought that once a particular linkage is formed 
subsequent Ubs will maintain this linkage in the polyUb chain (13).  Once attached to 
a target protein, the Ub or polyUb signal can be recognized by different receptors 
which ultimately determine the fate of the ubiquitinated protein (14).  For example, 
attachment of a single Ub to a target protein generally signals for its transport across 
cell membranes, while attachment of four or more Ubs internally linked through K48 
to the same protein would signal for its destruction by the 26S proteasome (15, 16).  
Modification with Ub is reversible and a special class of enzymes termed 
deubiquitinases (DUBs) can remove Ub from a target protein and also fully reduce 
polyUb to its component monomeric units (17, 18).  Under normal conditions the 
ubiquitination state of a given protein is tightly regulated, but dynamic due to the 




Figure 1.1 – Critical residues of the Ub molecule involved in isopeptide bond 
formation.   
(A) Cartoon representation of Ub with lysine residues (magenta sticks), M1 (black 
sticks), and the L8,I44,V70 hydrophobic patch (yellow spheres).  (B) The free C-
terminus of G76 in Ub is used to form an isopeptide bond with the ε-amine of a lysine 




1.2 Enzymatic modification with ubiquitin 
 
Ubiquitination of a target protein is accomplished by the actions of three 
enzymes; E1 activating, E2 conjugating, and E3 ligase.  In humans there is only one 
E1 activating enzyme, around thirty-five E2 conjugating enzymes and hundreds 
(>630) of E3 ligases (19).  Generally E1s can directly interact with virtually all E2s, 
while E2/E3 interactions are slightly more selective, but still very promiscuous (20).  
Ubiquitination of a specific “substrate” protein is achieved by its corresponding E3 
ligase which is extremely selective for that particular substrate protein (21).  The 
structural details of how an individual E3 ubiquitinates its target protein are unknown, 
however the mechanisms by which an E3 attaches Ub to a target have been classified 
in two sub-groups, “homologous to the E6-AP carboxyl terminus” (HECT) and 
“really interesting new gene” (RING) based on sequence homology.  Regardless of 
the E3 type, in the first step of ubiquitination E1 hydrolyzes ATP to generate the 
energy needed to form a high energy thioester bond between its active site cysteine 
and the C-terminus of Ub.  Next, the Ub “loaded” E1 binds an E2 which allows the 
Ub from its active site to be transferred to an active site cysteine on the E2 resulting 
in the same thioester bond, now on the E2.  Next, if a HECT E3 is involved, the 
HECT E3 will simultaneously bind its substrate and the Ub loaded E2, transfer the 
Ub to an active site cysteine on itself, and finally catalyze the formation of an 
isopeptide bond between the C-terminus of Ub and a free amine group on the 
substrate protein.  While a RING E3 will produce the same outcome for the substrate 
protein, but instead this is accomplished by the RING E3 positioning the Ub loaded 
E2 close enough to the ubiquitination site on the substrate protein which catalyzes the 
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formation of an isopeptide bond without the RING E3 directly transferring Ub to 
itself.  Inside the cell ubiquitination of a target protein happens in a large complex 
which can contain many other proteins depending on the E3 ligase (22).  
Interestingly, it has been shown that proteins in ubiquitinating complexes which lack 
any E1, E2 or E3 activity still have the ability to influence ubiquitination, a property 
that has been mainly attributed to their scaffolding roles (23).  One clear example is a 
group of proteins termed “E4s” which have no E1, E2, or E3 activity and little 
sequence homology, but nevertheless are essential for elongating polyUb chains on 
certain substrates (24, 25).  The schematics of ubiquitination are shown in (Figure 
1.2). 
Recent in vitro studies demonstrated that heterogeneous Ub-Ub linkages form 
with certain E2/E3 combinations, but the addition of an ubiquitin binding domain 
(UBD) induces the E2/E3 pair to generate polyUb chains with homogeneous Ub-Ub 
linkages (26-29).  This suggests that entities other than E1, E2s, or E3s direct the 
formation of Ub-Ub linkages during ubiquitination in some cases.  This is in contrast 
to other known E1, E2, E3 combinations which form homogenous Ub-Ub linkages 
without the need for external entities, such as the E3s E6AP and TRAF6, which 
ubiquitinate their substrates with K48 and K63 Ub-Ub linkages, respectively.   After 
the action the E1, E2, E3/(E4) enzyme cascade, the newly ubiquitinated protein is 
ready to embark on a specific pathway, dictated by which Ub-Ub linkages are present 




Figure 1.2 – The E1, E2, E3 ubiquitination cascade.   
The attachment of Ub (green) to a substrate begins with a thioester bond between the 
C-terminus of Ub and the active site cysteine of E1 (magenta), next Ub is transferred 
to an E2 (orange).  Then the E3(blue) binds the loaded E2 and substrate (red) and 
catalyses the transfer of Ub to a lysine on the substrate.  The E3 can keep adding Ubs 
to create a chain or just attach one Ub to the substrate.  Once modified with Ub, the 
substrate can embark on signaling pathway or DUBs can remove the Ub 
modification.        
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1.3 Deubiquitinases    
 Deubiquitinases (DUBs) are a diverse class of enzymes, which have one 
common property, the ability to recognize Ub and remove a modification beyond 
Ub’s C-terminus.  Enzymatically DUBs are all classified as (EC 3.1.2.15), however 
they can employ different catalytic mechanisms, centered around a single cysteine 
residue or a coordinated zinc (Zn+2) ion.  DUBs in conjunction with the E1,E2,E3 
enzymes  are responsible for maintaining the free Ub pool in the cell by creating a 
balance between the opposing processes of ubiquitination and deubiquitination.  
Aside from having a domain with DUB activity, a majority of the proteins classified 
as DUBs also contain other domains, mainly used for regulatory functions (18).  
Around 100 DUBs have been identified in humans, while there is direct evidence for 
just 20 DUBs in yeast (30).  Schematics for all known human DUBs are show in 
(Figure 1.3).  Pinpointing similarities between DUBs is difficult since they vary 
greatly in size, cellular location, and even in the structures of their catalytic DUB 
domains.  Given that we know Ub is present in virtually all parts of the cell and 
ubiquitination occurs in many diverse locations as well, it is reasonable that proteins 
which interact with Ub exhibit a high degree of diversity to function in so many 








Figure 1.3 – Schematic representation of all known human deubiquitinases.  
Individual DUBs are clustered into the five families USP, UCH, OTU, MJD, and 
JAMM/MPN+.  Note the diversity and prevalence of non-catalytic domains.  adopted 
from (18).  
 
 1.3.1 The five families of deubiquitinases    
 Although there are many differences across DUBs, structural and 
bioinformatics data has shown that some DUBs share similar 3D folds and primary 
sequences in their catalytic domains (31-34).  Given these properties are some of the 
only clear similarities between DUBs, they have been classified into five families 
which reflect the fold of their catalytic domains: ubiquitin C-terminal hydrolases 
(UCH), ubiquitin specific proteases (USP), ovarian tumor proteases (OTU), 
Machado-Joseph disease proteases (MJD), and JAB1/MPN/MOV34 metalloenzymes 
(JAMM/MPN+).  UCHs, USPs, OTUs, and MJDs are all cysteine proteases, while the 
JAMM/MPN+ family of DUBs are zinc dependent metalloproteases.  Of the five 
families, the USP family is the best characterized by a large margin with over sixty 
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members identified in humans.  In addition, the size of the USP family is also 
significantly larger compared to the other four families which each have no more than 
ten members each. 
 DUBs in the UCH family contain a catalytic domain ~200 residues with an 
active site cysteine shielded by a crossover loop which governs what can be cleaved 
(35-40).  Upon Ub binding there are significant conformational changes in the active 
site crossover loop, however only small adducts or unfolded proteins attached to the 
C-terminus of Ub can enter.  This mechanism allows UCHs to have activity for Ub 
attached to small adducts, but not the Ub-Ub bond. 
 The USP family of DUBs share a distinct hand-like fold (thumb, fingers, and 
palm) and are generally large proteins ~1,000 residues.  Aside from their catalytic 
domain, many USPs contain a variety of other domains including ubiquitin-binding 
domains (UBDs).  As with the UCH family, there are significant conformational 
changes upon Ub binding, however USPs readily cleave Ub-Ub bonds which makes 
determining the catalytic structural conformations difficult.  One of the more 
intriguing properties of USPs is their cross reactivity or ability to hydrolyze bonds 
between ubiquitin-like (UBL) polymers, such as the cleavage of ISG15 (UBL) by the 
DUB USP21 (33, 41).  Another important functional property of select USP DUBs is 
their ability to autoregulate using UBL domains contained in their sequence as 
reported with USP4 and USP7 (42).  The activity of USPs in respect to linkage 




 The OTU family exhibits a wider variation between members in respect to the 
size of the catalytic domain and its three dimensional fold.  Similar to USPs, OTUs 
also typically contain other UBDs in their full sequences.  The OTUs are unique in 
that they exhibit some of the greatest Ub-Ub linkage specificity among DUBs and do 
so across a wide variety of linkages (41, 43-46).  It has been established that OTUB1 
has an almost antibody-like selectivity for K48 linkages, OTUD5 (DUBA) has a 
preference for K63 linkages, TRABID has its greatest activity for K29 and K33 
linkages, and Cezanne is highly selective for K11 linkages (44-48).  In addition to 
their remarkable linkage selectivity, OTUs are considered true Ub-isopeptidases and 
preferentially act on only Ub-Ub isopeptide bonds, unlike other families which can 
cleave Ub-substrate bonds or native peptide bonds (e.g. M1 linkages). 
The MJD family of DUBs is the least studied by far.  Ataxin-3 has been well 
studied due to its relevance in Machado-Joseph disease, however much remains 
unclear.  For instance, it has been suggested that Ataxin-3 functions optimally when it 
is polyubiquitinated and although UIM domains in Ataxin-3 have a preference to bind 
K48 linked polyUb, it has increased DUB activity for K63 linkages.  MJDs do share a 
similar cysteine active site with UCH, USP, and OTU family DUBs and also undergo 
significant conformational changes upon Ub binding.  In the MJD family, a long α-
helix controls access to the active site which changes upon Ub binding, similar to the 
crossover loop in the UCH family.   
JAMM/MPN+ are the only family of DUBs that utilize a coordinated Zn+2 ion 
in their active sites.  Although their catalytic domains differ slightly, virtually all 
JAMM/MPN+ DUBs are found as components in multi-subunit complexes.  A 
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handful of studies have isolated JAMM/MPN+ DUBs and demonstrated that they can 
function alone in vitro (49-51).  To demonstrate the utility of this DUB family 
consider that POH1 (Rpn11 in yeast) is a critical component of the proteasome, 
AMSH and AMSH-LP are essential in the ESCRT complexes, CSN5 has a major role 
in the COP9 signalosome, and a number of JAMM/MPN+ members (BRCC3, 
MYSM1, and PRPF8) are involved with multi-subunit complexes that interact with 
DNA (52).  The JAMM/MPN+ family of DUBs has clearly evolved to take on 
essential roles in many parts of the cell.  Similar to the USP family, JAMM/MPN+ 
DUBs have a wide range of properties e.g. AMSH is highly specific for K63 linkages, 
POH1 is reported to cleave the Ub-substrate isopeptide bond, and CSN5 can cleave 
heterologous Nedd8-Ub chains (34, 53, 54).                                       
1.3.1 Deubiquitinases and disease 
As previously stated, abnormal or irregular ubiquitination patterns can lead to 
many adverse outcomes in the cell.  In the most general terms, an overactive E3 
which destroys a disease suppressing protein or an E3 which is underactive against a 
pathogenic protein are both scenarios that have been documented to trigger disease 
(25, 55).  However, since DUBs can also directly influence the ubiquitination state of 
a specific protein, it has also been shown that a DUB which excessively removes Ub 
from a disease causing protein targeted for degradation by the UPP or a situation 
where a DUB that does not efficiently remove Ub from a disease suppressing protein 
cause a disturbance in ubiquitination that leads to disease just as the E3 examples (56, 
57).  Given that several DUBs and DUB families are named for disease which they 
are involved (recall MJD for Machado-Joseph disease and OTU for ovarian tumor 
12 
 
proteases) I will highlight several less obvious DUBs with functions directly related 
to disease. Proteasome associated DUBs, to be discussed (section 1.4.6) are 
extremely important across a range of diseases.      
The level of p53, "guardian of the genome" is chiefly regulated through 
ubiquitination, which is controlled by the actions of the E3 ligase Mdm2 and the 
DUB USP7. Several studies have shown that the delicate balance between p53, 
Mdm2, and USP7 is perturbed in a variety of malignancies and that USP7 activity 
promotes oncogenesis (58).  In the case of p53, the DUB activity of USP7 saves 
proteins that ubiquitinate p53 from their own destruction by the UPP, allowing p53 to 
be excessively destroyed by the UPP (59).  This observation has triggered many to 
develop USP7 inhibitors, which have shown highly promising results in the early 
stages and at the present time P005091 (Progenra, Inc) is set to be the first approved 
DUB inhibitor for cancer treatment (60).         
In contrast to USP7, another USP family DUB cylindromatosis (CYLD) has 
been shown to be a tumor suppressor due to its ability to modulate NF-κB (61).  Thus 
pathology is caused by a loss of function in CYLD and several rare genetic diseases 
arising from mutations (mostly truncations) in the USP domain of CLYD have also 
be reported, which further highlights the importance of CYLD’s DUB activity (62).  
Unlike other characterized USP DUBs, which show a preference for K48 linkages, 
CLYD preferentially cleaves K63 linkages due to subtle structural arrangements in 
the USP domain (41).  The unique structural features of CYLD compared to other 
USP family DUBs is shown (Figure 1.4).  Logically no CLYD inhibitors have been 
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proposed, but gene therapy to restore CLYD function is currently being explored 
(63).      
 
Figure 1.4 – Structural comparison of K48 and K63 linkage selective USP DUBs.  
(A) Alignment of USP7 (PDB-1NB8) in red with CYLD (PDB-2VHF) in black revels 
major structural differences in the general fold of the USP domain.  CYLD also 
contains two Zn+2 ions shown as yellow spheres.  (B) Alignment of K48 selective 
USP DUBs USP2 (PDB-2HD5) in green, USP7 (PDB-1NB8) in red, and USP14 




AMSH, a JAMM/MPN+ DUB which regulates ESCRT machinery has been 
found to have both beneficial and pathological roles.  The best understood function of 
AMSH is to cleave K63 linked Ub modifications on endosomal cargo when it is 
recruited to membranes by ESCRT complexes (64).  On one hand, AMSH function 
can be extremely beneficial since it has been reported to reduce the accumulation of 
disease associated proteins in the central nervous system (65).  On the other hand, 
AMSH function is also responsible for the maturation of several oncogenic G protein-
coupled receptors (GPCRs) and receptor-tyrosine kinases (RTKs) (66).  Thus it has 
been proposed and also demonstrated in several cancer cell lines that with proper 
delivery systems, AMSH inhibitors are highly effective against rapidly growing 
cancers (67).  In some cases EGFR is also deubiquitinated by the OTU K11 specific 
DUB Cezanne-1, which also contributes to cancer progression (68).              
     
1.4 The ubiquitin proteasome pathway 
1.4.1 Overview of protein homoeostasis  
 Just as protein production is critical to the cell, so is the opposite process of 
protein destruction.  Many proteins are required for optimal cell function, however 
proteins generally have relatively short lifetimes and must be disposed of properly.  
All proteins in the cell originate from DNA starting with transcription to mRNA and 
ending with ribosomal translation.  Yet, the cell has several distinct mechanisms for 
the destruction of proteins at the end of their lifetimes.  Ultimately proteins reach 
their end in lysosomes through autophagic pathways, which also can be signaled by 
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polyUb or they are destroyed by the proteasome with the aid of Ub signaling (69).  It 
has been suggested that short lived proteins are generally destroyed by the UPP, while 
proteins with longer life times are targeted to the lysosomes (70).  Although many 
mysteries surround both, it is clear that the proper function of lysosomes and the 
proteasome are essential for cell survival.             
1.4.2 Architecture of the 26S proteasome 
 The full, "doubly capped" 26S proteasome is a 2.5 MDa complex composed 
from thirty-three distinct subunits (71, 72).  The proteasome, just like the Ub 
molecule is highly conserved across eukaryotes and many subunits are nearly 
identical in structure and sequence between yeast and humans (73).  There are three 
distinct components of the proteasome, the 20S core and the 19S regulatory particle 
(RP) that consists of the base (RP-base) and lid (RP-lid) (30, 74, 75).  The 20S core 
particle resembles a barrel and is composed of four heptameric rings in a α7β7β7α7 
arrangement. The outer α rings of the CP regulate access to the inner chamber where 
proteolysis occurs (76).  The 20S CP can simultaneously associate with two 19S RPs 
on either end to form a “doubly capped” proteasome or accept just one 19S RP to 
form a “singly capped” proteasome (74).  A native gel assay which separates the 
various states of the CP in combination with a fluorogenic substrate is commonly 







Figure 1.5 – Native gel assay to characterize the 20S CP.  
Both lanes show purified yeast proteasomes run on a 4% gel, then assayed by a 
fluorogenic peptide substrate.  The left lane shows that a four year old proteasome 
sample looses most RPs.  The weaker signal intensity also indicates a decreased 
proteolytic activity in the aged proteasomes.  The right lane contains freshly prepared 
proteasomes with both singly and doubly capped CPs and virtually no disassociation 
from the RP.  The strong intensity of bands for the singly and doubly capped 
proteasomes indicates their high proteolytic activity.        
 
The main feature of the RP base is a hexameric ring of AAA-ATPases (Rpt1-
Rpt6) which inserts directly to the alpha subunits of the 20S.  Rpn1 and the 
structurally similar Rpn2 subunit are the largest subunits in the proteasome and are 
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also components of the RP-base.  It is proposed that Rpn1 and Rpn2 serve as 
scaffolds, but studies have shown that Rpn1 takes on other roles such as serving as a 
receptor for UBL containing proteasome associated proteins (78, 79).  Rpn10 and 
Rpn13 are also found in the RP-base and contain the only known polyUb receptors in 
the proteasome, VWA and UIM domains of Rpn10 and the Pru domain of Rpn13 (80, 
81).  A majority of the subunits that form the RP-lid (Rpn3, Rpn5, Rpn6, Rpn7, 
Rpn9, and Rpn12) contain PCI domains and are critical for holding the RP-lid to the 
RP-base.  Rpn11 and Rpn8 are structurally similar and contain the JAMM/MPN+ 
fold.  Rpn11 is the only known subunit of the proteasome to have DUB activity and is 
positioned directly over the hexameric ring of ATPases.     
The assembly of the proteasome has been intensely studied.  The consensus is 
that many cofactors are involved, which direct the step wise assembly of the 26S 
proteasome by parts, such that the CP, RP-base, and RP-lid are preassembled before 
combining to form the 26S proteasome (82).  The 20S CP, which is usually studied as 
a whole can be crystallized or selectively labeled for solution NMR studies (83, 84).  
High resolution structures of individual subunits of the RP have been studied in 
isolation since the RP is not suitable for crystallization by conventional means (85).  
Interestingly, the structure of the whole 26S proteasome has eluded everyone who has 
attempted.  Low resolution cryoEM models often lacking many key subunits have 
been the closest success produced by modern structural biology (86-89).  There has 
been no success in determining where a polyubiquitinated substrate binds the 
proteasome, yet this information is critical for our understanding of how substrates 
are processed.          
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1.4.3 Substrate targeting to the 26S proteasome and polyUb processing 
 A polyUb chain of at least four units internally linked through K48 was the 
first definitive signal for proteasomal degradation discovered (15, 16).  Since that 
particular study it has also been found that some proteins, such as ornithine 
decarboxylase (ODC) can be degraded by the 26S proteasome in an Ub independent 
manor, while others simply require monoubiquitination (90, 91).  In fact, many 
different ubiquitin modifications including virtually all linkage types can interact with 
purified proteasomes in vitro and K63-linkages have been show to be sufficient for 
degradation (92, 93).  However, in the cell many other proteins interact with the Ub 
signal and generally ensure that only K48 signals reach the proteasome (94).  Hence 
the caveat: in the absence of other cellular proteins, the proteasome can interact with 
any Ub-Ub linkage, but in the cell this does not happen because other proteins 
intercept the Ub signal upstream of the proteasome.  K48-linkages are also 
intercepted upstream of the proteasome by UBL/UBA shuttle proteins, which 
facilitate the transport of ubiquitinated substrates to the proteasome.  The shuttling 
proteins recognize the polyUb signal with a UBA domain and the Rpn1 subunit of the 
proteasome with their UBL domain (95-98).  In yeast, Ddi1, Rad23, and DSK2 are 
the known UBL/UBA shuttling proteins (30).  Once a polyubiquitinated substrate is 
docked to the proteasome by a shuttle protein, little is known about how the Ub signal 
is processed.  It is assumed that the Ub signal is transferred from the UBA of the 
shuttle to one of two Ub receptors, the UIM of Rpn10 or the Pru-domain of Rpn13 on 
the proteasome via competitive binding interactions (86, 95, 99).   
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After the proteasome receptors accept the polyubiquitinated substrate, the 
polyUb signal can be removed by the Rpn11 subunit.  Alternatively other proteasome 
associated DUBs such as Ubp6 can be recruited to facilitate processing of the polyUb 
signal.  For a substrate, recognition by the proteasome does not necessarily ensure its 
immediate destruction.  In some cases proteasomal DUBs prematurely remove the 
polyUb signal, sparing the substrate from degradation (100).  While in other cases 
Hul5 an E3/E4 Ub ligase is recruited to speed up the degradation of a substrate by 
adding more K48 linkages or slow down the degradation of a substrate by adding K63 
linkages to the existing polyUb signal (101).  The substrate is committed for 
proteasomal degradation when the hexameric AAA-ATPase ring initiates its 
unfolding and it begins to enter the chamber of the 20S (102).  From in silico 
simulations it is thought that attachment of Ub helps destabilize substrates, facilitating 
their unfolding at the proteasome, but this theory has yet to be proven (103).  Also, 
given that the proteasome functions in protein quality control i.e. to degrade 
misfolded proteins it is thought that some components can recognize abnormal 
proteins (104).  During its destruction a substrate will enter one end of the 20S CP 
and exit from the other in the form of peptides ranging from 3-22 residues in length 
(105). This is accomplished by three proteolytic subunits β1, β2, and β5 that have 
activity similar to trypsin (basic residues), caspase (acidic residues), and 
chymotrypsin (hydrophobic residues) (106).  Interestingly these peptides released 
from the 20S may hold significant biological functions in both the immune system 
and as general regulators of apoptosis (107, 108).     
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1.4.5 Therapeutic intervention on the UPP 
The proteasome itself became a drug target after some very astute 
observations by Alfred Goldberg made over the course of several decades.  Early 
studies noted that proteasome inhibition gave a brief protective effect to many cells 
(ranging from yeast to human), but if the proteasome was inhibited long enough, 
abnormal proteins would build up in the cytosol and ER, which led to JNK-kinase 
induced apoptosis (109).  Initially small molecule proteasome inhibitors were 
developed by a biotech company Goldberg helped start (MyoGenics/ProScript) for 
studies in cell culture, not therapeutics.  Other observations established that a majority 
of the cell’s proteins, both short and long lived are degraded by the UPP as opposed 
to autophagic (lysosomal) pathways (107).  A little know fact is that initially the 
intended therapeutic use of proteasome inhibitors was for muscle atrophy and to 
modulate MHC class I antigen presentation (107).  However, advances in oncology 
along with many of the pieces coming together led to a new hypothesis: if cancer 
cells (particularly the blood cancers) over express proteins which need to be degraded 
by the proteasome, then inhibiting the proteasome’s ability to degrade substrates will 
causes extensive ER stress and induce apoptosis (110).  At the present this now 
validated hypothesis represents a great success story of translational research that 
paved the way for Velcade® (Millennium Pharmaceuticals) and other small molecule 
proteasome inhibitors.   
Generally, proteasome inhibitors are peptide-like small molecules that 
reversibly bind the proteolytic subunits located in the proteasome’s 20S core.  The 
first generation proteasome inhibitors were designed based on peptide mimics without 
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any structural knowledge of the actual target (111).  The basic science behind 
proteasome inhibitors has come a long way and second generation molecules are still 
in various stages of testing (110, 112).  The architecture of the 20S core has been well 
characterized and many structures of inhibited 20S CPs have been solved by X-ray 
crystallography (Figure 1.6).  The therapeutic effectiveness of proteasome inhibitors 
is proven, but first generation drugs (Velcade®) produced many severe off target 
effects and some cancers are developing resistance with mutations in the proteolytic 
β5-subunit where Velcade® binds (112-115).  Structural data along with special 
chemistry that changes the binding mechanism from reversible to irreversible has 
allowed subsequent proteasome inhibitors (e.g. Carfilzomib, Onyx Pharmaceuticals) 
to be much more effective by overcoming resistance and minimizing off target effects 







Figure 1.6 – Overview of proteasome inhibitors.  
(A) 20S CP from yeast proteasome (PDB-1RYP) with outer α7 rings colored blue, 
inner β rings colored yellow, and proteolytic β1, β2, and β5 subunits colored red.  (B) 
Arrangement of heptameric (β7) ring of β subunits with proteolytic units shown in 
red. (C) Structure of the proteasome inhibitor Velcade and in complex with the β5 
subunit (red) from (PDB-2F16).  (D) Structure of a lead second generation 
proteasome inhibitor "compound-1" in complex with β5 subunit (red) from (PDB-
3MG4). (E) Alignment of Velcade (blue) and compound 1 (green), note the 
substituent groups of compound 1 extend to different surfaces of the β5 subunit (red) 









1.4.6 Proteasome associated DUBs 
The proteasome harbors a single DUB, Rpn11 (POH1 in humans, also known 
as PSMD14, MPR1, S13, or CeP1) from the JAMM/MPN+ family.  Of the many 
other proteins that can associate with the proteasome there are two DUBs, Ubp6 
(USP14 in humans) a UBL containing DUB that binds the proteasome via Rpn1 and 
UCH37 (also called UCHL5) that is recognized by the Rpn13 subunit.  These three 
DUBs all play an important role, recycling the Ub signal back into the cell, which 
maintains the free pool of Ub.  Rpn11 deletions are lethal to yeast since the subunit is 
essential for proteasome assembly, while mutations that eliminate DUB activity have 
profound phenotypes marked by the accumulation of polyUb conjugate (49).   The 
function of Ubp6 has been extensively pioneered by Finley and coworkers who have 
also found that Ubp6 itself can modulate substrate processing on the proteasome non-
catalytically (119).  Finley has generally concluded that Ubp6 prematurely removes 
the polyUb signal from substrates, delaying their destruction by the proteasome (120).  
The role of UCH37 is less studied, reports show that it has functions similar to Ubp6 
(54).  Interestingly, these proteasome associated DUBs have also been found to have 
roles outside of the proteasome.  For example, Ubp6 functions in telomeric silencing 
by modulating histone modifications (121).   
Much has been learned about substrate processing from yeast and simple in 
vitro studies, however the actual sequence of events in which a substrate goes through 
on the proteasome is not clear.  It is accepted that Rpn11 only acts after a substrate is 
completely committed to degradation (51).  Yet a body of work by Finley and 
coworkers demonstrates there is indeed many events including chain remodeling that 
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can happen before a substrate is degraded.  Regardless of the details, the DUB 
function of both Rpn11 and Ubp6 have been proposed as therapeutic targets in a 
range of diseases (122, 123).  To date, there is a strong effort underway to develop 
inhibitors for both Ubp6 and Rpn11, but it seems that Ubp6 inhibitors are the furthest 
in development with IU1 showing many promising results (124).  The vital role of 
proteasome associated DUBs has been well established and the development of 
specific inhibitors is the next logical step for this field.  Fully understanding substrate 
processing requires techniques and capabilities that have yet to be developed.                        
 
1.5 Non-degradative ubiquitin signaling outcomes 
1.5.1 DNA damage repair   
DNA damage repair pathways were the first non-degradative Ub signaling 
pathways discovered.  In contrast to the UPP, DNA repair employs the K63-linkage 
as opposed to the K48 linkage.  Initially these non-degradative pathways were found 
to recruit a novel K63 forming E2 heterodimer (Ubc13:Mms2), in UV sensitive yeast   
(125, 126).  Once the K63 signal is formed DNA repair is initiated by localization of 
RAP80 at double strand DNA breaks, which recruits the BRCA1-BARD1 
heterodimer (127).  Many E3 Ub ligases that form K63 linkages have also been found 
to have other roles in DNA repair and transcription.  Aside from their roles in double 
strand break repair, TRAF6 (tumor necrosis factor receptor-associated factor 6) and 
RNF4 have also been found to have important roles for genomic stability and the 
progression of cancers (128-130).           
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1.5.2 Histone modification  
Ub also has other roles inside the nucleus aside from DNA repair.  Histones, 
the most fundamental unit of chromatin structure allow transcription to be regulated 
through several post-translational modifications on C-terminal lysine residues.  Ub 
and the UBL (SUMO) are the only protein modifiers known to be directly attached to 
histones and it is still not fully understood how the post-translational modification of 
histones alters transcription and chromatin structure (131).  The Ub modification has 
also been found to be essential for development and is key to ensuring the correct 
genes are expressed at the exact time they are required (132).  Specialized E3 Ub 
ligases, Ring1B and E6-AP (E6 associated protein) which directly modify histones 
with Ub have been implicated in Angelman syndrome and there are other examples 
for other developmental diseases (132).      
1.5.3 Membrane trafficking  
One of the most vital non-degradative functions of Ub signaling is membrane 
trafficking.  Typically monoubiquitination, multiple monoubiquitination, or K63 
polyubiquitination are required for proteins to cross several eukaryotic membranes 
and also for endosomal trafficking (133).  In fact, many transmembrane proteins are 
known to carry UBDs or have E3 ligase activity.  The Ub modification can also help 
control the sequence of events in complex systems.  For example the endosome 
transport factor Vps9 (Rab5 in humans) is composed of a CUE domain (a type of 
UBD) and GEF (guanine nucleotide exchange factor) domain that is only active after 
the CUE domain binds Ub (134).  Since the Ub or polyUb signal must be removed, 
DUBs also play key roles in membrane trafficking.  Several USP family DUBs 
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(USP27X and USP29) have evolved transmembrane domains or are able to be 
recruited to membrane complexes like the JAMM/MPN+ family DUB AMSH.         
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Chapter 2:  Structural and conformational review of ubiquitin 
signaling 
2.1 Introduction 
 Although Ub is just one protein its ability to be conjugated into distinct 
polymeric chains allows it to function on divergent signaling pathways.  Proteins that 
interact with Ub have evolved several varieties of binding domains and recognition 
surfaces to differentiate between Ub and numerous UBL proteins in the cell.  
Typically the affinity of Ub for its receptors is moderate with equilibrium dissociation 
constants (Kd) ranging between 10-120 µM.  It is important to note that not all 
polyUb chains are the same and the Kd of a particular receptor changes based on the 
Ub-Ub linkage and number of Ubs in the chain.  For example, the K63 selective 
tandem UIM (tUIM) from RAP80 binds K63-Ub2 with a Kd = 21.6 ± 0.8 µM, K63-
Ub4 with a Kd = 3.6 µM,  and K48-Ub2 with a Kd = 157 ± 8 µM (135).  The structures 
of M1, K48, and K63 linked free polyUb chains and in complex with various UBDs 
represent a majority of our structural knowledge (136-139).  However, there is still a 
void of structural data for atypical K27, K29, and K33 Ub linkages.  Recent advances 
in bioorganic chemistry have led to several structures of Ub in complex with various 
E1, E2, E3 enzymes (140).  Similar methods have also been employed to covalently 
attach Ub to active site cysteine residues of several DUBs (31).  Structures of Ub 
modified substrates have eluded structural biologists and there are several pressing 
questions regarding the outcome of Ub modification.  In general, there is much data 
for Ub interacting with individual domains, however in the cell this only represents a 
tiny piece of much larger complexes.  Determining the complete layout of such 
complexes is regarded as a "Holy Grail" by many structural biologists and there is an 
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intense effort to tackle SCF E3 complexes, spliceosomes, the proteasome, the COP9 
signalosome, mitotic complexes, and many other multisubunit complexes involved 
with Ub signaling.         
2.2 Structural properties of monomeric Ub and UBL molecules 
2.2.1 The Ub molecule 
 Ub is highly conserved across eukaryotes with just three subtle differences 
(P19S, E24D, A28S) in primary structure going from humans to yeast.  The structure 
of monomeric Ub has been studied extensively using many techniques for a wide 
range of purposes.  Aside from its biological significance, Ub has become a model 
protein for method development due to its many favorable properties, most notably its 
ease of production, small size, incredible stability (Tm~100oC), and long shelf life.  In 
addition to the seven lysine residues discussed earlier, Ub from all species retains the 
beta grasp (β-grasp) fold created by five antiparallel β-sheets, packed against a long 
α-helix.  Many bulky hydrophobic residues (I3, V5, I13, L15, V26, I30, L43, L50, 
L67 and L69) are essential for maintaining the packing of Ub's hydrophobic core 
(Figure 2.1).  This was highlighted in several studies which demonstrated that single 
point mutations (e.g. L67S or L69S) can dramatically impact the three dimensional 
structure of Ub (141).  Interestingly the eight linkage sites are not restricted to one 
face on Ub, but are distributed about the surface of the molecule, with K27 being 
slightly buried.  Surface exposed hydrophobic residues L8, I44, and V70 located on 
the β-sheets form the hydrophobic patch, which is essential for Ub to be recognized 
by receptors.  Other notable structural features on Ub include a small 3(10) helix, 
several loops, and a highly flexible C-terminus or “tail” (residues 72-76).  Although 
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the tail residues typically do not directly bind UBDs, they are essential for recognition 
by E1, E2, E3 enzymes and DUBs (142).   
 
Figure 2.1 – Comparison of yeast and human Ub 
Ub is highly conserved across all species.  The primary sequence (top) shows three 
subtle mutations (red arrows) between yeast and human Ub.  All known structures for 
monomeric Ub align nearly perfectly and the β-grasp fold is always conserved.  The 
hydrophobic core residues (red sticks) are mainly responsible for the packing of the 
front five β-sheets against the long α-helix.  Note both the β-sheets and α-helix have a 
network of hydrophobic residues with long side chains oriented inward.   
 
2.2.2 UBL molecules 
 UBL molecules, which are "like Ub" in respect to their three dimensional 
structures also contain the hallmark β-grasp fold and can be found as monomeric 
units, polymers, or as domains in a variety of proteins.  A number of UBLs (ISG15, 
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FAT10, Nedd8, and SUMO) are commonly conjugated to themselves or other 
proteins via isopeptide bond with a dedicated set of E1, E2, E3 enzymes and 
deconjugation is possible with isopeptidases just as with Ub.  UBLs that exist as 
domains, such as the UBLs of DUBs or shuttling proteins have been show to have 
defined regulatory functions and remain confined to the proteins they originate i.e. the 
UBL of USP14 cannot be attached to another protein.  The linkable UBLs (listed 
above) can modify a variety of proteins just as Ub, and in some cases these UBLs are 
attached to the same site as Ub (143).  Recent studies have shown that there is much 
crosstalk between UBLs and Ub signaling pathways, and heterologous mixed Ub-
UBL modifications exist in the cell (144-147).  Of the numerous UBLs, Rub1(Nedd8 
in humans) is the closest related to Ub with a nearly exact three-dimensional 
structure, 77% sequence similarity, and also the L8, I44,V70 hydrophobic patch 
residues (148)  see (Figure 2.2).  Many linkable UBLs are also cross-reactive with 
E1, E2, E3 enzymes and DUBs.  For example, the E1 for Nedd8 can catalyze 
ubiquitination and the DUB USP21 can cleave ISG15 modifications as well as 





Figure 2.2 – UBLs share a similar fold to Ub 
The structure of human Ub (green) is shown alone in the top row.  The middle row 
shows the structure of Nedd8 (blue), SUMO-2 (red), and the UBL of USP14 (yellow).  
Below in the bottom row, Ub (green) is aligned to each UBL molecule.  Note the 
alignment of Nedd8 (blue) and Ub (green), the structures are nearly identical even 
down to the position of the L8,I44,V70 hydrophobic patch residues.  SUMO-2 (red), 
which is slightly larger also shows good alignment with Ub (green).  The UBL of 
USP14 (yellow) has a β-grasp fold, however it differs in the arrangement of β-sheets 
and has more unstructured loop regions.      
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2.3 Structure and conformations of polyUb chains 
2.3.1 Different as night vs. day: K48 and K63 polyUb chains 
 K48 and K63 polyUb chains represent essentially opposites in structure and 
signaling outcomes.  These linkages account for just over 67% of all Ub-Ub linkages 
in the cell and are the best studies by far (150).  It is generally accepted that K48 
linkages signal for proteasomal degradation while K63 linkages signal for regulatory 
pathways, such as DNA repair.  Until the landmark studies of Fushman and Pickart, 
little attention was given to the actual structure of the polyUb signal itself.  In a series 
of papers published from 2001-2006, it was established that in solution K48 Ub 
linkages adopted compact conformations with extensive interdomain contacts, while 
the K63 Ub linkage resulted in an extended conformation with virtually no 
interdomain contacts (Figure 2.3) (151-155).  The surface exposed L8, I44,V70 
hydrophobic patch was found to be key in forming interdomain contacts between K48 
linked Ubs and the structural arrangement of K63 linked chains prevented this 
interaction.  This observation would become the main principle in explaining how a 




Figure 2.3 – The major structural conformations of K48 and K63 linkages. 
(A) The Structure of K48-Ub2 has extensive interdomain contacts created through 
hydrophobic patch residues L8,I44,V70 (yellow spheres), which contributes to the 
compact conformation.  (B) Conversely, K63-Ub2 adopts an extended conformation 
with essentially no interdomain contacts.    
 
Perhaps more importantly, these studies also established that polyUb chains were 
dynamic and took on distinct conformations.  Later X-ray derived structures would 
also corroborate this observation and this led to the hypothesis that specific Ub-Ub 
linkages resulted in distinct signaling outcomes due to the ability of the polyUb chain 
to interact with specific receptors.  After these initial studies much attention was 
directed at determining the exact populations of each conformation for a given 
linkage.  Prof. David Fushman with his cutting edge solution NMR techniques was 
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the first to determine the intricacies of the conformational equilibria that governed 
K48 and K63 linkage (151, 155).   Years later other solution methods such as small 
angle X-ray and neutron scattering, (SAXS) and single molecule FRET (smFRET) 
studies confirmed Prof. Fushman’s early observations that  K48 linkages had two 
predominant conformations,  "open" and "closed" with populations of 15% open and 
85% closed (Figure 2.4), while K63 linkages had two predominate conformations 
86% extended and 14% compact (Figure 2.5) (156, 157).  The protonation state of 
the H68 side chain was shown to dictate the conformational equilibrium of K48 
linked chains in an unique electrostatic phenomenon (158).  At neutral pH, above the 
pKa of histidine, H68 has a net charge of 0 that allows for extensive hydrophobic 
interaction favoring the closed conformation.  While below the pKa at acidic pH, H68 
has a +1 charge that causes repulsion between the two Ubs favoring the open 
conformation (158).  Interestingly the crystal and solution structures conflicted in this 
regard for K48 linkages, with the crystal structures showing an open conformation of 
K48-Ub2 at neutral pH and the closed conformation at acidic pH.  This discrepancy is 
explained by crystal lattice forces dictating the conformation of K48 linked polyUb  






Figure 2.4 – Open and closed conformations of K48-Ub2 
(A) The closed conformation of K48-Ub2 is represented by PDB-1AAR with the 
distal Ub (red), proximal Ub (green), and the L8,I44,V70 hydrophobic patch residues 
as (yellow spheres). (B) An open conformation of K48-Ub2 showing the hydrophobic 
patch residues do not interact, distal Ub (salmon) and proximal Ub (green). (C) 









Figure 2.5 – Extended and compact structural conformations for K63-Ub2 
(A) The DUB AMSH-LP (blue) binds K63-Ub2 extending the chain in the process.  
(B) FAB fragment of the K63 linkage specific antibody (blue) creates a compact 
conformation in the K63-Ub2 chain.  (C) Alignment of the extended and compact 
structures of K63-Ub2 shows a dramatic difference, however both conformations lack 





Interestingly, the distinct conformations for each linkage appear to be independent of 
the number of Ubs in the chain i.e. Ubs linked through K48 will remain compact and 
Ubs linked through K63 will remain extended in both di and tetra Ub chains (Figure 
2.6).  For technical reasons, longer chains (greater than four Ubs) have not been 
explored structurally, but modeling suggests that the conformation of the shorter 




Figure 2.6 – The unique conformations of K48 and K63 linkages are retained in 
longer chains. 
(A) Crystal structure (PDB-2O6V) of K48-Ub4 shows that the interdomain contacts 
between the L8,I44,V70 hydrophobic patch residues (yellow spheres) is maintained in 
the tetrameric chain. (B) Crystal structure of K63-Ub4 (PDB-3HM3) shows the Ubs 
retain their extended conformation with no interdomain contacts. (C) Schematic of 




2.3.2 K11-linked polyUb chains 
Following K48 and K63 linkages, K11 is the next most abundant Ub-Ub 
linkage in the cell.  Defined pathways such as ERAD, the UPP, and also mitotic 
events have been shown to involve K11 linkages (46, 160).  In addition, the cell has 
developed specific machinery for K11 linkages such as the DUB Cezanne (OTUD7B) 
and the E2 Ube2S which are highly selectively for cleaving and synthesizing K11 
linkages, respectively (161).  X-ray derived structures for K11 linked chains (PDB-
2XEW and PDB-3NOB) certainly illustrate that these chains adopt different 
conformations from K48 and K63 linked chains (160, 161).  However, these “snap 
shots” of K11-Ub2 completely ignore dynamics and are dramatically different 
between each other, shown in (Figure 2.7), thus it is hard to accept that either PDB-
2XEW or PDB-3NOB provides an accurate representation of K11-Ub2.  A recent 
solution study by Prof. Fushman (unpublished) has established that K11 chains 
mainly populate conformations that fall between the compact K48 and extended K63 
linkages.  Although K11-Ub2 is slightly compact, it does not appear that the 
L8,I44,V70 hydrophobic patch forms strong interdomain contacts as it does with the 
K48 linkage.  Furthermore, the K11 linkage has only recently begun to be studied and 
there are no structures showing any UBD in complex with K11 linked Ub, making it 






Figure 2.7 – Radically different crystal structures of K11-Ub2 
(A) PDB-2XEW shows a slightly extended conformation of K11-Ub2 with proximal 
Ub (green), distal Ub (orange), and hydrophobic patch residues (yellow spheres).  (B) 
Contact between hydrophobic patch residues (yellow spheres) in PDB-3NOB, with 
proximal Ub (green) and distal Ub (beige).  (C) Alignment of K11-Ub2 structures by 
proximal Ub (green) shows the distal domain must undergo a large conformational 





2.3.3 K6-linked polyUb chains 
The initial discovery of K6-linked polyUb chains sparked great interest since 
the linkage was found to be created by the BRCA1/BARD1 heterodimer (RING E3 
Ub ligase), a key tumor suppressor in breast cancer (162).  Since then only a handful 
of other studies have identified pathways or enzymes that create K6 linkages and this 
is most-likely due to their low (<4%) abundance in the cell (163, 164).  Interestingly, 
a HECT-like E3 Ub ligase from bacteria (NLEL) can create mixed K48 and K6 
linkages with mammalian E2s (163).  K6 linked chains have several notable features 
including an asymmetric interdomain interface. Aside from the K48 linkage, K6 is the 
only other linkage known that forms significant interdomain contacts between 
adjacent Ubs in the same chain (Figure 2.8).  Unlike the structures reported for K11-
Ub2, the K6-Ub2 structure is in good agreement with data from solution NMR and the 
conformation creating the new interface accounts for a major proportion of all 
conformations.  Given the asymmetric interface of K6 there is much speculation 
regarding how longer K6 linked chains would appear.  For K48 linkages tetrameric 
chains retain their same interaction, however it may be possible for longer K6 linked 
chains to take one some unique conformations.  There are no known K6 specific 










Figure 2.8 – Crystal structure of K6-Ub2 revels a new interface 
(A) Two distinct hydrophobic patches on Ub, the L8, I36, L71, L73 patch (orange 
spheres) and L8, I44, V70 patch (yellow spheres) with L8 as red spheres.  (B)  Crystal 
structure (PDB-2XK5) of K6-Ub2.  As opposed to the symmetric K48 interface 
formed by the L8,I44,V70 patch, the asymmetric K6 interface is formed by the 
L8,I36,L71,L73 patch (orange spheres).      
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2.3.4 M1-linked polyUb chains 
M1 linked chains are also referred to as “head-to-tail” or “linear chains,” 
which can be confusing.  For simplicity I will use the unambiguous M1 designation to 
refer to such chains.  In the cell, all Ub starts as M1-linked chains when it is 
expressed from the Ub gene, that encodes a fusion of four M1-linked Ubs (165).  
DUBs from the UCH family help process the M1 linked Ub gene product into 
monomeric Ub units.  However if M1 linked Ub chains are needed they can be 
reassembled by the linear ubiquitin chain assembly complex (LUBAC), which 
contains two RING E3’s haem-oxidized iron-regulatory protein 2 ubiquitin ligase-1 
(HOIL-1) and HOIL-1 interacting protein (HOIP) (166).  Similar to K63 linked 
chains, M1 linked chains adopt an extended conformation with minimal interdomain 
contacts (Figure 2.9).  Although M1 linked chains are similar to K63 linked chains in 
structure, they appear to be used for very different pathways in vivo.  NF-κB 
activation is one of the only characterized pathways for M1 linkages (167).  One this 
pathway M1 linkages are recognized by the ubiquitin binding in ABIN and NEMO 
(UBAN) domain in the IKK subunit NF-kappa-B essential modulator (NEMO).  
Structures of M1 linked dimers in complex with a linkage specific antibody and 
UBAN of NEMO are shown in (Figure 2.9 D,E).  These examples show another 
similarity between K63 and M1 linked chains, in that upon binding, the conformation 




Figure 2.9 – Representative structures of M1 linked polyUb chains. 
(A) Crystal structure (PDB-2W9N) shows and extended conformation of M1-Ub2 
with proximal Ub (green), distal Ub (black), the L8,I44 hydrophobic patch (yellow 
spheres), and M1-G76 linkage (magenta sticks). (B) Compact crystal structure (PDB-
3AXC) of M1-Ub2, same coloring as (A) with the exception of the distal Ub (gray).  
(C) Alignment of the extended (black) and compact (gray) M1-Ub2 structures by the 
proximal Ub (green).  (D) M1 linkage specific antibody (black) recognizes a compact 
form of M1-Ub2 (E) The UBAN motif from NEMO in complex with M1-Ub2    
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 2.3.5 Cyclized polyUb    
 
 The possibility of cyclized polyUb chains was first proposed when such 
chains were discovered as a product from the in vitro enzymatic synthesis of K48 
chains by E2-25K (168).  To date, K48 linkages have been the only linkage found to 
allow for cyclization of the Ub chain.  However, synthetic chemists have reported that 
other linkages with artificial modifications can be cyclized (169).  A recent study has 
eluded that such chains exist in the cell and may even play specific roles (170).  
DUBs designed to process cyclized chains also support an in vivo function for 
cyclized chains (170).  Based on the crystal structure (PDB-3ALB) of cyclic K48-Ub4 
and several solution studies, it appears that cyclization of K48 linked Ub results in a 
similar conformational ensemble to non-cyclized K48 linked chains (171, 172).  The 
tight locking of the L8, I44,V70 hydrophobic patch between the Ub units is the most 
pronounced feature, however the interdomain interaction and conformation are nearly 
identical to non-cyclized K48 linked chains in that the overall compact conformation 
is preserved (Figure 2.10).  Essentially cyclization of K48 linked chains locks the 
closed conformation and does not impact the overall structure.  Even when cyclized it 
appears the L8,I44,V70 hydrophobic patch is still slightly accessible, which hints that 
cyclized K48 chains can still participate in binding interactions (172).    This theory 
remains to be tested, but there certainly will be some difference in binding given the 










Figure 2.10 – Structural similarities between cyclized and non-cyclized K48 
polyUb chains. 
(A) Crystal structure (PDB-3ALB) of cyclized K48-Ub4 with all Ubs (green), G76-
K48 linkage (magenta sticks), and the L8,I44,V70 hydrophobic patch (yellow 
spheres).  (B) Alignment of cyclized (PDB-3ALB) in green and non-cyclized (PDB-
2O6V) in red K48-Ub4 shows similarity, with a RMSD=0.284 Å.  (C) The K48-Ub2 
unit is taken from each K48-Ub4 structure and aligned showing the hydrophobic 
interface in the non-cyclized form (red) is well maintained in the cyclized form 




2.3.6 K27, K29, K33, and other linkages 
 The true non-canonical linkages are K27, K29, and K33 which are all located 
on Ub's long α-helix.  No structural data exists for these linkages, however it is 
proposed that they form extended conformations similar to M1 or K63 linkages, 
while it is also possible a few could form transient interdomain contacts (173).  
Together these three linkages account for slightly over 10% of all linkages in yeast 
and have been reported to exist in low abundance for higher eukaryotes (174).  The 
close proximity of the linkages has made it hard to create antibodies for their 
detection. Unlike M1, K6, K11, K48, and K63 linkages which have specific 
antibodies, no attempt has been successful in creating a reliable K27, K29, or K33 
linkage specific antibody.  K27 linkages have been detected in vivo by MS studies, 
but there has yet to be a defined role attributed to this linkage type.  Some enzymes, 
such as Ubch5b (an E2), the E3 ligase Ring1b, and the E4 protein Ufd2 can create 
K27 linkages as well as other linkages, resulting in mixed linkage chains (20, 164, 
175).      
 More studies have elucidated the roles of K29 and K33 linkages.  The best 
characterized role for K29 linkages is signaling lysosomal degradation (176).  K29 
and K33 linkages have been found to modify several AMPKs (AMP-activated protein 
kinase), which are essential for cellular proliferation.  Interestingly, USP9x is one of a 
few DUBs that can efficiently remove K29 and K33 modifications (177).  A more 
extensive study on the linkage preferences of DUBs has revealed the OTU DUB 
TRABID preferentially cleaves K29 and K33 linkages suggesting the linkages do 
indeed have distinct signaling pathways (178).  It is also speculated that there are 
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selective UBDs for either K29 or K33 linkages, but this is still to be determined.  The 
fact that K27, K29 and K33 are in such close proximity hints that they could be 
recognized similarly.  Studies by Goldberg and coworkers demonstrated that it was 
possible to generate “forked” i.e. simultaneously attach two Ubs at K27&K29 or 
K27&K33 on a proximal Ub with Ubch5b, an E2 conjugating enzyme (29).  This 
work supports that the α-helix of Ub can potentially carry many different signals.    
 Ubiquitination does not always occur at the N-terminus, lysine side chain, or 
the active cysteine of enzymes.  The mouse gamma-herpesvirus protein mK3 encodes 
a special E3 Ub ligase that can attach Ub to serine or threonine residues, as well as 
the traditional lysine residues of its substrate, major histocompatibility complex I 
(MHC-1) heavy chain (179, 180).  The advantage of ligating an Ub to serine or 
threonine residues is not fully understood, but this does add another dimension to Ub 
proteomics.  Attachment of Ub to cysteine residues results in a high energy bond that 
has favorable energetics for Ub transfer between E1, E2, and E3 enzymes.  By 
definition ubiquitination with a HECT-E3 requires the transfer of Ub to flow from the 
E1, then the E2, next to the E3 and finally to the substrate, resulting in three Ub-
cysteine thioester linkages.  As an autoregulatory mechanism, E2’s such as Ubc7 can 
even become polyubiquitinated at active site cysteine residues, targeting themselves 
for degradation by the proteasome (181).   
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Chapter 3: Materials and Methods 
 
3.1 Protein expression and purification 
3.1.1 Plasmid construction and design 
All double stranded (ds) DNA plasmids contained a commercially available 
vector and a single gene sequence for expression, optimized for E. Coli.  When a 
plasmid was needed it was grown and then isolated from chemically competent 
DH5α cells.  To express gene products several variations of BL-21(DE3) cells were 
used.  For large proteins with established protocols, expression was carried out in BL-
21(DE3) pLysS cells.  BL-21(DE3) Rosetta™ II cells were used to express a majority 
of human proteins under the T7 promoter with rare codons for E. Coli.  Noted by 
Prof. CM Pickart it was absolutely essential to express Ub mutants containing KtoR 
mutations with rare arginine codons AGA and AGG in Rosetta II cells (182).  In 
addition, Rosetta II cells also have a library of tRNAs to ensure other rare codons are 
properly introduced into the expressed protein.  A subset of proteins under the T5 
promoter in the pQE30 vector (Qiagen) were expressed in M15 E. coli cells.   
With just one exception, all gene sequences were already contained in 
plasmids for expression and required no additional cloning or ligations.  Certain 
plasmids were obtained through collaborators or via the addgene data base.  Many 
point mutations were introduced on various plasmids for different purposes.  This was 
accomplished using mutagenic primers designed with primerX software and PCR 
with KOD high fidelity hot start DNA polymerase (Novagen).  Truncations were also 
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introduced with the insertion of a stop codon.  Up to eight residues were inserted to 
particular constructs (e.g. 6xHis tag or strep-tag), again using similar PCR conditions 
in 50 µL reactions.  Following PCR all template DNA was digested with 15 U of 
Dpn1 (New England Biolabs) for 3 hours at 37oC following the manufacturer’s 
instructions.  PCR products were checked on a 1% agarose gel with ethidium bromide 
staining, then transformed into DH5α cells.  The plasmid was then extracted and the 
presence of the desired product was confirmed by sequencing with the appropriate 
primer.      
3.1.2 Bacterial growth conditions and expression 
Detailed growth and expression conditions for 87 different proteins are 
outlined in (Table 3.1).  There were several different media employed based on the 
need for autoinduction and isotope labeling.  Highly stable proteins such as Ub and 
GST constructs could be expressed in autoinducing media which required just a 
single temperature for incubation.  6xHis tagged proteins generally required induction 
with IPTG, however IPTG concentration and the expression temperature needed to be 
optimized for each protein.  Antibiotics were added from 1,000x stock solutions to a 
final concentration in culture: chloramphenicol (50 mg/L), ampicillin (100 mg/L), and 


















Protein plasmid promoter auto	  inducing Induce	  [IPTG] OD600	  Induction Expression	  temperature	  (C)	   Expression	  time	  (hr) Affinity	  tag
1 Ub pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
2 Ub-­‐F45W pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
3 Ub-­‐K48R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
4 Ub-­‐K63R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
5 Ub-­‐D77 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
6 Ub74 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
7 Ub-­‐G76C pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
8 6xHis-­‐Ub pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
9 Ub-­‐T12C pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
10 Ub-­‐I36C pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
11 Ub-­‐K48C pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
12 Ub-­‐T55C pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
13 Ub-­‐K63D pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
14 Ub-­‐6xHis pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
15 Ub-­‐strep pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
16 Ub-­‐6xHis/K48R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
17 Ub-­‐K11R/K48R/K63R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
18 Ub-­‐K48R/K63R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
19 Ub74/K48R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
20 Ub74/K63R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
21 Ub-­‐D77/K48R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
22 Ub-­‐D77/K63R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 none
23 Ub-­‐K0 pET14b T7 YES 1mM 0.7-­‐1.0 37 4 none
24 Ub-­‐K6 pET14b T7 YES 1mM 0.7-­‐1.0 37 4 none
25 Ub-­‐K11 pET14b T7 YES 1mM 0.7-­‐1.0 37 4 none
26 Ub-­‐K27 pET14b T7 YES 1mM 0.7-­‐1.0 37 4 none
27 Ub-­‐K29 pET14b T7 YES 1mM 0.7-­‐1.0 37 4 none
28 Ub-­‐K33 pET14b T7 YES 1mM 0.7-­‐1.0 37 4 none
29 Ub-­‐K48 pET14b T7 YES 1mM 0.7-­‐1.0 37 4 none
30 Ub-­‐K63 pET14b T7 YES 1mM 0.7-­‐1.0 37 4 none
31 Ub-­‐K0/6xHis pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
32 Ub-­‐K6/6xHis pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
33 Ub-­‐K11/6xHis pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
34 Ub-­‐K27/6xHis pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
35 Ub-­‐K29/6xHis pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
36 Ub-­‐K33/6xHis pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
37 Ub-­‐K48/6xHis pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
38 Ub-­‐K63/6xHis pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
39 MMS2 pET16b T7 YES .8mM 0.7 37 4 6xHis
40 GST-­‐Ubc13 pGEX4T2 T7 YES 1mM 0.7-­‐1.0 37 4 GST
41 E2-­‐25K pGEX4T2 T7 YES 1mM 0.7-­‐1.0 37 4 GST
42 Ube2S pMAL T7 NO 1mM 0.7-­‐1.0 37 4 MBP/	  6xHis
43 human	  E1 pet15b T7 NO 0.5mM 0.7 16 16 6xHis
44 Ubch5b pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
45 Ubch5b-­‐C85A pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
46 Ubch5b-­‐C85K pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
47 Ubch5b-­‐K4R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
48 Ubch5b-­‐K8R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
49 Ubch5b-­‐K63R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis






Table 3.1 (continued) – Proteins and expression conditions 
 
1L of the autoinducing media for unlabeled proteins was prepared by 
combining 10 g NaCl, 10 g tryptone, 5 g yeast extract, 50 mL of 20x NPS, and 1 mL 
of 1M MgSO4 in a final volume of 1L.  20x NPS contains 90 mL of H2O, 6.6 g 
(NH4)2SO4, 13.6 g KH2PO4, and 14.2 g Na2HPO4.  After the 1L culture was sterilized, 
25 mL of 50x ZYP5052 was syringe filtered (0.45 µm) into the culture.  50x 
ZYP5052 is composed of 25 g glycerol, 73 mL H2O, 2.5 g glucose, and 10 g lactose 
in a final volume of 100 mL.  The antibiotic(s) and starter culture were added last.  
Cells were harvested 16-22 hours after allowing growth at a constant temperature. 
Protein plasmid promoter auto	  inducing Induce	  [IPTG] OD600	  Induction Expression	  temperature	  (C)	   Expression	  time	  (hr) Affinity	  tag
51 Ubch5b-­‐K101R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
52 Ubch5b-­‐K128R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
53 Ubch5b-­‐K133R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
54 Ubch5b-­‐K144R pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
55 Ubch5b-­‐K4 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
56 Ubch5b-­‐K8 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
57 Ubch5b-­‐K63 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
58 Ubch5b-­‐K66 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
59 Ubch5b-­‐K101 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
60 Ubch5b-­‐K128 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
61 Ubch5b-­‐K133 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
62 Ubch5b-­‐K144 pET3a T7 YES 1mM 0.7-­‐1.0 37 4 6xHis
63 RAP80-­‐tUIMy pET28a T7 NO 1mM 0.8 37 5 6xHis
64 RAP80-­‐v7-­‐tUIMy pET28a T7 NO 1mM 0.8 37 5 6xHis
65 hHR23a-­‐UBA(2) pGEX T7 YES 1mM 0.7 37 5 GST
66 UBQ1-­‐UBA pGEX T7 YES 1mM 0.7 37 5 GST
67 RPN1 pQE30 T5 NO 0.1mM 0.8 16 16 6xHis
68 DSK2 pQE30 T5 NO 0.5mM 0.7 20 16 6xHis
69 DSK2-­‐Sti1 pQE30 T5 NO 0.5mM 0.7 20 16 6xHis
70 DSK2-­‐UBA pQE30 T5 NO 0.5mM 0.7 20 16 6xHis
71 DSK2-­‐UBL pQE30 T5 NO 0.5mM 0.7 20 16 6xHis
72 DSK2-­‐ΔUBL pQE30 T5 NO 0.5mM 0.7 20 16 6xHis
73 DSK2-­‐ΔUBA pQE30 T5 NO 0.5mM 0.7 20 16 6xHis
74 Rpn10 pQE30 T5 NO 0.5mM 0.7 20 16 6xHis
75 Rpn10-­‐UIM pQE30 T5 NO 0.5mM 0.7 20 16 6xHis
76 Rpn10-­‐VWA pQE30 T5 NO 0.5mM 0.7 20 16 6xHis
77 Ubp6 pQE30 T5 NO 0.5mM 0.8 18 18 6xHis
78 Ubp6ΔUBL pQE30 T5 NO 0.5mM 0.8 18 18 6xHis
79 Ubp6-­‐C129A pQE30 T5 NO 0.5mM 0.8 18 18 6xHis
80 YUH1 pET21 T7 NO 0.75mM 0.7 37 4 none
81 AMSH pGEX-­‐6p-­‐1 T7 NO 0.35mM 0.8 16 16 GST
82 OTUB1 pProEx T7 NO 0.5mM 1mM 16 16 6xHis
83 Rpn11 pQE30 T5 NO .3mM 0.8 16 16 6xHis
84 Rpn11	  D122A pQE30 NO .3mM 0.8 16 16 6xHis
85 Rpn8 pQE30 T5 NO .3mM 0.8 16 16 6xHis
86 Rpn8	  (1-­‐186) pQE30 T5 NO .3mM 0.8 16 16 6xHis
87 Rpn9 smt3-­‐X T5 NO 0.5mM 0.8 20 12 SUMO	  /	  6xHis
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 For isotope labeling in autoinducing media 1 mL of 1M MgSO4 was added to 
50 mL of 20x (15N)NPS in a final volume of 1L then autoclaved.  The 20x (15N)NPS 
contains (90 mL H2O, 2.84 g Na2SO4, 13.6 g KH2PO4, 14.2 g Na2HPO4).  After 
sterilization 25 mL of 50x ZYP5052 was syringe filtered (0.45 µm) into the culture, 
followed by a solution containing 1 g 15NH4Cl dissolved in 10 mL of H2O.  The 
antibiotics were then added and the starter culture was pelleted, then resuspended in 
the 1L culture to avoid any incorporation of 14N.  Once prepared the cells were 
allowed to grow for 16-22 hours.   
Standard Luria broth (LB) expression was achieved by mixing 10 g NaCl, 10 
g tryptone, 5 g yeast extract, and 1 mL of 1M MgSO4 in a final volume of 1L and 
autoclaving.  Starter cultures and antibiotics were then added.  The OD600 was 
monitored every 30 minutes after an initial growth period of 3 hrs.  When the culture 
reached the desired OD600 the appropriate amount of IPTG was added.  If needed for 
expression, the temperature of the incubator was also changed.  For growths at 37o C 
a time of 4 hrs was sufficient for expression, but for low temperature expression times 
of 16-24 hours were necessary, (see Table 3.1).   
13C/15N, 13C, and 15N labeled proteins that could not express with 
autoinducing media were expressed in M9 media.  6 g Na2HPO4, 3 g KH2PO4, and 
0.5 g NaCl were added in a final volume of 1L, then autoclaved.  Next all nutrients 
were combined in a 50 mL conical and vortexed into solution.  If 15N labeling was 
desired, 1 g of 15NH4Cl was added in place of 14NH4Cl.  For 13C labeling 3 g of 13C 
glucose was added, while 5 g of standard glucose was added for all other proteins as 
the carbon source.  The final for concentration for the rest of the nutrients was 1 mg/L 
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of biotin, 1 mg/L of thiamin, 50 µM CaCl2, and 0.5 mM MgSO4.  After these 
nutrients were syringe filtered into the culture, the antibiotics and pelleted starter 
culture were added.  The OD600 was checked frequently after an initial 5 hour growth 
period due to the slow growth in M9 media.  The proper amount of IPTG was added 
when the optimal OD600 was reached.    
After induction the cultures were harvested at 4,000 rpm.  The cell pellet was 
immediately frozen at -80oC or prepared for lysis.  The buffer used for lysis varied 
depending on the affinity tag and next steps for purification, GST fusion proteins 
were suspended in PBS pH 7.4, the buffer for 6xHis tagged proteins was 20mM 
phosphate, 0.5M NaCl, pH 7.4, and for untagged proteins (mostly Ub variants) 50mM 
Tris, pH 8.0.  The lysis solution contained the cell pellet resuspended in ~25 mL of 
the appropriate buffer along with 0.02% Triton X-100, lysozyme (0.4 mg/mL), 
DNase1 (20 µg/mL), 10 mM MgCl2, and a homemade protease inhibitor cocktail with 
1 mM PMSF, 50 µM TLCK, soybean trypsin inhibitor (5 µg/mL), and leupeptin (2.5 
µg/mL).  This lysis mixture was lysed on ice by three rounds of a two minute 
sonication followed by a two minute recovery.  Due to the excess heating and stress 
from sonication, some proteins were lysed using the French press method.  After lysis 
the debris was cleared by spinning the mixture in an ultracentrifuge at 22,000 rpm on 
a Ti-45 rotor for 20 minutes.  From lysis to every subsequent step, the protein and 
buffer solutions were kept with 0.02% (v/v) NaN3 to inhibit the growth of unwanted 
microbes.  Following lysis proteins were purified using affinity columns or using 




3.1.3 Purification of highly stable Ub and Ub mutants 
Directly after lysis, the cleared supernatant containing a stable Ub variant was 
transferred to a 50 mL beaker with a stir bar on ice.  With constant stirring, 70% 
perchloric acid (HClO4) was added drop-by-drop to a final concentration of 1% (v/v), 
usually around 300 µL for 30 mL of lysis supernatant.  This step is unique in that the 
addition of HClO4 drops the pH to 1.85 where many proteins precipitate, however Ub 
remains stable.  If slightly unstable Ub mutants were being purified a variation of this 
technique substituting 3% (v/v) glacial acetic acid in place of 1% (v/v) HClO4 could 
be used, which dramatically increased yields.  Following the acid precipitation step, 
the milky white precipitate was cleared by ultracentrifugation, 22,000 rpm for 15 
minutes.  The supernatant was then transferred into 3 kDa MWCO dialysis tubing and 
dialyzed against 2L of 50 mM ammonium acetate, pH 4.5 at 4oC for 8-12 hours.  The 
Ub solution was then moved from the dialysis tubing, syringe filtered (0.45 µm), and 
loaded on to a pre-equilibrated 5 mL cation column (GE Life Sciences, SP FF) at a 
flow rate of 1.5 mL/min with buffer A (50 mM ammonium acetate, pH 4.5).  Ub was 
eluted using a program that went from 0% to 35% buffer B (50 mM ammonium 
acetate, 1M NaCl, pH 4.5) over 20 cv and the major Ub peak was detected a 16% 
buffer B.  The major peak was then pooled, concentrated, and exchanged into a 
desired buffer (50 mM Tris pH 8.0 for chain synthesis, 20 mM sodium phosphate pH 
6.8 for NMR studies, or PBS pH 7.4 for assays) using a centrifugal unit with a 3,500 
kDa MWCO.  The purity of Ub was checked by 15% SDS-PAGE and if needed the 
Ub was further purified on a superdex 75 120 mL size exclusion column (GE Life 
Sciences) with a flow rate of 0.5 mL/min in PBS pH 7.4 buffer.  After acid 
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precipitation and the cation exchange step most Ub preparations were highly pure and 
did not require the size exclusion step.  This protocol is virtually identical to those 
established by Prof. CM Pickart (183, 184).  Wild type Ub, KtoC mutants, and a 
majority of the KtoR Ub mutants were purified following this method.           
3.1.4 Purification of marginally stable Ub mutants 
For Ub mutants unable to withstand the harsh acid precipitation, I developed 
another purification method.  Eventually a 6xHis tag was added to these mutants as 
an alternative, but for many the lack of an affinity tag was advantageous.  After lysis, 
the supernatant was added to a 50 mL conical suspended in a 65oC water bath.  With 
the top of the 50 mL conical perforated to release pressure.  The solution was allowed 
to incubate at 65oC for 15 minutes and a white precipitate was observed.  
Immediately after heating, the 50 mL conical was placed on ice for 12 minutes to trap 
unfolded proteins before they could refold.  The debris was cleared by 
ultracentrifugation, 22,000 rpm for 20 minutes.  The supernatant was then syringe 
filtered into a fresh 50mL conical which was used to load it on to a pre-equilibrated 
5mL anion exchange column (GE Life Sciences Q FF) at 1 mL/min in buffer A (50 
mM Tris, pH 8.0).  In the anion step, Ub flows through and does not bind while many 
other proteins bind the anion column.  The Ub flow through was pooled and dialyzed 
against 2L of cation buffer A (50 mM ammonium acetate, pH 4.5) for 8-12 hours at 
4oC.  Following dialysis the Ub solution was loaded onto a pre-equilibrated 5 mL 
cation column at flow rate of 1.0 mL/min.  Marginally stable Ub mutants were eluted 
just as in section 3.1.3 above, but usually required a size exclusion step for high 
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purity.  K0-Ub, single lysine Ubs (e.g. K63), and the F45W mutants were all 
originally purified with this protocol.   
3.1.5 YUH1 purification 
YUH1, an important DUB for removing D77 in chain synthesis was purified 
without a tag using a modified protocol from Cohen and coworkers (40).  Following 
lysis, YUH1 was syringe filtered onto a 10 mL anion column in buffer A (50mM 
Tris, pH 7.6).  Then YUH1 was eluted with 5 cv steps of 15%, 30%, 50%, and 100% 
buffer B (50mM Tris, 1M NaCl, pH 7.6).  The 30% buffer B fractions containing the 
25 kDa YUH1 were pooled, exchanged in to PBS pH 7.4 and further purified with a 
superdex 75 size exclusion column at 0.4 mL/min.  This method, initially developed 
by Dr. Daoning Zhang efficiently isolated highly active YUH1 without the need for 
salt precipitation or reverse-phase chromatography.  To remove D77 from monomeric 
Ub or polyUb chains containing D77 at the proximal end, the Ub species were 
incubated with a 1% molar ratio of YUH1 at 37oC for 2 hours in a buffer containing 
50 mM Tris pH 7.6 and 1mM EDTA.  The concentration of the D77 Ub was kept less 
than 1 mM for all reactions.  After the incubation, 8 mL of anion buffer A (50mM 
Tris, pH 7.6) was added and the mixture, then slowly hand injected on to a 1 mL 
anion column (GE Life Sciences Q FF) column.  An additional 5 mL of anion buffer 
A was slowly injected to remove the unbound proteins and both Ub containing flow 
through portions were collected.  The YUH1 that bound the anion column was eluted 
in buffer B (50mM Tris, 1M NaCl, pH 7.6) while the Ub that did not bind flowed 
through effectively separating YUH1 from Ub.                 
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3.1.6 Purification of standard proteins (6xHis and GST) 
Many proteins simply required lysis and affinity purification with the only 
caveat being expression.  After lysis 6xHis and GST fusion proteins were purified on 
a 5 mL His-Trap column (GE Life Sciences) or 10 mL GST column (GE Life 
Sciences), respectively.  Once ideal expression conditions were determined, all of the 
GST proteins listed in (Table 1.3) were easily purified following the manufacturer’s 
GST protocol, loading in buffer A (PBS pH 7.4) and elution with buffer B (10 mM 
glutathione, 50 mM Tris, pH 7.6).  6xHis tagged proteins were loaded in buffer A (20 
mM sodium phosphate, 0.5 M NaCl, pH 7.4) and eluted over an 8 cv gradient from 
10-100% buffer B (20 mM sodium phosphate, 0.5 M imidazole, 0.5 M NaCl, pH 7.4).  
Following purification, many proteins were found to function fine with the affinity 
tag left on so no effort was wasted removing it.  For example, the 6xHis tag on Mms2 
was left on for K63 chain synthesis, the 6xHis tag was on tUIM of RAP80 for binding 
assays, and GST-fusions GST-Ubc13 and GST-E2-25K were used in chain synthesis.  
However, GST did need to be removed from GST-UBA fusions and this was 
accomplished by a thrombin cleavage site and separating the 5 kDa UBA from 23 
kDa GST on the size exclusion column.    
 
 
3.2 Enzymatic Synthesis and purification of polyUb chains and conjugates 
3.2.1 Enzymatic synthesis of Ub2 chains  
With the exception of M1 linked chains that could be produced as linear 
fusions, all Ub-Ub linkages involving a lysine residue were created enzymatically 
from purified monomeric units.  Standard reactions were in volumes of 2 mL 
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primarily containing 50 mM Tris pH 8.0 and incubated in a 30oC water bath for 24 
hours.  Each reaction contained 4 mM TCEP in place of DTT.  The reason being was 
that at high concentrations DTT could disrupt the E1 or E2 thioester bonds with Ub, 
however TCEP selectively reduces only disulfides.  TCEP contains three carboxylic 
acid groups and the pH of the 0.1 M stock solution was adjusted from pH 4 to pH 7 
with NaOH.  20 mM ATP was enough to keep the E1 activating enzyme highly 
functional.  To regenerate ADP to ATP and provide Mg+2 for E1, a 5x regeneration 
system resulting in a final concentration of 15 mM MgCl2, 20 mM creatine phosphate, 
1.2 U/mL inorganic yeast pyrophosphate, and 1.2 U/mL creatine phosphokinase was 
used.  Due to the high activity of our human E1, concentrations of 500 nM were 
found to be ideal.  The rest of the 2 mL reaction was made up of the Ub monomers 
and the E2 conjugating enzyme.  For dimers, 15 mg of each monomer was added and 
for trimers (dimer + monomer) a slight 1.25 molar ratio excess of the desired 
monomer was added to ensure the best yield of the trimer.  Reactions designed to 
produce a distribution of chain lengths with wild type Ub used 30 mg.  In these 
particular reactions, the E2 dictated the linkage formed.  For K11 linkages MBP-
Ube2s was used at a final concentration of 20 µM, K48 linkages made with GST-E2-
25K were also at 20 µM, while the Ubc13:Mms2 heterodimer used both proteins at 




Figure 3.1 – Synthesis schemes for K48 and K63 linked di and tri Ub chains 
The simple enzymatic synthesis scheme can be used to make (A) K48-Ub2 and K48-
Ub3 or (B) K63-Ub2 and K63-Ub3.  For each linkage the D77 blocking extension 
from the proximal end can be removed with YUH1.  The K48R/K63R double Ub 
mutant prevents extension from the distal end. 
 
After the 24 hour incubation period, the reactions were either stored at -20oC 
or 5 mL of cation buffer A (50 mM ammonium acetate, pH 4.5) and 100 µL of glacial 
acetic acid was added for immediate purification.  2 minutes after the addition of the 
acetic acid the reaction was spun down at 13,000 rpms on a microcentrifuge to 
remove precipitated proteins.  The supernatant was then added to a 5 mL loop and 
injected to a pre-equilibrated 5 mL cation exchange column at 0.25 mL/min in buffer 
A (50 mM ammonium acetate, pH 4.5).  Other proteins flowed through and were 
monitored by UV.  After the UV baseline stabilized, the polyUb chains bound to the 
cation column were eluted using 100% buffer B (50 mM ammonium acetate, 1M 
NaCl, pH 4.5).  The eluted polyUb was collected then exchanged into PBS pH 7.4 for 
size exclusion (0.35 mL/min flow rate) to separate the polymeric chains.  The size 
exclusion superdex 75 resin failed to resolve polyUb chains longer than four Ubs, but 
could separate distributions of significantly longer chains from shorter chains (e.g. 
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Ub1-4 from Ub7-10).  Fractions containing pure dimers or trimers were verified with 
15% SDS-PAGE, concentrated in a 3,500 MWCO centrifugal unit, and exchanged 
into a different buffer is necessary.  In some cases triUbs eluted such that they 
overlapped with the dimer on the size exclusion column.  To take the burden off of 
the size exclusion column a long cation separation which can isolate di and triUbs 
was preformed prior to size exclusion.  For this long cation step polyUb reactions 
were transferred into 5 mL of cation buffer A and slowly loaded onto a 5 mL cation 
column at 0.20 mL/min.  After the UV base line stabilized, polyUb was eluted using a 
shallow gradient from 0% to 30% buffer B over 80 cv.  Fractions containing the 
desired chain length were pooled and exchanged into PBS pH 7.4 for size exclusion.  
This scheme allowed for the synthesis and purification of virtually any polyUb dimer 
or trimer. Variations of enzymatic synthesis for mixed linkage polyUb chains (see 
chapter 4) were also successful.     
3.2.2 Autoubiquitinated E2-Ub conjugates  
Several E2 conjugating enzymes have been reported to autoubiquitinate on 
their active site cysteine as well as lysine residues.  Given that the Ub thioester bond 
to cysteine residues is marginally stable and of less physiological interest, I attempted 
to isolate E2-Ub conjugates with Ub linked via isopeptide bond to lysine residues of 
E2 (see section 6.3.1 for more details).  Enzymatic reactions were identical to the 
ones described in section 3.2.1, with two exceptions.  The E2, Ubch5b containing a 
C-terminal 6xHis tag was used in 2 mL reactions at a concentration of 100 µM and 3 
mM DTT was used in place of TCEP to ensure polyUb chains did not accumulate on 
cysteine residues.  The Ub monomer was kept at a concentration of 1 mM.  If mono 
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ubiquitination was desired Ub(K0), a mutant with all lysine residues mutated to 
arginine was used.  For a specific linkage the corresponding single lysine mutant was 
used e.g. Ub(K63) to make only K63 linkages.  Following the reaction 8 mL of His-
Trap buffer A (20 mM sodium phosphate, 0.5 M NaCl, pH 7.4) was added and this 
mixture was slowly injected by with a 10 mL syringe onto a 1 mL His-Trap column.  
Then an additional 5 mL of buffer A was injected to wash unbound proteins form the 
column.  Next, 8 mL of buffer B (20 mM sodium phosphate, 0.5 M imidazole, 0.5 M 
NaCl, pH 7.4) was used to elute the 6xHis tagged Ubch5b and ubiquitinated 
conjugates.  The 6xHis tag on Ubch5b does not contain a cleavage site, however the 
6xHis tag on human E1 does.  Given the molecular weight difference between the E1 
(~110 kDa) and Ubch5b conjugates (less than 50 kDa) I found it unnecessary to 
remove the 6xHis tag from E1 since this issue could easily be resolved with a size 
exclusion step.  Once the Ubch5b conjugates were eluted from the 1 mL His-Trap 
column they were exchanged into PBS, pH 7.4 and DTT was added to a concentration 
of 50 mM.  The DTT mixture was incubated at 30°C for 2 hours and exchanged back 
into PBS pH7.4 as it was concentrated in a 10,000 kDa MWCO centrifugal unit for 
size exclusion.  Unligated Ubch5b was separated from other forms modified with 
varying amounts of Ub on a superdex 75 120 mL size exclusion column with a flow 
rate of 0.3 mL/min in PBS pH 7.4 buffer.  Fractions were checked using 15% SDS-
PAGE gels and desired fractions were concentrated and stored at -20°C for later use. 
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3.3 Standard biochemical assays 
3.3.1 DUB digests and analysis 
Digests of polyUb conjugates with DUBs was carried out in PBS pH7.4 
buffer.  After several controls studies, I found it unnecessary to use a reducing agent 
for any DUB, even the cysteine proteases as their activity is largely dependent on pH 
(185).  The digest reactions were kept simple only containing the DUB, polyUb 
conjugate, and PBS pH 7.4 buffer in a total volume of 50 µL incubated in a 30oC 
water bath.  The concentration of the polyUb to be digested was kept at 25-50 µM 
and the concentration of the DUBs were as follows: OTUB1 500 nm, AMSH, 1 µM, 
Ubp6 5-10 µM, Rpn11 10 µM. Note for some assays, these concentrations changed, 
but this was found to be an ideal working concentration for each DUB.   4µL samples 
for each time point were taken over the digest a stored in 4µL of 4x SDS sample 
buffer at -20oC.  The samples were run on 15% SDS-PAGE gels, stained with 
Coomassie brilliant blue, photographed, and also scanned on densitometer.  Gel bands 
from images were analyzed with ImageJ software and Adobe Photoshop, then plotted 
against time (186).  Sections of the actual gels containing the polyUb bands are 
typically displayed next to these plots to provide a different perspective.                 
3.3.2 F45W tryptophan emission titrations 
The buffer system for these fluorescence experiments was modular and could 
accommodate a variety of different buffers.  To allow for direct comparison to NMR 
measurements, the NMR buffer (20 mM sodium phosphate pH 6.8) was used.  A 
concentration of 50 µM F45W Ub was selected since it was above the reported Kd  
for many ligands tested and it also allowed for a robust emission signal from 
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tryptophan.  Spectra were acquired by excitation at 280 nm with 5 nm slit widths, 
over an emission range spanning 300 to 600 nm in 0.5 nm increments. For each point 
in titration three spectra were collected and averaged.  The averaged spectra were 
used for analysis and the emission maximum was used for fitting.  
 
3.3.3 F45W-AEDANS FRET assays  
For K48-Ub2 chains used for FRET assays consisted of F45W on a proximal 
Ub serving as a FRET donor for 5-((((2-iodoacetyl)amino)ethyl)amino)naphthalene-
1-sulfonic acid (IAEDANS) located on T12C of a distal Ub, this construct is formally 
named Ub(T12CAEDANS) –48Ub(F45W).  Note since the iodine leaves upon 
attachment, IAEDANS is commonly referred to as AEDANS throughout.  To create 
the di-Ub, Ub-74/F45W, or Ub-D77/F45W was enzymatically reacted with Ub-T12C.  
The K48 dimer was purified as described above and exchanged into the desired 
phosphate buffer with TCEP kept in a fivefold molar excess of T12C.  Labeling with 
IAEDANS was performed on 200 µM of K48-Ub2 in a 30oC water bath for 3 hours in 
the presence of 1.2 mM IAEDANS and 600 µM TCEP.  Excess IAEDANS was 
buffer exchanged out and the K48-Ub2 was run through the size exclusion column to 
ensure no residual IAEDANS was present.  All ANS steps were performed in the 
dark or properly wrapped in foil to preserve the lifetime of the fluorophore.  Once 
created Ub(T12CAEDANS) –48Ub(F45W) was tested for a characteristic AEDANS 
FRET emission signal at 485 nm using an excitation at 285 nm.  After the expected 
FRET signals were observed, 50 µM Ub(T12CAEDANS) –48Ub(F45W)  was titrated 
with UBA(2) from hHR23A.  The spectra were acquired as described above, with 
excitation at 285 nm and monitoring every 0.5 nm in the emission spectra range 300-
65 
 
700 nm.  The average of three spectra for each point was taken for analysis and the 
emission maxima for the tryptophan and AEDANS were used.                
 
3.4 Solution NMR studies 
3.4.1 Sample preparation for solution NMR  
Isotope enriched protein samples for NMR were transferred to NMR buffer 
(20 mM sodium phosphate, pH 6.8) for traditional solution NMR studies, PBS pH 7.4 
for select DUB assays, or acidic buffer (20 mM sodium acetate, pH 4.5) for low pH 
studies.  All samples contained 5% D2O for a reliable lock signal and for titration 
experiments in which the sample was diluted from the addition of ligand, extra D2O 
was added to compensate for this effect.  All samples were measured in standard 5 
mm NMR tubes with sample volumes of 450 µL or 5 mm Shigemi tubes with sample 
volumes of 250 µL.  With the exception of the experiments for DUB kinetics carried 
out at 303.0 K, all other experiments were acquired at 298 K.       
3.4.2 Chemical shift perturbation (CSP) mapping and titration analysis   
 
Differences between signals in 1H-15N NMR spectra for two species (A and B) 
were quantified as chemical shift perturbations, defined as follows:  
 
CSP = [(δHA – δHB)2 + ((δNA – δNB)/5)2]1/2          (1) 
 
where δH and δN are chemical shifts of 1H and 15N, respectively, for a given backbone 
N-H group. The scaling factor of 5 for 15N of is commonly accepted and adopted 
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from (187).  An in-house MATLAB based software package PICK was used to 
ensure the maximum intensity for each 2D peak was properly picked.  For titration 
analysis the same equation was used to quantify spectral perturbations upon titration; 
in this case, A refers to the unbound species, and B corresponds to spectra from 
subsequent points in the titration.  Titrations were performed until there were no 
detectable shifts in 1H,15N-HSQC.  For cases of tight (sub µM Kd) binding i.e. slow 
off rates that resulted in signal attenuation, the effect was noted and residues 
exhibiting this behavior had to be excluded from CSP analysis due to signal loss.    
 To determine the Kd for 1:1 binding of a ligand to a protein (the 15N enriched 
species) Eq. 2 was used to fit residue specific CSPs.  
 
𝑝! =
!! ! !! !  !!  !   !! ! !! !!! !!! !! !!
! !!
   (2) 
 
Where 𝑝!  is the population of bound protein, 𝑃!  represents the total concentration 
of protein, 𝐿!  is the total concentration of ligand, and 𝐾!is the variable to be fit.  
The CSP titration data were fit using an in-house MATLAB software package, 
KDFIT.  The trajectories of each peak were also plotted using the same software 
package to ensure they were linear.  To describe a protein with two equivalent 
binding sites and a ligand that can only occupy one at a time, Eq. 3 was used.     
𝑝! =
!! ! !! !  
!










In the case where a protein presents two independent, but equivalent binding sites Eq. 
4 was used to fit the data. 
𝑝! =






  (4) 
 
After determining the residue specific Kd values, the overall Kd reported was obtained 
by averaging residue specific Kd values that showed an excellent agreement to the 
binding model.  Eq.2-4 are taken from (153); these equations are incorporated into 
MATLAB program KDFIT (Prof. Fushman).      
 
3.4.3 15N relaxation rates    
15N longitudinal relaxation rates (T1) were used to measure the overall size of 
polyUb chains and Ub/ligand complexes.  Experiments were run in the pseudo 3D 
format as a series of 2D 1H,15N-HSQC planes with only two delays (short and long) 
repeated in multiple 2D planes for each delay.  Relaxation data was analyzed with in-
house software, ROTDIF.  The development of this software is described in (188).  
Following peak picking and integration of noise, the T1 for each residue was fit using 
the RELAXFIT module set for a single exponential decay, two parameter fit.  The 
RELAXFIT module was also used to determine the error in each T1 measurement, 
which was mainly dictated by the noise in each spectrum, see (188).    
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3.4.4 Translational diffusion measurements   
Diffusion ordered spectroscopy (DOSY) experiments were acquired in a 
pseudo 2D format as a series of 1D increments that differed by the strength of the 
gradient applied.  To distinguish between signals from 15N labeled Ub and those of 
the unlabeled ligands, a 15N inept filter was used to suppress Ub signals in the amide 
region (7-10 ppm).  The data for each point was fit using the in-house TRANSDIF 
module.          
3.4.5 Site specific paramagnetic spin labeling and analysis   
Ub cysteine mutants were labeled with MTSL (S-(2,2,5,5-tetramethyl-2,5-dihydro-
1H-pyrrol-3-yl)methyl methanesulfonothioate) at several different positions (T12C, 
I36C, K48C, and K63C).  Purified Ub cysteine mutants were exchanged into NMR 
buffer (20 mM phosphate pH 6.8) containing no reducing agent.  A threefold molar 
excess of MTSL was added and allowed to incubate with Ub for 12 hours at ambient 
temperature.  The excess MTSL was removed by buffer exchanging three times into 
NMR buffer.  MTSL Oxidized NMR spectra were recorded as 1H,15N-HSQC and 1D 
1H-NOESY with 15N filtering.  After allowing the NMR sample to incubate with a 
threefold molar excess of sodium ascorbate (added form a stock solution, 140 mM, 
pH 7.0) for one hour, the reduced spectra were acquired using settings identical to the 
oxidized spectra.  All NMR experiments were run with a high number of scans to 
provide for more reliable downstream analysis.  The exact position of the 
paramagnetic center in MTSL was fit from the intensities between the oxidized and 
reduced 1H,15N-HSQC spectra using SLFIT, an in-house MATLAB package.  PDB-
1D3Z was taken as the reference structure for Ub.   Once the position of the 
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paramagnetic center was determined, the distance to individual protons on the 
ubistatin observable 1D 1H-NOESY spectra was calculated.  The peak intensities and 
input parameters for SLFIT were generated in Bruker Topspin.  An unpaired election 
in the nitroxide group of MTSL represents the paramagnetic center.  When NMR 
active nuclei are in close proximity to this center, there is a distance dependent effect 
on their transverse (T2) relaxation rates, which results in a decrease of signal 
intensity.  This paramagnetic relaxation enhancement (PRE) effect for a spin S is 
described by Eq. 5. 
 
 ∆𝑅!!"#"   = 𝐾 4𝜏! + 3  
!!
!!!!!!!!
       ∕ 𝑟!                 (5) 
 
Where ∆𝑅!!"#"  is the effect on T2 relaxation of a 1H nucleus, 𝑟 is the distance to the 
paramagnetic center, 𝜏! is the T2 rotational correlation time, and K= 
!
!"
S(S+1)γH2βe2ge2 (γ is the gyromagnetic ratio of 1H, βe	  is the Bohr magneton, and	  ge 
is the electron g-factor).	  	  Between the oxidized and reduced states of MTSL Eq. 6 
applies, and Eq. 5 allows the distance between the paramagnetic center and each 
nucleus to be determined using the SLFIT software package.  For practical reasons 
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In Eq. 6 Iox and Ired are the intensities of either 1D or 2D peaks in the oxidized or 
reduced form of MTSL.  Note that oxidized is the paramagnetic state of MTSL, while 
the reduced state is diamagnetic: in this state MTSL does not have any paramagnetic 
effect on signal intensity.  tH represents the time that magnetization is on 1H during 
the INEPT elements of the NMR experiment.    
3.4.6 Detection of intermolecular NOEs in protein/small molecule complexes  
Intermolecular NOEs between Ub and ubistatins were detected using double 
labeled 13C/15N-Ub1 in a series of 3D TOCSY and NOESY experiments.  Assignment 
of Ub and the ubistatin in the bound state was critical.  The 1H,15N-HSQC spectra 
served as a starting point for assignment of residues in Ub.  3D 1H-CCCONH 
TOCSY and 2D 13C,1H-HSQC were used to assign the chemical shifts for residues in 
the bound state of Ub.  Intermolecular NOEs between Ub and ubistatins were 
detected in 2D NOESY experiments with 15N filtering and also with a 3D NOESY 
(Bruker hsqcgpnowgx33d) with 1H and 13C INEPT transfer that shows NOEs 
between 1H’s in the ubistatin and both 1H’s and 13C’s in Ub  (189).  Using the 
chemical shifts for the bound state, NOEs were assigned between individual 1H’s in 
the ubistatin and 1H/13C groups in Ub.  Intensities for these NOEs were integrated 
from the 2D NOESY-inept spectrum and converted into distance using Eq. 7.  For 
calibration purposes, known distances from intramolecular NOEs were used for 
determining the constant A in Eq. 7.  If an NOE was between a methyl group which 
contained three indistinguishable protons, this was accounted for in the calculation. 
𝑣𝑜𝑙𝑢𝑚𝑒 =    !
!!
                        (7) 
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3.4.7 DUB kinetics by 1H,15N-HSQC  
The kinetics of cleavage in 15N-Ub conjugates was determined using 
sequential series of identical sofast 1H,15N-HSQC experiments covering a broad time 
range.  Each experiment was run as a normal 1H,15N- HSQC with 128 15N points and 
16 scans.  Time was carefully monitored manually and critical points such as when 
the DUB was added, when the first experiment was started, and when the last 
experiment finished were recorded.  The intensity corresponding to the free G76 
signal was picked in each experiment and any other peaks relevant to the linkage such 
as the peak corresponding to the ligated G76 were also used if available.  Given the 
amount of resources needed for such experiments, it was difficult to assess multiple 
samples under varying amounts of DUB or polyUb concentrations.  This led me to fit 
the apparent rates of cleavage as opposed traditional steady state parameters.  Using a 
modified version of RELAXFIT, the intensity of free G76 was fit to the single 
exponential decay model to determine the apparent rate of cleavage.           
 
3.5 Modeling and structural calculation with HADDOCK v2.1  
Out of the many commercial and open source biomolecular docking programs 
available Prof. A.M.J.J. Bonvin’s (Utrecht University) HADDOCK (High Ambiguity 
Driven biomolecular DOCKing) was chosen (190).  Unlike other docking programs 
HADDOCK allows accurate docking with CSPs (see section 4.3), as well as other 
ambiguous restraints.  The software has also been constantly developed for over a 
decade and used for solving many complexes of biomolecules. In fact, K48-Ub2 was 
used as a test system in the past for design of the optimal strategy for incorporation of 
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CSPs together with residual dipolar couplings in HADDOCK (191).  In addition 
HADDOCK has also gained high scores in CAPRI (192) and its incorporation of 
CNS (193) is fine tuned for proteins and nucleic acids.  With the proper use of custom 
CNS files HADDOCK is also ideal for small molecule-biomolecule docking (194).     
3.5.1 Modeling of complex polyUb chains 
Models for theoretical complex (mixed linkage) triUbs were generated on the 
HADDOCK web server (195).  All Ub units were from PDB-1D3Z and the 
unambiguous distance restraints creating the isopeptide bond between the Ubs were 
adopted from Prof. Walker’s study (173).  The coefficients for the distance energy 
penalty were Edist=0.02, Edist=0.4, Edist=0.7 for rigid body energy minimization, 
simulated annealing, and solvent refinement in water, respectively.  Residues 72-76 
were defined as fully flexible for all Ubs.  As an ambiguous restraint, the L8, I44,V70 
hydrophobic patch residues were defined as active which allowed each Ub to explore 
many potential interactions with the other two Ubs.  For each theoretical tri-Ub chain 
3,000 structures were generated for rigid body docking, 300 structures were taken for 
simulated annealing, and 300 structures were take for refinement and analysis in 
water.  The CNS topology and parameter files along with the other energy settings 
were optimized for proteins by default and left unchanged.  Cluster analysis was 
performed by the HADDOCK web server with a RMSD cut off of 7.5 Å and 
minimum cluster size of 10 structures.  Clusters were sorted by HADDOCK score 
which is a summation of many energy parameters.  The clusters were then analyzed 
in PyMol to define distinct conformations (see section 4.3.2).           
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3.5.2 Ubistatin/Ub structure calculation 
PDB-1D3Z was used to model the c112/Ub complex.  The HADDOCK web 
server only has CNS topology and parameter files available for proteins and nucleic 
acids.  In order to run HADDOCK with small molecule ligands (i.e. ubistatins), 
custom CNS topology and parameter files were created for each molecule using the 
Dundee PRODRG2 server (196).  Since the web server could not accept these custom 
files, calculations were run on a local 64 node Intel based cluster.  To guide the 
docking residues I44, V70, and H68 were defined as active for the AIR restraints.  
The distances determined from intermolecular NOEs and paramagnetic relaxation 
enhancement with MTSL were used as unambiguous restraints.  Docking was run 
with the custom CNS files for the ubistatin, the temperature for the early rigid body 
docking steps was increased to 3000 K, and the number of MD steps was reduced to 
0.  3,000 structures were generated during rigid body docking, 300 structures were 
taken for simulated annealing, and 300 structures were take for refinement and 
analysis in water.  Clusters were very tight and showed little deviation.  The output 
was checked extensively for any distance violations.  To ensure our structure 
conformed to the real experimental distances the penalty for the unambiguous 
distance restraint (Edist) was increased for each step.  Many runs were performed 
varying the Edist penalties and also excluding certain distances.  After numerous runs a 
consensus was reached and a single cluster was chosen as the structure of the 
c112/Ub1 complex.  A similar approach lacking extensive experimental data was used 
to model other ubistatin/Ub complexes.                    
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Chapter 4:  Laying the foundation for structural studies of 
complex polyubiquitin chains  
 
4.1 Background and research aims 
 Since the discovery of Ub it was typically assumed that once formed a polyUb 
chain would retain a high degree of linkage homogeneity (13).  However, more recent 
studies found numerous examples where the polyUb chains exhibit linkage 
heterogeneity to accomplish specific tasks in the cell (164).  In addition, studies on 
isolated E2/E3 enzymes and model substrates have also demonstrated that 
heterogeneous polyUb chains are routinely formed (20, 26, 28).  Although intriguing 
it is almost impossible to gauge the extent that heterogeneous polyUb chains are 
present in the cell since they are virtually undetectable with current methods and the 
polyUb chain itself is constantly being remodeled (144).  Nevertheless, when 
heterogeneous polyUb chains are formed they could potentially provide for novel 
signaling outcomes based on the unique three-dimensional conformations they could 
present for receptors. 
 In 2009 we introduced the term “complex polyUb chains” to describe any 
polyUb chain with linkage heterogeneity.  To limit confusion it is important to 
understand that heterogeneous, mixed linkage, and complex are all synonyms and 
used interchangeably to refer to polyUb chains containing more than one type of Ub-
Ub linkage.  To clearly communicate my findings a formal nomenclature system with 
standardized terms had to be devised in order to report on this new frontier.  Our 
original nomenclature system was adequate for specific cases, however after careful 
evaluation we ultimately would settle on the Cohen-Nakasone-Fushman convention 
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for complex chains, which preserved the same principals from our original system, 
but employed different symbols.    The objective of this study is rather 
straightforward: determine if linkage branching or mixing in the same polyUb chain 
results in new conformations and signaling properties.  However, the different 
polyUb chains that must be explored are nearly infinite.  Often it is assumed that there 
are just eight polyUb signals resulting from the different linkages (K6, K11, K27, 
K29, K33, K48, K63, and M1).  This assumption has led the field to study individual 
homogeneous linkage types without considering complex chains.  To illustrate 
exactly what the field is missing by myopically studying homogeneous chains and 
discounting complex chains, allow for just three Ubs and only two Ub-Ub linkages. 
When complex chains are allowed there are now 92 unique polyUb signals of which 
only 8 are homogeneous, and exponentially more depending on the number of Ubs 
introduced (Figure 4.1).  In fact, my initial plunge into this concept identified 
23,190,029,720 complex polyUb chains with just 10 Ubs and the possibility for many 
more depending on the number of linkages and Ubs allowed.  I stopped naming 
complex polyUb chains after sixteen Ubs since that number is generally accepted as 
the most Ubs found in a polyUb chain from living cells and naming 8.26 x 1017 
chains is computationally restrictive (197).  Although not clearly stated in the 
literature, when complex polyUb chains are accounted for, Ub becomes one of the 
most sophisticated naturally occurring biopolymers.  In this chapter I will use 
molecular modeling to explore the possibility that linkage branching or mixing in the 
same polyUb chain will create new signals.  Then I present my findings on the 




Figure 4.1 – All possible chains from three Ubs and two linkages.  
If we account for all possible linkages (7 lysines and M1) between three Ubs we get 
92 distinct tri-Ub chains, of which only 8 are homogeneous-linkage chains (A) and 
the rest are mixed-linkage chains. Of the 84 mixed-linkage tri-Ub chains, 28 are 
branched (B) and 56 are unbranched chains (C).  In the schematic representations on 
the right, i and j indicate the two linkages in tri-Ub: i = j for homogeneous-linkage 
chains, and i ≠ j for mixed-linkage chains.  The order of the linkages (i and j) is 
important for the unbranched mixed-linkage chains (C), where i & j  ≠  j & i.  If we 
continue adding Ubs we find that with eight possible linkage sites per Ub, the total 
number of possible distinct chains is 1,240 for tetra-Ub, 18,276 for penta-Ub, 285,384 




4.2 A historical perspective: Original Nomenclature  
4.2.1 Describing the topology of the chain: Linear, mixed, branched 
By default homogeneously linked polyUb chains have a linear topology where 
each Ub is linked to another Ub through the same bond with no mixing or branching.  
Mixed linkage chains also have linear topologies provided that each Ub in the chain 
has one and only one linkage site (K6, K11, K27, K29, K33, K48, K63, or M1) per 
individual Ub in the chain.  Branched chains arise from more than one linkage site on 
any individual Ub in the chain.  The term “forked” was introduced by Alfred 
Goldberg to describe branched chains where the Ub-Ub linkages occur at adjacent 
positions on a Ub e.g. K6&K11, K27&K29 or K29&K33 (20), however these forked 
chains still fall under the definition of branched.  In practice mixed- and branched-
linkage chains are different sub-groups of complex chains and great care should be 
taken to report as specifically as possible to limit confusion.   For shorthand I 
designate linear-mixed linkages chains with (L) and branched chains with (B).     
4.2.2 Pinpointing an individual Ub in a complex chain 
Communicating the interactions of individual Ubs in a given polyUb chain is 
critical for understanding cellular processes.  For example explaining a 
polyUb/protein complex or how polyUb is cleaved by a DUB requires that the exact 
position of an individual Ub in a chain is clearly identifiable.  Traditionally chains 
studied have been very simple, often dimers, and an individual Ub could be referred 
to as “distal” or proximal” in the case of a dimer.  These terms were popularized by 
the late Prof. C.M Pickart to describe the Ub unit closest to the substrate (proximal) 
and the furthest Ub (distal).  For di-Ubs distal and proximal can be used 
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unambiguously to referrer to the specific Ub, however for longer chains we must 
introduce other terms.  If the chain is of linear topology, regardless if it is 
homogeneous or mixed-linkage, the proximal Ub is still the proximal Ub, the 
terminating Ub remains the distal Ub, and any Ubs between connecting the two are 
sequentially referred to as “endo-X” where X indicates the Ub counting from the 
proximal Ub.  For example, say we have two hexameric Ub chains (Ub6), one all 
K63-linked and another with five different linkages (K6, K11, K27, K29, and K33 in 
order from the proximal Ub) (Figure 4.2).  Given that the two chains are linear we 
can describe the domains as follows; proximal, endo-1, endo-2, endo-3, endo-4, and 
distal.  The chains would be named K63-Ub6 and (L)-[K6-K11-K27-K29-K33]-Ub6 
respectively.  If we reverse the order of linkages in (L)-[K6-K11-K27-K29-K33]-Ub6 
the name changes since the chain is named according to the order of linkages starting 
from the proximal end (Figure 4.2).  In this original nomenclature system all chains 
have the format “(A)-[B1-B2…-Bn]-Ubx.”  The first part “(A)” refers to any special 
topology the chain may have, if it is purely homogeneous this entry is left blank and 
if it is a linear-mixed linkage or branched the section will have “(L)” or “(B),” 
respectively.  The next portion of the name “[B1-B2…-Bn] indicates the linkages 
present in the chain written as they appear from the proximal Ub.  If a branched chain 
is being described the linkages are written with the lowest residue number first e.g. 
[M1K11K48]-Ub4 not [K48M1K11]-Ub4.  The last part of the chain name “Ubx” 






Figure 4.2 – Nomenclature in practice for hexa-polyUb chains.   
(A) homogeneous Ub6 linked exclusively through K63 is simply termed K63-Ub6, 
while the other linear-mixed linkage chains are named according to the order of their 
linkages from the proximal Ub (B) (L)-[K6K11K27K29K33]-Ub6 and  
(L)-[K33K29K27K11K6]-Ub6 (C).  The proximal Ub initiates the chain, while the 
distal Ub terminates the chain and anything in between is termed “endo-X”, where X 





4.2.3 Dimensions of complexity   
The signaling possibility of complex polyUb chains is mainly due to the ability of one 
Ub to contain multiple linkages.  For homogenous chains each Ub can create a 
linkage with its C-terminus and through one of eight linkage sites, while the simple 
complex polyUb chains (e.g. (B)-[K48K63]-Ub3) use only two of the eight sites.  The 
real intricacy in the polyUb signal arises when complex chains contain multiple 
linkages on a single Ub.  Experientially, I have shown that a single Ub can be ligated 
with five other Ubs using different combinations of linkage specific E2s.  My results 
from in silico modeling clearly show that eight Ubs can be ligated to a single Ub 
without any steric conflicts and there is even room for the C-terminus to be ligated to 
a ninth Ub (Figure 4.3).   
 
Figure 4.3 – Molecular modeling of an 8D branched Ub9.  
The HADDOCK v2.1 generated model suggests that eight Ubs can easily be attached 
to all eight linkage sites on a single Ub (green).  The distal “D” Ubs are colored as 
followed; M1 Ub D1 (yellow), K6 Ub D6 (magenta), K11 Ub D11 (orange), K27 Ub 
D27 (cyan), K29 Ub D29 (rust), K33 Ub D33 (gray), K48 Ub D48 (red), and K63 Ub 
D63 (blue).  The chain represented, (B)-[M1K6K11K27K29K33K48K63]-Ub9 has 




Given that the attachment of a single Ub can potentially serve as an anchor for any 
other linkage we refer to this as adding a dimension such that every Ub added to a 
given Ub accounts for a single dimension.  For example homogeneous chains are all 
1D as well as linear-mixed linkage chains, while a branched chain with two Ubs 
attached to K48 and K63 on single Ub is a 2D chain and eight Ubs attached to a 
single Ub in a chain results in an 8D chain.  Not every Ub in the chain may be 
branched equally, some will contain more linkages while others have less.  To 
determine the dimension of complexity for a chain we simply take the highest 
dimension for any part of the chain.  For example, if the 8D (B)-
[M1K6K11K27K29K33K48K63]-Ub9 chain had one of its distal Ubs modified with a 
K11+K6 branch, one part of the chain would be 8D while another part is only 2D, 
however the chain as a whole would be 8D since that represents the most dimensions 
of complexity.     
 
4.3 The standardized Cohen-Nakasone-Fushman nomenclature system for complex 
polyUb chains 
4.3.1 The new standard in poly Ub chain nomenclature   
 After extensive consideration we revised the nomenclature system in the 
previous section 4.2 to be more intuitive and easier to conceptualize.  The (B) and (L) 
designations are abandoned and we have switched to a schematic system, which 
allows readers to visualize the Ub chains from just their printed names.  This system 
also can accurately describe heterotypic (also called heterologous) chains that contain 
both Ub and UBL molecules.  We formally introduced this system in 2013 to the 
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scientific community as the Cohen-Nakasone-Fushman nomenclature system for 
complex polyUb chains.  
4.3.2 Guidelines   
 The common abbreviations, Ub and UBLs (e.g. SUMO2, Nedd8) designate 
that specific protein.  Point mutations or other special modifications on these proteins 
can be noted within parenthesis (e.g. the K63R mutant of Ub is written as Ub(K63R),  
Ub(K0) for all lysine residues mutated to arginine, if a particular Ub is 15N-labeled 
enriched Ub(15N)). This can be expanded to Ub or UBL modified substrates and their 
modifications can be noted in the chain also using their common abbreviation.  In the 
formal name the distal Ub unit within a polyUb chain is written to the left, whereas 
the proximal Ub (or the substrate if present) is to the right.  Accordingly, internal 
"endo" Ub units are listed from left to right transitioning from the distal to proximal 
direction.  The Ub-Ub, Ub-UBL, or UBL-UBL linkage is represented with an en dash 
(–). Specific linkage sites of the distal component at each linkage are indicated as 
superscripts.  If there is a traditional isopeptide linkage to a lysine ε-amine, a residue 
number is sufficient, however this notation can include any amino acid type or side 
chain atom.   
 For two simple dimers, one containing a single K63 linkage is written as Ub–
63Ub, another dimer linked “head-to-tail” through M1 would be Ub–M1Ub, and the 
substrate p53 with mono Ub attached to lysine 101 is represented as Ub–101p53. 
Uncertainties in linkage length and multiple sites of modification can be 
accommodated as well.  If the p53 now becomes modified with K48 linked polyUb at 
two sites K101 and K124, but the chain length is uncertain it would be named Ub(–
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48Ub)n–101/124p53 to indicate K48 linked polyUb of undetermined length (n) attached 
to K101 orK124 of p53.  If the site of modification is unknown, the superscripts can 
be omitted from the substrate.  The notation for polyUb (also polyUBL) chains 
comprised of identical monomers and one linkage type can employ parentheses to 
indicate repeated units. Thus, the K63-Ub6 example from the previous section is 
(Ub)5–63Ub and a mixture of polymers 3 ≤ n ≤ 10 of Nedd8 is described as  
Nedd8(–48Nedd8)1–8–48Nedd8. 
 Mixed linkage (complex) chains containing more than one type of Ub-Ub or 
UBL-UBL linkage, are specified with the appropriate superscripts to indicate linkage.  
For a linear mixed-linkage chain with a distal Ub linked to K11 of a middle (endo-1) 
Ub that in turn is linked to K27 of a proximal Ub the proper name would be, Ub–
11Ub–27Ub.  Heterotypic Ub-UBL chains can be written following the pattern above, a 
K48 linked di-Ub attached to K11 of SUMO2 would be Ub–48Ub–11SUMO2. 
  For branched chains containing more than one linkage per unit the point of 
the branch is highlighted by the use of brackets (brackets = branching). Ub[Ub]–
6,48Ub or [Ub]2–6,48Ub indicates two distal Ub units linked to K6 and K48 of a 
proximal Ub which now has two superscript indicating linkage sites. Different 
extensions of branches are assigned according to the order that they are written e.g., 
[Ub–29Ub][Ub]–29,63Ub is tetra-Ub in which the proximal Ub of K29 linked trimer is 
also modified with mono Ub at K63.  After implementing these nomenclature rules in 
a simple in-house program, the names for all 92 possible chains with three Ubs and 





Table 4.1 – Cohen-Nakasone-Fushman nomenclature system applied to mixed 
linkage Ub trimers.  
The formal names for the 92 possible Ub trimers discussed in section 4.2 are written 
in full.  Note the brackets for branched trimers and how the order of linkages going 






 It is possible to cyclize a chain using the K48 linkage and this may also be 
possible with other UBLs.  A cyclized chain is represented with an unattached en 
dash on the left and right, representing its circular conformation with no beginning or 
end.  To indicate the number of the Ub units in the chain a subscript can be written 
outside of the parenthesis of the units with the Ub or the UBL name.   (–48Ub–)3 and 
(–48Ub–48Ub–48Ub–) would both indicated a cyclized K48 linked Ub trimer.  If the 
similar UBL, Need8 cyclized it would be (–48Nedd8–)3.       
     
4.3 Theoretical structural outcomes of branched and unbranched mixed linkage 
chains 
 Only three of the ninety-two complex tri-Ub chains identified in (Figure 4.1) 
have been addressed experimentally, while the remaining have yet to be synthesized.  
The tedious work involved with assembling the chains, their sheer numbers, and also 
the time needed for data collection and analysis combine to make the study of 
complex chains prohibitive.  However, given that we know which surfaces Ub uses to 
form interdomain contacts, several in silico approaches have been used to predict the 
possible three dimensional conformations of polyUb chains (173).  Using the same in 
silico approach I analyzed the remaining complex trimeric Ub’s to explore which 
structural ensembles were possible.  
4.3.1 Validity polyUb models from in silico docking software  
Regardless of whether a chain is complex or simply homogeneous, the 
structural ensembles a chain can adopt are greatly dependent on the ability of 
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individual Ubs in the chain to interact with other Ubs.  This type of interaction is 
mainly achieved by hydrophobic contact between different Ubs in the chain via two 
solvent exposed hydrophobic patches, the well known L8, I44, V70 patch (for K48 
linkages) or another created by L8, I36, L71, L73 that creates the interface between 
K6 linkages (Figure 4.4).  As show in (Figure 4.4) there are other important solvent 
exposed regions on Ub, however the L8, I44, I70 and L8, I36, L71, L73 hydrophobic 
patches are the only ones that have been observed to create interdomain interactions 





Figure 4.4 – Important surfaces on Ub. 
Ub has several solvent exposed patches which are important for interactions with both 
UBDs and maintaining the proper conformation of polyUb chains through 
interdomain contacts.  Surface representation (top) and cartoon representation 
(bottom).     
 
    
Given the existing knowledge of how Ubs interact within the same chain, one 
can use molecular modeling to determine if certain interactions are possible.  
HADDOCK v2.1 is tailored for biomolecules and can properly maintain critical 
properties of proteins such as backbone torsion angles (ω, Φ, and ψ) while allowing 
for multiple domains to sample different conformations, which are governed by user-
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defined parameters (173).  In the case of two or more Ubs, the resulting structures 
will reflect a majority of the possible conformations for a given chain.  Using just the 
L8, I44,V70 hydrophobic patch with no other restraints, HADDOCK can accurately 
predict the structure of K48-Ub2 with a Cα RMSD=1.72Å (Figure 4.5).  With this 
approach I determined which structural conformations were possible in complex 
polyUb chains and formulate several new theories on the signaling properties of these 
unique chains.    
 
Figure 4.5 – HADDOCK accurately predicts the K48 interface from minimal 
input. 
The HADDOCK generated K48-Ub2 (proximal=green and distal=red) results in a 
structure nearly identical to the X-ray derived PDB-1AAR (gray).  The key interface 
between the L8,I44,V70 hydrophobic patches is shown as yellow spheres.  Restraints 







4.3.2 Structural ensembles from linkage branching  
 With branched linkages it is possible that interactions between distal domains 
could form an entirely novel Ub signal, which would not be possible with 
homogeneously linked chains.  To determine which branched Ub trimers could create 
this type of interaction, I modeled all twenty-eight of them using HADDOCK v2.1 
following an established protocol which creates Ub-Ub linkages and simulates all 
possible interdomain interactions (173).  The actual structures calculated for each run 
varied greatly, however based on generalized observations a conformation for a 
branched chain can be classified in one of four sub groups: (i) “free form” with no 
inter domain interactions, (ii) “distal hug” where branching causes the two distal Ubs 
to form an interaction, (iii) “clump” where all Ubs appear to interact, and (iv) “classic 
interface” that is defined by a K6 or K48 linkage retaining the same interface it would 
in a homogeneously linked chain.  For a visual representation of each possible 













Figure 4.6 – Representation of possible outcomes from linkage branching with 
tri-Ub chains 
The four possible outcomes were assigned to each cluster after analysis of 
HADDOCK output with every possible branched tri-Ub.  (A) Depicts the “free form” 
in which no Ub has any interdomain contacts, [Ub]2–27,63Ub.  (B)  The novel “distal 
hug” is represented by [Ub]2–11,33Ub where the D11(orange) and D33 (gray) Ubs 
create a hydrophobic contact.  (C) [Ub]2–6,33Ub exemplifies a “clump” where all 
hydrophobic patches from each Ub interact.  (D)  The “classic interface” is retained in 
[Ub]2–27,48Ub where D48 (red) interacts with the proximal Ub (green) using the same 
mechanism as the homogeneous chain, while the D27 Ub is excluded and not 
disruptive to the K48 signal.         
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4.3.3 Theoretical outcomes of linkage branching with Ub trimers 
After analyzing the lowest energy clusters from HADDOCK, it was apparent 
that the theoretical structures did indeed represent all four possibilities that could 
result from linkage branching.  Of particular interest were the distal hugs, which are 
the most likely to present new signals for receptors since the moiety formed by the 
distal Ubs can only result from linkage mixing.  Perhaps even more interesting was 
the fact that linkages such as K27 and K63, which do not form any interdomain 
contacts in homogeneous chains, were able to create distal hugs in several branched 
chains.  It is important to note that many of the tri-Ubs predicted to form distal hugs 
had varying degrees of hydrophobic interaction (buried surface area) and different 
interfaces even though they were classified in the same group.  Several examples of 
distal hugs are depicted (Figure 4.7).  Analysis of all clusters suggests that distal hugs 
could be more prevalent than thought.  An interesting possibility is that linkages that 
do not promote interdomain contacts (e.g. K63) appear to promote distal hugs, 
suggesting that extended polyUb conformations may be susceptible to these 
interactions.  This implies that although a homogenous chain is extended, once it is 
branched, new signals would arise from the distal hug interaction.  This theory needs 
to be tested more extensively, but if true it would add much more versatility to Ub 








Figure 4.7 – Theoretical models of the distal hug conformation 
(A-I) Nine, selected models from clusters classified as distal hugs.  The proximal Ub 
(green) is free from interactions with the distal Ubs (colored by linkage).  Formal 
names are listed below and the L8,I44,V70 hydrophobic patch is shown as yellow 
spheres.        
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4.3.4 A failed prediction [Ub]2–11,63Ub  
Simulating the conformations of branched trimers is relatively straight 
forward, but proving these conformations is both difficult and time consuming.  The 
K63 linkage is the easiest to test with our solution NMR methods.  The fact that the 
distal Ub in K63-Ub2 does not experience any interdomain contacts makes the linkage 
an ideal candidate to search for distal hugs.  If a distal hug is formed in a branched 
trimer, the distal K63 Ub will show a characteristic pattern in 1H,15N-HSQC, resulting 
from the new interdomain interactions in the conformation.  Therefore, as an initial 
search synthesizing any 2D branched trimers with the distal 63 Ub 15N labeled would 
provide an easy means for determining if a distal hug can be formed.  The following 
unique branched trimers were candidates for investigation: Ub[Ub(15N)]–1,63Ub, 
Ub[Ub(15N)]–6,63Ub, Ub[Ub(15N)]–11,63Ub, Ub[Ub(15N)]–27,63Ub, Ub[Ub(15N)]–
29,63Ub, Ub[Ub(15N)]–33,63Ub, and Ub[Ub(15N)]–48,63Ub.  Given that [Ub]2–11,63Ub 
was predicted to form a distal hug, I decided to test if Ub[Ub(15N)]–11,63Ub showed 
any evidence of this conformation.  As a control I recorded the spectrum of the 
corresponding Ub monomer and Ub(15N)–63Ub, (15N enriched distal Ub in K63-Ub2).  
Alignment by the proximal Ub of existing structures PDB-2XEW for K11-Ub2 and 
PDB-2JF5 for K63-Ub2 hints that the distal hug in [Ub]2–11,63Ub would require the 
D11 and D63 Ub to undergo significant rearrangement to adopt the conformation 
(Figure 4.8).  The overlay of the 1H,15N-HSQC show no significant difference 
between Ub1, Ub(15N)–63Ub, and Ub[Ub(15N)]–11,63Ub and there are barley any CSPs 
between Ub(15N)–63Ub and Ub[Ub(15N)]–11,63Ub (Figure 4.8).  Taken together this 
suggest that the distal hug conformation of [Ub]2–11,63Ub is invalid and the theoretical 
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alignment of the component dimers provides for a more accurate representation.  
However, determining the true structure requires a more extensive investigation.   
 
Figure 4.8 – Testing for the [Ub]2–11,63Ub distal hug. 
(A) Structure of K11-Ub2 (PDB-2XEW) and (B) K63-Ub2 (PDB-2JF5).  (C) Proximal 
alignment of model for [Ub]2–11,63Ub based on existing X-ray structures with no 
distal hug.  (D) Theoretical HADDOCK model for [Ub]2–11,63Ub showing the distal 
hug between D11 and D63.  (E) 1H,15N-HSQC overlay of Ub1 in black, Ub(15N)–63Ub 
in blue, and Ub[Ub(15N)]–11,63Ub in green. (F) Residue specific CSPs between 
Ub(15N)–63Ub and Ub[Ub(15N)]–11,63Ub, (G) Ub1 and Ub[Ub(15N)]–11,63Ub, and (H) 
Ub1 and Ub(15N)–63Ub.      
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4.5 Structural studies of K48 and K63 mixed linkage polyUb chains 
4.5.1 Precedent and research aims 
Although many homogeneous linkages remain uncharacterized, there is a 
mounting body of evidence that polyUb chains contain mixed linkages in the cell (28, 
29, 144, 164, 198-201).  Mass spectrometry studies have confirmed that all eight Ub 
linkages are present in vivo and quantitative analyses has established that K48 and 
K63 linkages are the most abundant by a large margin (202, 203).  Recent advances 
have led to the development of linkage-specific antibodies (for K11, K48, K63, and 
M1) which have revealed that the polyUb signal is remodeled on several substrates, 
and also instances where K48 and K63 linkages co-localized in the cell  (160, 201, 
202, 204, 205).  However, it is still unclear if linkage mixing or branching creates a 
new polyUb signaling property unavailable to homogeneous chains, or if the 
signaling properties of the individual linkages in mixed-linkage chains would be 
preserved.   
Precedent for a functional mixed-linkage chain comes from Ring1b, an E3 Ub 
ligase that requires autoubiquitination with a mixed polyUb chain containing K6, 
K27, and K48 linkages (164).  For this example, our understanding of the structural 
and signaling properties is limited because the topology and sequence of Ub–Ub 
linkages in this novel polyUb chain are unknown. In addition, because the solution 
structures of homogenous K6 and K27 polyUb chains are unavailable, comparisons of 
the conformation of the chains from Ring1b chain with component homogenous 
chains are not possible. A mixed linkages chain containing K11 and K63 linkages has 
also been shown to facilitate internalization of MHC I membrane proteins (200).  At 
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some point during substrate processing on the 26S proteasome, the polyUb chain can 
be remodeled by proteasome associated DUBs and E3 Ub ligases and in yeast, the 
E3/E4 Ub ligase Hul5 has been shown to make linkages primarily through K63, but 
also K11 and K48 (199).  Although these and other studies indicate that complex 
polyUb chains occur in vivo, they do not provide clues about the structures of the 
chains or how they could be recognized differently by receptors. Thus, our 
understanding of the roles and signaling properties of branched or unbranched mixed 
linkage chains is quite limited, in part because structural information is lacking.  
   
4.6 Design and synthesis of unbranched and branched mixed linkage polyUb chains  
4.6.1 Justification for K48 and K63 mixed linkages as a starting point 
One challenge to studying complex polyUb chains is that, depending on the 
number of individual Ub units, there are theoretically quadrillions of unique chains 
(discussed in section 4.1). Even discussion of this problem is confounded by the 
absence of a standardized nomenclature system for such chains, which required me to 
design such a system to clearly communicate my findings (see section 4.3.1).  To 
initiate the first structural study of complex polyUb chains I focused on branched and 
unbranched mixed-linkage chains containing K48 and K63 linkages as a logical 
starting point. The fact that the two linkages are essentially “orthogonal” with respect 
to (i) their location on the surface of Ub, (ii) the resulting structural conformations 
(compact versus extended (153, 155)), and (iii) the signaling properties (proteolytic 
versus regulatory (154)) of the corresponding homogeneously-linked chains suggests 
that combinations of K48 and K63 linkages could provide the most extreme example 
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of linkage mixing and branching. Additionally, the high relative abundances of both 
K48 and K63 linkages in the cell suggest that these linkages would predominate in 
randomly assembled mixed-linkage chains. Although a cellular process that requires 
both K48 and K63 linkages has yet to be identified, it has been reported that K48 and 
K63 linkages co-localize in the cell, both linkages were detected on the same 
substrate, and at least one DUB, ataxin-3, preferentially cleaves mixed K48 and K63-
linkage chains in vitro (201, 202, 206). These studies hint that polyUb chains 
containing both K48 and K63 linkages form in the cell, but whether they serve a 
specific function or are simply a mistake that is later “edited” remains to be seen.  
Thus the main objective of this study is to determine the structural and functional 
outcomes of K48 and K63 linkage mixing in polyUb chains.      
 
4.6.2 Fundamental unbranched and branched chains 
Given that this is the first structural study of such chains, I found it logical to 
focus on the simplest possible model system by limiting chains to just three Ubs with 
combinations of K48 and K63 linkages. With these constraints, the resulting set of Ub 
timers included a single branched chain, [Ub]2–48,63Ub, and two unbranched mixed-
linkage chains, Ub–63Ub–48Ub and Ub–48Ub–63Ub (Figure 4.9).  To have an 
unprecedented look at the solution properties of these chains, I had to create each 
chain with only one Ub 15N enriched resulting in a total of nine chains for analysis, 




Figure 4.9 – Fundamental unbranched and branched trimers.  
Chain schematics, nomenclature, and unit-specific 15N-enrichment (gray checker 
pattern) for each of the nine chains studied.  Rows depict isotope labeling schemes for 
an individual chain and the 15N labeled Ub is written out (distal-48, distal-63, distal, 
proximal, or middle).  The formal name of each chain, including labeling is shown 
under each schematic. (A-C) the branched chain [Ub]2–48,63Ub, (D-F) unbranched 




4.6.3 Synthesis of chains  
To assemble the nine polyUb chains for this study I utilized the well 
established enzymatic synthesis approach (207), but had to make several 
modifications.  The linkage specific E2s, E2-25K forK48 linkages and Ubc13:Mms2 
for K63 linkages efficiently created the desired linkages, however I needed to ensure 
no unwanted modifications were introduced.  This required several new KtoR Ub 
mutants as well as a carefully thought out stepwise synthesis scheme.  The need to 
selectively label specific Ubs in each chain also dictated the use of the stepwise 
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approach.  The necessary steps for the synthesis of each chain are show in (Figure 
4.10).  The finding that E2-25K could easily create K48 linkages on an existing K63 
chain and Ubc13:Mms2 could introduce K63 linkages to a K48 chain was 
encouraging and suggested that these naturally occurring E2s could do the same in 
the cell.      
 
Figure 4.10 – Stepwise enzymatic synthesis of trimers for study.  
D77 terminates chain elongation from the proximal end while a K-to-R mutation 
terminates chain elongation from that lysine on the distal end. D77 can be removed 
after treatment with YUH1, exposing a free G76 terminus to be used for chain 
formation. Alternatively, a truncated (Ub-R74) variant of Ub that lacks G75 and G76 
can be used for the proximal-to-be unit in these chains. (A) Steps used to create Ub–
63Ub–48Ub with full control of which Ub unit is 15N enriched. (B) Assembly of Ub–
48Ub–63Ub in two separate steps. (C) Two linkage-specific E2s are used 
simultaneously to form [Ub]2–48,63Ub. (D) Alternative method to assemble the 






In the one step synthesis of the branched chain [Ub]2–48,63Ub, E2-25K and Ubc13-
Mms2 simultaneously add each linkage in the same reaction.  I explored this concept 
further by adding Ube2s, an E2 that forms K11 linkages to the mixture which yielded 
[Ub]3–11, 48,63Ub (Figure 4.11).  The results demonstrate that these naturally occurring 
linkage-specific E2s could readily form branched or unbranched polyUb chains 
working together and on existing chains, suggesting this was a common property of 







Figure 4.11 –Assembly of a branched [Ub]3–11,48,63Ub tetra-Ub by simultaneous 
action of three linkage specific E2s.  
Various linkage-specific E2 ubiquitin-conjugating enzymes can be used 
simultaneously to create highly branched polyUb chains in which a single Ub unit is 
ubiquitinated with multiple Ubs attached through different lysines. Here we 
demonstrate the formation of a branched tetra-Ub, [Ub]3–11,48,63Ub, containing a 
single proximal Ub and three distal Ubs, linked to it via K11, K48, and K63. (A) 15% 
SDS PAGE gel showing that enzymatic reactions with individual linkage-specific E2s 
Ube2S, E2-25K, and Ubc13:Mms2 efficiently create only di-Ub chains.  (B) 
Synthesis scheme to assemble [Ub]3–11,48,63Ub from Ub monomers using the 
simultaneous action of all three linkage specific E2s.  (C) 15% SDS PAGE gel 






4.6.4 NMR validation of isopeptide linkages 
Initially, quality control was one of the most pressing concerns after the 
synthesis of each mixed linkage chain.  Knowing the linkage type (K48 or K63) and 
its exact position in the chain were essential to confirming that the exact chain was 
synthesized.  Simple gel assays could easily confirm the presence of tri-Ub and also 
contaminants di-Ub and mono-Ub.  While more sensitive techniques such as tryptic 
digestion or linkage-specific antibodies could detect the linkages present, but the 
methods provided no information about the sequence of the linkages in the chain.  To 
determine that the exact linkage(s) were present on the desired Ub, I used 1H,15N-
HSQC to observe diagnostic isopeptide signals in each of the nine chains.  Unlike any 
other method, a single Ub in each timer can be noninvasively monitored to revel 
which linkages it contains.  If the Ub under observation is a distal or middle (endo-1), 
then the C-terminus should reflect a ligated G76, while a proximal Ub should have a 
completely free G76 signal.  Each of the nine trimers adhered to these rules as 
expected.  To determine the linkage type, I looked for the diagnostic signals that 
result from the newly formed N-H group in the ligated lysine side chain.  Provided 
the ligated lysine is 15N enriched, the transition from a free εNH2 group to the NH 
isopeptide will create a new signal in 1H,15N-HSQC.  This new signal has a specific 
chemical shift, whose position depends on the lysine forming the linkage.  For 
example, the signal resulting from K48 has a different position from the same εNH2 
group in K63 (see Figure 4.12).  This unconventional, but robust 1H,15N-HSQC assay 





Figure 4.12 – Linkage specific diagnostic isopeptide signals in 1H,15N-HSQC. 
(A) 1H,15N-HSQC spectrum of [Ub]2–48,63Ub(15N)  with isopeptide zoomed in.  (B-C) 
Overlay of the 1H-15N-HSQC spectra of the proximal Ub in (B) Ub–48Ub(15N) or (C) 
Ub–63Ub(15N) (black contours) with the corresponding spectra of the distal Ub in the 
distal-labeled constructs: Ub(15N)–48Ub (red contours) and Ub(15N)–63Ub (blue 
contours), reveal extra signals corresponding to the isopeptide bonds. (D) If we then 
overlay the 1H-15N-HSQC spectrum of the proximal Ub of [Ub]2–48,63Ub(15N) (green) 
with the spectra of the proximal Ubs of Ub–48Ub(15N) (red) and Ub–63Ub(15N) (blue) 
it is obvious that the spectrum of [Ub]2–48,63Ub(15N) contains isopeptide signals from 
both the K48 and K63 linkages, while the spectra of Ub–48Ub(15N) and Ub–63Ub(15N) 
alone each contains only one isopeptide signal. This allows for NMR detection of 
both K48 and K63 linkages in [Ub]2–48,63Ub as well as the other chains.    
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4.7 Structural properties of component linkages are preserved in K48, K63 mixed 
linkage chains  
4.7.1 Chemical shift perturbation mapping of inter Ub contacts 
NMR chemical shift perturbation (CSP) mapping was used to identify 
interactions between the Ub units in the mixed linkage chains. In order to unravel 
monomer-specific contacts, each Ub unit in [Ub]2–48,63Ub, Ub–63Ub–48Ub, and Ub–
48Ub–63Ub (see Figure 4.9 for chain notations) was individually 15N enriched (i.e., 
one 15N-Ub per chain) resulting in nine distinct 15N-labeled tri-Ub constructs. 1H,15N-
NMR spectra of each chain were acquired under identical conditions and compared to 
those of monomeric Ub and of the corresponding Ub unit in Ub–48Ub and Ub–63Ub.  
Consistent with the absence of detectable non-covalent contacts between Ub units in 
Ub–63Ub, the only CSPs (versus mono-Ub) observed in that chain were in the C-
terminal residues of the distal Ub and those immediately surrounding K63 of the 
proximal Ub, reflecting the residues involved in the isopeptide linkage between these 
two units (Figure 4.13 A,C). By contrast, CSP mapping of Ub–48Ub revealed that 
both the distal and the proximal Ubs exhibited highly specific spectral perturbations 
in and around the hydrophobic surface patch residues (L8, I44,V70). These CSPs, 
observed in addition to those in the vicinity of the isopeptide linkage between the C-
terminal G76 of the distal Ub and K48 of the proximal Ub, are a clear indicator of the 
hydrophobic interface between the two Ubs in Ub–48Ub (Figure 4.13 B,D). These 
distinctive features of the NMR spectra of Ub–63Ub and Ub–48Ub serve as hallmarks 




Figure 4.13 – CSP analysis from 1H,15N-HSQC spectra 
(A) 1H,15N-HSQC overlay of Ub1(black) and Ub(15N)–63Ub (blue) shows similar 
residues specific chemical shifts with the exception of the C-terminus (B) 1H,15N-
HSQC overlay of Ub1(black) and Ub(15N)–48Ub (red) shows different residue specific 
peaks for the C-terminus and hydrophobic patch residues. (C) Calculated residue 
specific CSPs between spectra for Ub1(black) and Ub(15N)–63Ub (blue).  (D) 
Calculated residue specific CSPs between spectra for Ub1(black) and Ub(15N)–48Ub 
(red).             
 
 
 NMR spectra of [Ub]2–48,63Ub show that the amide resonances in the distal 
K63-linked Ub are almost identical to those in monomeric Ub with the exception of 
the C-terminal residues 74-76, where the observed CSPs are caused directly by 
ligation to K63 of the proximal Ub (Figure 4.14 C). Consistent with this observation, 
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there are virtually no spectral differences between distal K63-linked Ub and the distal 
Ub in Ub–63Ub, indicating their close structural similarity and the absence of non-
covalent contacts with the proximal Ub in the corresponding chains (Figure 4.14 I).  
A similar comparison of the spectra of the distal K48-linked Ub in [Ub]2–
48,63Ub revealed a strikingly different picture. Here I detected large site-specific CSPs 
between the distal K48-linked Ub and mono-Ub (Figure 4.14 B) and almost 
negligible spectral differences between the distal K48-linked Ub and the distal Ub in 
Ub–48Ub (Figure 4.14 E). These results show that the distal K48-linked Ub in [Ub]2–
48,63Ub makes essentially the same interdomain contacts (i.e., the hydrophobic 
interface with the proximal Ub and the isopeptide linkage through G76) as the distal 
Ub in Ub–48Ub. Predictably, these contacts result in large site-specific spectral 
differences between the distal K48-linked Ub and the distal Ub of Ub–63Ub (Figure 
4.14 H), which are also similar to the CSPs between the distal K48-linked Ub and 
monomeric Ub (Figure 4.14 B).  
 Careful analysis of the spectra for the proximal Ub of [Ub]2–48,63Ub revealed 
two signals originating from the isopeptide εNH groups of K48 and K63 (Figure 
4.12). These signals are diagnostic for the isopeptide linkage through the ε-amino 
group of the corresponding lysine. That they are at the same resonance frequencies as 
in the respective homogeneous di-Ub (K48- or K63-linked) supports that there is little 
difference in the linkage between the branched and component homogenous di-Ub 
chains.  For both unbranched mixed-linkage tri-Ub chains (see below) the isopeptide 
εNH signals appeared at nearly identical positions in 1H,15N-HSQC.  
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Because the proximal Ub of [Ub]2–48,63Ub is ubiquitinated at two lysines 
simultaneously, its NMR spectrum could differ from the proximal-Ub spectrum in the 
respective isolated di-Ubs. Nevertheless, a clear picture emerged from comparison of 
the corresponding spectra. For example, a comparison to mono-Ub indicates that the 
hydrophobic-patch residues of the proximal Ub form an interface with another Ub 
unit, while its C-terminus is unligated (as in monomeric Ub) unlike those of the distal 
K48- and K63-linked Ubs (Figure 2.14 A). The spectral differences between the 
proximal Ubs of [Ub]2–48,63Ub and Ub–48Ub are minimal except for the region around 
K63 which is linked to another Ub only in the branched trimer (Figure 2.14 D). As 
with the distal K48-linked Ub (see above), the strong site-specific CSPs with respect 
to the proximal Ub in Ub–63Ub reflect the hydrophobic-patch contacts between the 
two K48-linked Ubs (Figure 2.14 G).  Based on these and the abovementioned data, I 
conclude that the two K48-linked Ubs (the distal-48 and proximal) in [Ub]2–48,63Ub 
form essentially the same hydrophobic contact as in Ub–48Ub whereas only the distal 
K63-linked Ub behaves as in Ub–63Ub, where non-covalent contact were not 





Figure 4.14 – 1H,15N-HSQC CSP characterization of [Ub]2–48,63Ub. 
Data for the proximal Ub are shown in green, for distal K48-linked Ub in red, and for 
distal K63-linked Ub in blue (see pictograph, top). (A-I) Spectral differences 
(quantified as CSPs) between each Ub in [Ub]2–48,63Ub and monomeric Ub (top row), 
the corresponding Ub units in Ub–48Ub (middle row), and Ub–63Ub (bottom row). 
Left column: CSPs between the proximal Ub in [Ub]2–48,63Ub and (A) Ub1, (D) 
proximal Ub in Ub–48Ub, and (G) proximal Ub in Ub–63Ub. Middle column: CSPs 
between distal K48-linked Ub in [Ub]2–48,63Ub and (B) Ub1, (E) distal Ub in Ub–
48Ub, and (H) distal Ub in Ub–63Ub. Right column: CSPs between the distal K63-
linked Ub in [Ub]2–48,63Ub and (C) Ub1, (F) distal Ub in Ub–48Ub, and (I) distal Ub 












When we rearranged the linkages to form an unbranched mixed-linkage chain, 
Ub–63Ub–48Ub, the Ub units maintained their expected contacts and spectral 
properties. The proximal Ub of Ub–63Ub–48Ub has its K48 ligated, and a hydrophobic 
interface indicated from the large site-specific CSPs relative to mono-Ub and Ub–
63Ub (Figure 15 A,G) was detected. The spectral differences are minimal between the 
proximal Ub in Ub–48Ub and that in Ub–63Ub–48Ub, which indicates close similarity 
between the two units ligated via K48 (Figure 15 D). The next (i.e., middle) Ub of 
Ub–63Ub–48Ub has features of both a proximal unit (linked through its K63) and a 
distal unit linked through its C-terminal G76. The large site-specific CSPs versus 
mono-Ub (Figure 15 B) clearly support that the middle Ub participates in a 
hydrophobic interface. Based on the spectral similarity with the distal Ub of Ub–48Ub 
(Figure 15 E), I conclude that the K48-linked proximal and middle Ubs in Ub–63Ub–
48Ub retain the hydrophobic interface characteristic of Ub–48Ub. Note also that the 
large CSPs observed around K63 in the middle Ub reflects the linkage at K63 to the 
distal Ub.  
The NMR spectra of the distal Ub in Ub–63Ub–48Ub demonstrate that this unit 
is excluded from the hydrophobic interface formed between the middle and proximal 
Ubs. Indeed, the CSPs in distal versus monomeric Ub are localized to the (ligated) C-
terminal region (Figure 15 C), whereas the spectral differences between the distal 
Ubs of Ub–63Ub–48Ub and Ub–63Ub are negligible (Figure 15 I). These observations 
strongly support that the distal Ub of Ub–63Ub–48Ub has the same structure and 





Figure 4.15 – 1H,15N-HSQC CSP characterization of Ub–63Ub–48Ub 
Data for the proximal Ub are shown in green, for middle Ub in orange, and for the 
distal K63-linked Ub in blue (see pictograph, top). (A-I) Spectral differences 
(quantified as CSPs) between each Ub in Ub–63Ub– 48Ub and monomeric Ub (top 
row), the corresponding Ub units in Ub–48Ub (middle row), and Ub–63Ub (bottom 
row). Left column: CSPs between the proximal Ub in Ub–63Ub– 48Ub and (A) Ub1, 
(D) proximal Ub in Ub–48Ub, and (G) proximal Ub in Ub–63Ub. Middle column: 
CSPs between middle Ub in Ub–63Ub– 48Ub and (B) Ub1, (E) distal Ub in Ub–48Ub, 
and (H) distal Ub in Ub–63Ub.  Right column: CSPs between the distal Ub in Ub–












With a similar pattern emerging from the other two chains I expected it to 
repeat for the Ub–48Ub–63Ub chain.  In Ub–48Ub–63Ub, the proximal Ub should be the 
only unit that does not form a hydrophobic interface. Indeed, this is evident from the 
strong spectral similarity of that proximal Ub with the proximal Ub of Ub–63Ub 
(Figure 4.16 G) as well as with mono-Ub (Figure 4.16 A).  Comparison of the 
proximal Ub in Ub–48Ub–63Ub to that of Ub–48Ub clearly indicates the absence of the 
hydrophobic interface (Figure 4.16 D).   In contrast to the proximal Ub which 
exhibits no non-covalent contacts, the middle and distal units of Ub–48Ub–63Ub form 
a characteristic K48-linked Ub–Ub interface. This is particularly apparent from the 
minimal CSPs (except for the ligated C-terminus) between the middle Ub of Ub–
48Ub–63Ub and the proximal Ub of Ub–48Ub (Figure 4.16 E), and the virtual absence 
of CSPs between the distal Ub and Ub–48Ub (Figure 4.16 F).  As expected from 
previous observations, the middle and distal Ubs in Ub–48Ub–63Ub show significant 
spectral differences when compared to monomeric Ub and Ub–63Ub (Figure 4.16 
B,C,H,I).   
CSP analysis of all of all nine tri-Ubs clearly demonstrated that K48 linked 
elements retain their structural properties and could override K63 linkages in some 
cases such as the branched chain [Ub]2–48,63Ub where the proximal is also K63 








Figure 4.16 – 1H,15N-HSQC CSP characterization of Ub–48Ub–63Ub 
Data for the proximal Ub are shown in green, for middle Ub in orange, and for the 
distal K48-linked Ub in red (see pictograph, top). (A-I) Spectral differences 
(quantified as CSPs) between each Ub in Ub–48Ub– 63Ub and monomeric Ub (top 
row), the corresponding Ub units in Ub–48Ub (middle row), and Ub–63Ub (bottom 
row). Left column: CSPs between the proximal Ub in Ub–48Ub– 63Ub and (A) Ub1, 
(D) proximal Ub in Ub–48Ub, and (G) proximal Ub in Ub–63Ub. Middle column: 
CSPs between middle Ub in Ub–48Ub– 63Ub and (B) Ub1, (E) distal Ub in Ub–48Ub, 
and (H) distal Ub in Ub–63Ub. Right column: CSPs between the distal Ub in Ub–












4.7.2 Conformational mobility observed by T1 relaxation 
The CSP analysis from the previous section clearly indicates that the two 
K48-linked units in all three tri-Ub chains form a specific interface while the third 
unit, linked via K63, shows no contacts except for being tethered (via its flexible C-
terminus or via K63) and therefore is expected to be more mobile than the other two 
Ubs.  To test this assumption, 15N longitudinal relaxation times, T1, for each Ub unit 
in all nine chains were measured and compared. Generally, T1 senses the overall 
tumbling of the chain (reflecting its size and shape), the relative intra-chain mobility 
(on a ns time scale) of the Ub unit under observation (which could depend on its 
location and intra-chain contacts), and the local polypeptide backbone dynamics 
within the Ub protomer (which are expected to be similar for all Ubs).  Whereas the 
overall shape could differ between chains, the T1 values within the same chain are 
expected to reflect the relative mobility of each Ub unit. For example, if a particular 
Ub forms a hydrophobic interdomain interface it becomes less mobile and this should 
result in an increase in T1. Furthermore, a Ub that is linked to two other Ubs should 
also show an increase in T1 as its reorientation will partially depend on the movement 
of the other two Ubs. Therefore, one would expect the proximal Ub of [Ub]2–48,63Ub 
and the middle Ubs of Ub–63Ub–48Ub and Ub–48Ub–63Ub to have the largest T1 
values, while the K63 linked Ubs would have the smallest T1 values. 
Indeed, in [Ub]2–48,63Ub the proximal Ub has the longest T1, whereas of the 
two distal (singly-linked) Ubs, the distal K63-linked Ub shows the shortest T1 (i.e., 
the least restricted mobility), and the distal K48-linked Ub has longer T1, consistent 
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with its contact with the proximal Ub (Figure 4.17 A).  The T1 values for each Ub in 
[Ub]2–48,63Ub fully agree with the CSP analysis and structural models (section 4.7.4).  
Just as the CSPs followed a predictable pattern, the T1 data for each Ub in the 
two unbranched chains followed a pattern.  Expectedly, the middle Ubs in Ub–63Ub– 
48Ub and Ub–48Ub– 63Ub showed the greatest T1 (most restricted mobility). While the 
K63-linked Ubs, the distal Ub in Ub–63Ub– 48Ub and the proximal Ub in Ub–48Ub– 
63Ub are consistently the most mobile (i.e., smallest T1) regardless of whether they are 
at the distal or the proximal end of the chain (Figure 4.17 B,C). The K48-linked Ubs 
show intermediate T1 values, as its tumbling is slowed by the hydrophobic interaction 
with the middle Ub, again regardless if the K48 linked Ub is at the distal or proximal 
end.  However, in all of these chains the two K48-linked units have slightly different 
T1 values; thus, despite forming a hydrophobic contact, they are not rigidly locked. 
This is consistent with previous findings for Ub–48Ub (155) and indicates dynamic 
opening and closing of the hydrophobic interface, which is critical for the ability of 








Figure 4.17 – Unit specific 15N-T1 relaxation in each mixed linkage trimer 
(A) T1 relaxation rates for each Ub in [Ub]2–48,63Ub with proximal Ub (green), distal-
48 linked Ub (red), and distal-63 linked Ub (blue), (see pictograph, right). (B) T1 
relaxation rates for each Ub in Ub–63Ub–48Ub with proximal Ub (green), middle Ub 
(orange), and distal Ub (blue), (see pictograph, right).  (C) T1 relaxation rates for each 
Ub in Ub–48Ub–63Ub with proximal Ub (green), middle Ub (orange), and distal Ub 
(red), (see pictograph, right).     





4.7.3 The classic pH dependent hydrophobic interface is present 
One hallmark of K48-linked di-Ub is that its conformation is pH-dependent: 
lowering the pH shifts the equilibrium from the predominantly closed conformation at 
neutral pH to predominantly open.  This effect is caused by a +1 net charge from 
protonation of the δ1 nitrogen in the H68 side chain.  At neutral pH above the pKa of 
H68, there is no proton on the δ1 nitrogen and the net charge is 0.  This simple acid 
base chemistry controls the K48 interface.  Since the H68 side chains from the distal 
and proximal Ubs are in such close proximity with a net charge of 0 at neutral pH 
their hydrophobic interaction is strong, but at acidic pH the electrostatic repulsion 
from the +1 charges on each H68 heavily favors the open conformation, breaking the 
K48 interface.  With our solution NMR method this manifests itself as nearly 
complete disappearance of the CSPs at pH 4.5 (155).  
For the branched chain the CSP data (Figure 4.18) indicate the pH-dependent 
behavior of [Ub]2–48,63Ub is nearly identical to that reported for the corresponding 
Ubs in homogeneous K48- and K63-linked polyUb. This supports the conclusion that 
interdomain interactions in the branched tri-Ub are governed by the same forces as in 
the respective homogeneous-linkage chains.  Thus the same K48 interface is 










Figure 4.18 – CSP analysis at acidic pH reveals [Ub]2–48,63Ub retains the classical 
K48 interface.   
CSPs between each Ub unit of [Ub]2–48,63Ub and its respective Ubs in Ub–48Ub (left 
column) and Ub–63Ub (right column) in 20 mM sodium acetate buffer, pH 4.5. (A,B) 
residue specific CSPs for the distal-63 Ub shows that it remains free of any 
interdomain contacts at pH 4.5.  (C) Comparison of the distal-48 Ub in [Ub]2–48,63Ub 
and Ub–48Ub are nearly identical indicating an open conformation.  (E,F) CSP data 
shows the proximal Ub also adopts an open conformation at pH 4.5. There are some 
minor discrepancies in the CSPs attributable to the isopeptide bond that the Ub2 
controls lack, i.e. the large CSP observed in (E) around residue 63 is due to the K63 
linkage present in the proximal Ub of [Ub]2–48,63Ub but absent in the Ub–48Ub chain 
which it is being compared to. The other minor deviations in (F) CSPs match those 
reported for similar analysis of K48 and K63-linked polyUb. (G) neutral pH structure 
of Ub–48Ub representing the closed conformation and (H) acidic pH structure of Ub–
48Ub representing the open conformation with no interdomain contacts.   
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4.7.4 Structural models reveal preserved homogenous features 
With a consensus in the NMR CSP and 15N T1 relaxation data, structural 
models were generated for each of the three tri-Ubs studied using the biomolecular 
docking program HADDOCK, with site-specific CSPs to guide the docking.  
Although there were slightly different overall structures in the top clusters for these 
chains, all featured a distinct arrangement of the interdomain contacts in which the 
two K48-linked Ubs formed a well-defined contact mediated by their hydrophobic-
patch residues whereas the K63-linked Ub was represented in essentially random 
positions. For example, the generated structures for [Ub]2–48,63Ub (Figure 4.19 A) 
clearly shows that the proximal and distal K48-linked Ubs form the “canonical” L8, 
I44,V70 hydrophobic interface, whereas the distal K63-linked Ub samples several 
different orientations, depending on the HADDOCK cluster (Figure 4.19 D). This 
variation in the K63-linked Ub is not unexpected given that (i) the CSP data show no 
close non-covalent interactions involving this Ub unit and (ii) the 15N T1 relaxation 
data indicate that this unit has greater mobility compared to the other two K48-linked 
Ubs.  Moreover, the two K48-linked Ubs overlay quite well (RMSD = 1.72 Å) with 
the crystal structure (PDB: 1AAR) of Ub–48Ub.  For the unbranched mixed linkage 
chains Ub–63Ub–48Ub and Ub–48Ub–63Ub the structural models followed the same 
predictable pattern.  The two K48 linked Ubs, middle and proximal in Ub–63Ub–48Ub 
and distal and middle in Ub–48Ub–63Ub created an interface, while the K63 linked Ub 
was represented in a variety of positions just as the 15N T1 relaxation data suggested 
(Figure 4.19 B,C).  The overall structural models for all three chains are almost 
superimposable with their two K48 linked Ubs creating an interface and the K63 
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linked Ub with the exception of the linkage pattern.  Taken together these structural 
models suggest that the same outcome is reached regardless of the order of linkages 
and branching.            
 
Figure 4.19 – Structural models of mixed linkage tri-Ub chains.   
HADDOCK generated models using CSP contacts, (see chain schematics below), the 
L8,I44,V70 hydrophobic patch shown as yellow spheres (A) [Ub]2–48,63Ub with 
proximal Ub (green), distal-48 Ub (red), and distal-63 Ub (blue) (B) Ub–63Ub–48Ub 
with proximal Ub(green), middle Ub (orange), and distal Ub (blue)  (C) Ub–48Ub–
63Ub with proximal Ub (green), middle Ub (orange), and distal Ub (red).  (D) 
multiple cluster alignment of [Ub]2–48,63Ub showing the same K48 interface (green 
and red), but a variation in the position of the distal-63 Ub (blue).    
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4.8 Signaling properties of component linkages are preserved in K48, K63 mixed 
linkage chains  
4.8.1 K48 linkage selectivity of UBA(2) in [Ub]2–48,63Ub 
Having established that the branched and unbranched mixed-linkage chains 
combine the structural properties characteristic of both linkages, I set to examine 
whether these chains can be recognized by linkage-selective receptors. To determine 
if the K48-linkage in [Ub]2–48,63Ub retains its receptor selectivity, separate titrations  
of [Ub]2–48,63Ub (for each Ub unit 15N-enriched; see Figure 4.9) with the K48-
linkage selective receptor UBA(2) from the proteasomal shuttle protein hHR23A 
were carried out. UBA(2) binds Ub–48Ub in a “sandwich” mode and significantly 
more tightly (Kd=8 ± 7 µM) than to Ub–63Ub (Kd =180 ± 80 µM) or monomeric Ub 
(Kd = 400 ± 100 µM) (153, 208).  Strong residue-specific CSPs in both the proximal 
and the distal K48-linked Ubs were observed (Figure 4.20 C-F); these perturbations 
center around the hydrophobic-patch residues and the isopeptide linkage, consistent 
with UBA(2) insertion into the hydrophobic pocket formed by the K48-linked Ubs.  
The extent of binding can be gauged from titration curves of residue-specific CSPs or 
by comparing the CSPs for all residues at various points in titration. The CSPs in the 
proximal and distal K48-linked Ubs of [Ub]2–48,63Ub show little change between 
[UBA(2)]:[ [Ub]2–48,63Ub] = 1 and 3 (Figure 4.20 C-F), suggesting that UBA(2) 
binding to both Ubs reached saturation at approximately 1:1 molar ratio. Additional 
changes occurring in these Ubs above the 1:1 molar ratio could reflect binding of a 
second UBA(2) molecule, as observed for Ub–48Ub. Interestingly, the distal K63-
linked Ub exhibited an entirely different behavior and showed spectral perturbations 
only after the distal K48-linked and proximal Ubs were saturated with UBA(2).  Even 
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at [UBA(2)]:[[Ub]2–48,63Ub] = 1, there are virtually no CSPs in the distal K63-linked 
Ub, and it was not until after this point that we finally observed UBA(2) binding to 
this Ub (Figure 4.20 G,H).  
 
Figure 4.20 – UBA(2) K48 linkage selectivity in [Ub]–48,63Ub by NMR titration. 
Each Ub in [Ub]2–48,63Ub was individually titrated with UBA(2).  The results from 
each domain are color coded according to the pictograph on top: proximal green, 
distal-48 red, and distal-63 blue.  Normalized residue specific titration curves for (A) 
V70 and (B) L43.  Notice the lag phase for the distal-63 Ub (blue) in each.  (C-H) 
Residue-specific CSPs in individual Ub units at two points in titration with UBA(2): 
at the 1:1 molar ratio (left column) and at saturation (right column). Gray bars 
indicate residues with signals broadened beyond detection at the 1:1 molar ratio. Note 
that the distal K63-linked Ub exhibits virtually no binding until [UBA(2)]:[ [Ub]2–
48,63Ub] > 1. (I) A model of the [Ub]2–48,63Ub/UBA(2) complex at the 1:1 molar ratio, 
based on the observed CSPs and the structure of the Ub–48Ub/UBA(2) complex 




The titration curves for individual residues illustrate this trend from another 
angle by showing “standard” binding behavior for the distal K48-linked and proximal 
Ubs, but a “lag phase” for the distal K63-linked Ub (Figure 4.20 A,B). This strong 
binding preference for K48-linked Ubs is also supported by our relaxation data that 
showed a larger increase in 15N T1 of the distal K48-linked Ub compared to distal 
K63-linked Ub at saturation (Figure 4.21).  This difference in T1 relaxation rates 
between the UBA(2) bound forms of distal-48 and distal-63 is attributable to tighter 
binding of the distal-48 Ub. These results demonstrate that a K48-linkage receptor 
can selectively recognize this linkage in a branched polyUb chain using the same 





Figure 4.21 – 15N T1 relaxation analysis of the UBA(2):[Ub]–48,63Ub complex. 
T1 relaxation rates were measured for [Ub]2–48,63Ub in complex with UBA(2) at 
saturation.  (A)  T1 data for all Ubs in [Ub]2–48,63Ub show a systematic increase due to 
the increased size of the complex.  (B)  The distal-48 Ub in [Ub]2–48,63Ub has much 
lower T1 values in the unbound form (red lines) vs. the UBA(2) bound form (black 
lines).  (C) The distal-63 Ub in [Ub]2–48,63Ub shows a slight increase in T1 relaxation 
rates between the unbound form (blue lines) and the UBA(2) bound form (black 
lines).  This indicates that the distl-63 domain is still less restricted than any Ub in 







4.8.2 K63 linkage selectivity of Rap80 in [Ub]2–48,63Ub   
Rap80 contains a tandem Ubiquitin Interacting Motif (tUIM) that shows a 
strong binding preference for Ub–63Ub versus Ub–48Ub (135).  The tUIM contains a 
flexible linker region between its two helical UIMs which adopts an alpha-helical 
conformation upon binding to Ub–63Ub and perfectly aligns the two UIMs’ 
interacting surfaces for binding to adjacent Ubs in a K63 linkage (135, 209). To 
examine how the tUIM interacts with branched chains, [Ub]2–48,63Ub, as well as Ub–
48Ub and Ub–63Ub as controls were titrated separately using several NMR methods to 
monitor the interactions for each 15N-enriched Ub unit. As shown in (Figure 4.22) 
signals for all three Ubs in [Ub]2–48,63Ub were altered from the tUIM binding 
interaction. The observed perturbations were site-specific and centered around the 
hydrophobic-patch residues as well as the Ub C-termini. The distal K48-linked Ub 
showed noticeably smaller CSPs at saturation (suggesting weaker binding) compared 
to the other two Ubs. Importantly, during these titrations some residues in the 
proximal and distal K63-linked Ubs, but not in the distal K48-linked Ub, showed 
strong attenuations or even disappearance of the NMR signals.  This is caused by 
slow exchange (i.e., slow off-rates) on the NMR chemical shift time scale and is 
indicative of tighter binding to the K63-linked Ubs. Comparison of the domain-
specific CSPs in [Ub]2–48,63Ub with those in the control di-Ub samples (Figure 4.22), 
as well as comparison of the signal trajectories upon titration (Figure 4.23), led me to 
the following conclusions. First, the distal K63-linked and proximal Ubs of [Ub]2–
48,63Ub bind the tUIM in the same mode as their respective units in Ub–63Ub (Figure 
4.22 D,E). This is supported by the fact that at saturation with the tUIM virtually all 
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signals in the 1H,15N-HSQC NMR spectra of the distal K63-linked and proximal Ubs 
of [Ub]2–48,63Ub overlay perfectly with the corresponding signals of Ub–63Ub. Also, 
the signal trajectories (in the course of the titration) for the same residue in the K63-
linked components of the branched and control chains were nearly superimposable 
(Figure 4.23), consistent with identical binding interactions. Second, there is a stark 
difference between tUIM binding to the distal K48-linked Ub of [Ub]2–48,63Ub and 
the Ubs of Ub–48Ub. Indeed, our data show spectral differences (ΔCSP) at saturation 
between the distal K48-linked Ub and either Ub of Ub–48Ub (and even mono-Ub) that 









Figure 4.22 – CSP and ΔCSP analysis of Rap80 titration of [Ub]2–48,63Ub. 
All data are color coded as indicated in the pictograph on the top: proximal Ub data 
are shown in green, distal K48-linked Ub in red, and distal K63-linked Ub in blue. 
(A-C) CSP plots for each Ub unit in [Ub]2–48,63Ub at saturation: (A) distal K48-linked 
Ub at [tUIM]:[ [Ub]2–48,63Ub] = 2.43, (B) distal K63-linked Ub at [tUIM]:[ [Ub]2–
48,63Ub] = 1.52, and (C) proximal Ub at [tUIM]:[ [Ub]2–48,63Ub] = 2.00. Residues that 
showed strong signal attenuation during the titration are represented with gray bars. 
(D-E) Difference in the CSPs (ΔCSP) for each Ub of [Ub]2–48,63Ub and the 
corresponding Ub in the respective di-Ub controls at saturation with tUIM: (D) distal 
K48-linked Ub of [Ub]2–48,63Ub vs. distal Ub of Ub–48Ub, (E) proximal Ub of [Ub]2–
48,63Ub vs. proximal Ub of Ub–63Ub, and (F) distal K63-linked of [Ub]2–48,63Ub vs. 
distal Ub of Ub–63Ub. In complex with tUIM, the distal K63-linked Ub shows 
virtually no difference from Ub–63Ub, indicating a similar bound state. A similar 
conclusion holds for the proximal Ub, except for the CSP differences around K48 
resulting from the attachment of the distal K48-linked Ub. The distal K48-linked Ub 
in the branched trimer compared to Ub–48Ub shows large systematic ΔCSPs which 
suggests that this Ub does not bind the tUIM as its counterpart in Ub–48Ub. 
 
When the tUIM binds to Ub–48Ub it has to disrupt the hydrophobic interface 
between the two Ubs in order to access the Ub hydrophobic surface. Even though 
avid tUIM binding to K48-linked di-Ub has not been observed, the reported 
interaction (Kd ~ 160 µM) was still relatively strong (135). In the branched chain, 
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simultaneous tUIM binding to the proximal and distal K63-linked Ubs should 
displace the distal K48-linked Ub from its hydrophobic contact with the proximal Ub, 
thus freeing it and making it available for binding to excess tUIM molecules. To 
verify this model, the 15N T1 for each Ub of [Ub]2–48,63Ub at saturation with the tUIM 
was measured (Figure 4.23) and compared them with those of unbound [Ub]2–48,63Ub 
(Figure 4.17 A). The tUIM binding significantly increased the T1 values (reflecting 
slower tumbling) for both the distal K63-linked and the proximal Ub but caused 
almost no change in the T1 values of the distal K48-linked Ub, rendering it the 
lowest-T1 unit in the chain (Figure 4.23 A). This confirms that the Rap80 tUIM binds 
simultaneously to both the proximal and (formerly “free” and the most mobile) distal 
K63-linked Ubs, thereby restricting their conformational freedom. At the same time, 
the tUIM binding displaced and freed the distal K48-linked Ub from its contact with 
the proximal Ub, making it the most mobile (shortest T1 value) Ub in the chain. Thus, 
I conclude that the tUIM-induced perturbations detected in the distal K48-linked Ub 
are primarily due to this secondary effect rather than direct interaction with the tUIM. 
However, we cannot completely rule out that some small fraction of this distal Ub 





Figure 4.23 – Additional binding characterization of tUIM and [Ub]2–48,63Ub.  
All data are color coded as indicated in (B): proximal Ub data are shown in green, 
distal K48-linked Ub in red, and distal K63-linked Ub in blue.  (A) 15N T1 relaxation 
rates for proximal, distal K48-linked, and distal K63-linked Ubs in [Ub]2–48,63Ub at 
saturation with Rap80 tUIM. Binding of the tUIM significantly increased T1 for distal 
K63-linked and proximal Ubs of [Ub]2–48,63Ub, but had little effect on the T1 of distal 
K48-linked Ub although the molar ratio of tUIM to the (15N) distal-48 sample was the 
largest. (B) A model of the [Ub]2–48,63Ub/tUIM complex at 1:1 molar ratio, based on 
the observed CSPs and 15N T1 values, and the Ub–63Ub/tUIM complex structure 
(PDB: 3A1Q).  (C)Residue specific 1H,15N-HSQC trajectories show that the distal-63 
and proximal Ubs undergo a similar binding interaction whether they are in a 
homogeneous (right column) or branched (left column) chain.  The trajectories for the 
distal-48 domain show no similarities indicating that the interaction of the distal-48 






4.8.3 Linkage selectivity of DUBs  
Given that DUBs are critical for maintaining the pool of free Ub and 
regulating conjugate levels, linkage-selective DUBs were tested to determine if they 
would still retain their ability to recognize and cleave their cognate Ub–Ub linkage in 
the branched and unbranched mixed-linkage chains.  For this purpose OTUB1, which 
specifically cleaves K48 linkages (210), and AMSH, which is specific for K63 
linkages (64) were selected. As evident in (Figure 4.24), OTUB1 readily reduced 
[Ub]2–48,63Ub, Ub–63Ub–48Ub, and Ub–48Ub–63Ub to di- and mono-Ub. However, 
unlike the case with the homogeneously linked Ub–48Ub–48Ub substrate, OTUB1 
alone could not further process the di-Ub species generated from any of the mixed-
linkage chains (Figure 4.24). Only when both OTUB1 and AMSH were present was 
complete chain disassembly achieved, indicating that the uncleaved di-Ub was linked 
via K63. An essentially identical behavior was observed for AMSH, which readily 
cleaved the K63-linkage in all tri-Ub chains while leaving the K48-linkage intact in 
the three mixed linkage chains (Figure 4.24). Taken together, these results 
demonstrate that the K48 and K63 linkages in branched and unbranched mixed-
linkage polyUb can each individually be processed by linkage-selective DUBs.  
Recently, a similar finding using OTUB1 and AMSH was also reached with unnatural 
K48 and K63 mixed linkage chain analogs formed via a Nε-Gly-L-homothiaLys 
mimic (which is one C–C bond longer and contains a sulfur atom instead of carbon) 
of an isopeptide bond (211).  This work demonstrates linkage selectivity for fully 





Figure 4.24 – Linkage selective DUBs efficiently cleave their preferred linkages 
in mixed linkage chains.  
Linkage-selective DUBs cleave their cognate Ub–Ub linkages in homogeneous or 
mixed-linkage polyUb.  The indicated chains were incubated with OTUB1, GST-
AMSH, or both and the products evaluated by 15% SDS-PAGE followed by 
Coomassie staining.  Lanes 1-4 show reaction products of homogeneous Ub–48Ub–
48Ub and Ub–63Ub–63Ub. Lanes 5 and 6, 8 and 9, and 11 and 12 show that alone each 
DUB can only process one linkage in the unbranched or branched mixed-linkage 
chains. Only with both DUBs present were the mixed-linkage chains hydrolyzed fully 
to monomeric Ub (lanes 7, 10 and 13). 
* Assay performed by Prof. Robert E. Cohen 
 
 
4.8.4 Linkage selective antibodies and proteasomal processing 
The use of linkage specific antibodies led to the hypothesis that mixed linkage 
polyUb chains were formed in vivo mainly due to the observation that specific gel 
bands would blot with more than one linkage specific antibody.  However even with 
analysis by tryptic digest, it was not clear if the linkages were contained in the same 
chain, and assuming that the linkages were in the same chain it was undetermined if 
they were of branched or unbranched topology. Given that I could create excellent 
model chains with a controlled in vitro method, I found it absolutely necessary to test 
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if the K48 and K63 linkage specific antibodies could detect their respective linkages 
in my system.  Antibodies were provided as a kind gift to Prof. Michael H. Glickman 
from Genentech.  First it was established that both the K48 and K63 linkage-selective 
antibodies recognized their respective Ub–Ub linkages in [Ub]2–48,63Ub (Figure 
4.25). This result in itself clearly demonstrates that chain branching preserves both 
Ub-specific and linkage-specific epitopes for antibody recognition, and also shows 
that linkage-specific antibodies can be used to probe if a particular polyUb chain 
contains multiple linkage types. 
 
 
Figure 4.25 – Linkage selective antibodies detect [Ub]2–48,63Ub. 
Western blots of controls Ub–48Ub–48Ub, Ub–63Ub–63Ub and the branched [Ub]2–
48,63Ub.  (A) The non-linkage specific anti-Ub detects all trimers.  (B) anti-K48 
detects only Ub–48Ub–48Ub and [Ub]2–48,63Ub, and (C) anti-K63 detects Ub–63Ub–
63Ub and [Ub]2–48,63Ub.  The controls work as expected and [Ub]2–48,63Ub is the only 
trimer to blot against both linkage specific antibodies. (D) Model of the K63 linkage 
specific antibody (gray) binding [Ub]2–48,63Ub across the proximal Ub (green) and 
distl-63 Ub (blue).  The distal-48 Ub is far removed from the interaction and does not 
interfere with recognition.  However, in highly branched (5D) chains it could be 
possible to disrupt antibody recognition.   




One of the most studied outcomes of Ub modification is targeting to the 
proteasome. In a poorly understood process, proteasome-associated DUBs mainly 
function to modify or remove the polyUb tag from conjugated substrates (212, 213). 
The three major DUBs associated with the proteasomes are Rpn11 (POH1 in 
humans), Ubp6 (USP14 in humans), and Uch37 (only in humans). Whether and how 
branched polyUb chains are processed by the proteasome is an open question.  
A series of studies has shown that the so-called “forked” polyUb chains that 
are branched on two closely positioned lysine residues (i.e., K6 & K11, K27 & K29, 
or K29 & K33) are degraded slowly by purified proteasomes and inhibit proteasomal 
DUB activity and substrate degradation (20, 26, 28). Whether this observation holds 
for other chains such as those containing the more abundant K48 and K63 linkages 
was not reported. To evaluate the efficiency of proteasome processing of Ub–48Ub–
48Ub, Ub–63Ub–63Ub, or [Ub]2–48,63Ub signals, these tri-Ubs were incubated with 
purified yeast 26S proteasomes and the cleavage was assessed by blotting with anti-
Ub and linkage-selective antibodies.  
Processing of the homogenous Ub–63Ub–63Ub chains was faster than that of 
Ub–48Ub–48Ub (Figure 4.26); this result is consistent with previous reports (92, 214). 
Accordingly, the branched [Ub]2–48,63Ub chain was disassembled faster than Ub–
48Ub–48Ub, and generation of di-Ub (by removal of the single K63-linked Ub) was as 
efficient as from the Ub–63Ub–63Ub chain. These observations suggest that (i) the 
branching did not hinder proteasomal cleavage, and (ii) the presence of a K63 linkage 
in this chain facilitates its conversion to di-Ub. The latter was verified using a K63 
linkage-specific antibody, which revealed that only a minor fraction of the di-Ub 
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products generated from [Ub]2–48,63Ub were K63-linked (Figure 4.26). Taken 
together, these results demonstrate that the 26S proteasome can systematically 
process K48 and K63 mixed linkages polyUb chains. 
 
 
Figure 4.26 – Proteasomal disassembly of [Ub]2–48,63Ub. 
Time course of disassembly for homogeneous and branched chains by 26S 
proteasomes. Ub–48Ub–48Ub, Ub–63Ub–63Ub, or [Ub]2–48,63Ub were incubated with 
purified yeast 26S proteasomes and the digests were monitored at 0, 5, and 22 hrs by 
SDS-urea PAGE and blotting with (A) anti-Ub and (B) anti-K63 antibodies.  The 
trace di-Ub band for [Ub]2–48,63Ub in right lanes of (B) indicate that the K63 linkage 
is cleaved much faster than the K48 linkage.  
* Assay performed by Dr. Nurit Livnat-Levanon  





4.9 Discussion and Summary 
4.9.1 Theoretical complex chains 
As outlined, there are theoretically quadrillions of unique polyUb chains if 
linkage mixing is allowed.  Attempting to study all of these chains individually would 
be both impractical and produce data that is meaningless to the scientific community 
due to the overwhelming amount of information.  It is sterically possible for a single 
Ub to be simultaneously ligated at all eight linkages sites, but there is much to be 
learned from less complex systems and there currently is not a clear approach for the 
study of such chains.  For my theoretical study, I focused on a very simple system of 
just three branched Ubs containing just two linkages.  The four distinct conformations 
that could result from such chains (i) “free form” (ii) “distal hug” (iii) “clump” and 
(iv) “classic interface” are simple to define and give us meaningful insight on the 
structural properties of such chains.  For example, the classic interface conformation 
supports that individual linkage properties are preserved and the chain would be 
expected to act similar to its homogenous components, while a distal hug suggests 
that branching allows the chain to present a new signal for receptors.  These basic 
categories also help to classify the vast amount of complex chains and also simplify 
the field from a vast sea of individual complex chains.  With improved computational 
methods for docking and analysis, it would be logical to investigate more chains and 
there certainly is no shortage of them to study.  The predictions for the branched 
chains here should also be tested experimentally and it is highly possible a significant 
percentage of the predicted structures are valid.  The failure to experimentally detect 
the distal hug in [Ub]2–11,63Ub was disappointing, but this does not rule out the 
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possibility of the distal hug conformation in other branched tri-Ubs.  Furthermore, the 
distal hug conformation may in fact be over played considering a receptor carrying 
two different linkage selective UBDs also provides a unique mechanism to recognize 
complex polyUb chains.  In this case separate UBDs of the receptor recognizing two 
different linkages in close proximity on a mixed linkage chain would be the new 
signal, without the need for a novel conformation such as the distal hug.  Ultimately, I 
would expect the quadrillions of theoretical polyUb chains to have much degeneracy 
in their signaling properties, but future work could uncover particular combination of 
linkages that do present new signals for receptors.  Much remains to be explored in 
this new field and my study represents a good first step.           
4.9.2 K48 and K63 mixed linkage polyUb chains 
Ubiquitinating machinery has been shown to be possessive in generating 
homogeneously-linked chains.  I demonstrated here that, when acting together 
simultaneously or sequentially linkage-specific E2 enzymes (K11 Ube2s, K48 E2-
25K, and K63 Ubc13:Mms2) can form both branched and unbranched mixed-linkage 
forms of polyUb.  The extent of the branching is yet to be determined, but the 
example of [Ub]3–11,48,63Ub, indicates that exposure of Ub (or polyUb) to more than 
one E2 enzyme can result in highly branched chains carrying many linkage types.  
Thus, depending on the factors involved (which are currently unclear), the resulting 
polyUb landscape would include chains of unbranched and branched topologies.  This 
raises the question of why such chains have not been observed more often. Possible 
reasons are that intracellular DUBs rapidly edit mixed-linkage chains, or that 
assembly of mixed-linkage chains largely is prevented by regulation (e.g., via 
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compartmentalization) of the various E2 and E3 enzymes in cells.  However, because 
current methods are not suited for the detection of mixed-linkage chains, such chains 
may in fact be quite abundant but remain unseen. 
This study revealed that mixing of K48 and K63 linkages in the same polyUb 
chain retains structural the features of each individual linkage type.  The NMR data 
show unambiguously that the hydrophobic interface, characteristic of the K48-linkage 
is formed across the Ub–48Ub unit in both the branched and unbranched mixed-
linkage trimers, and that this interface exhibits the same pH dependence as the 
“classical” interface in homogeneous K48-linked polyUb.  Furthermore, the 15N T1 
relaxation data revealed that in the mixed-linkage chains the K63-linked Ub is highly 
mobile compared to the other two Ubs, which are restricted by their contacts in the 
K48-dimer.  
A major finding was that highly selective receptors for each of the two linkage 
types bind the branched [Ub]2–48,63Ub chain in a linkage-specific manner; i.e., 
binding to the cognate Ub–Ub unit was essentially as if the other linkage was not 
present.  It is noteworthy that the proximal Ub in [Ub]2–48,63Ub is highly adaptable 
and can bind in both K48 and K63 linkage-selective modes.  Furthermore, chain 
branching also preserves both Ub-specific and linkage-specific epitopes for antibody 
recognition.  Thus, the K48 and K63 linkages within the same polyUb chain can 
retain their characteristic signaling properties. This conclusion is further strengthened 
by the fact that linkage-selective DUBs can efficiently process their cognate linkages 
in both branched and unbranched mixed-linkage chains. The finding that the 26S 
proteasome recognizes and cleaves the branched chain suggests that in vivo polyUb 
137 
 
containing both K48 and K63 linkages can be disassembled by the proteasome 
essentially as a homogeneous chain.  Together, these observations demonstrate that 
the K48 and K63 signaling properties can be encoded into the same polyUb via 
linkage mixing or branching, thus allowing the chain to carry two distinct signals. 
Although this somewhat abstract study is the first attempt to investigate the 
structural properties of mixed linkage polyUb chains the mounting physiological data 
strongly supports roles for such chains and that this work paves the way into a new 
frontier of biology (144).  Another possible mechanism explaining the formation of 
mixed linkage polyUb chains is that the polyUb signal is constantly subject to editing 
or remodeling, and some branched or other mixed-linkage chains could simply be 
accidents that, in analogy to mismatched bases in DNA or misfolded proteins, are 
eventually corrected by cellular machinery.  Nonetheless, as I have demonstrated 
here, linkage mixing or branching could enhance the signaling capability of polyUb. 
That mixed-linkage chains can carry multiple recognition signals is an exciting 











 Chapter 5: Decrypting ubistatin-ubiquitin interactions  
5.1 Background and research aims 
5.1.1 History and prior work for ubistatins 
Ubistatin is a term given to class of naphthyl-based molecules introduced in 
2004 (215).  This stems from the observation that these molecules inhibited 
proteasomal degradation of polyubiquitinated substrates by directly binding the 
polyUb signal, preventing its recognition with receptors.  Dyes such as Congo Red, 
trypan red, and suramin were predecessors to ubistatins and well before their 
association with Ub, ubistatins were being pursued as lead compounds to treat HIV 
and other life threatening viruses, see US Patent 5,681,832 (1997 Haugwitz et al.).          
The interaction of ubistatins with Ub was discovered in 2004 when 109,113 
compounds from the NCI open library were screened in an assay designed to find 
molecules that inhibited cell cycle progression (215).  After the field of compounds 
was narrowed, several were found to block mitotic entry by disrupting either the UPP 
or APC/C activation.  However, only two compounds, c59 and c92 were found to 
inhibit the destruction of polyubiquitinated substrates, but they did not interfere with 
proteasome function directly.  Further testing revealed that both c59 and c92 could 
outcompete proteasomal polyUb receptor Rpn10 and the UBL/UBA shuttle Rad23 for 
polyUb chains (215).  In the same study, solution data from NMR mapped CSPs to 
the L8,I44,V70 hydrophobic patches in polyUb establishing that c92 directly bound 
the polyUb signal (215).  With the mechanism of ubistatins established, another study 
in 2008 used c92 to show that receptor/Ub interactions play a key role in the 
spliceosome assembly pathway and that factors such as Prp8 are polyubiquitinated 
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(216).  The use of ubistatins to probe receptor/Ub interactions on other pathways 
aside from the UPP is an interesting concept, but has yet to become common practice.      
5.1.2 Ubiquitin small molecule interactions and objectives 
Given the success of small molecule proteasome inhibitors, which essentially 
produce the same outcome as ubistatins, there has been an interest in the further 
development of these molecules as potential therapeutics.  Historically ubistatins are 
unique in that they were the first small molecules shown to bind Ub, however since 
Ub itself is a model protein, many others have characterized small molecule 
interactions with the protein.  There has recently been an interest in the interaction of 
Ub with gold nanoparticles and there is experimental data to support specific 
interactions (217, 218), yet there is no structural data other than MD simulations.  To 
further complicate matters the actual structure of the gold nanoparticles themselves is 
hard to determine.  Studies by Whitesides and coworkers have shown that at certain 
concentrations, the anionic detergent SDS binds specific regions of Ub and they have 
also characterized the stoichiometry of several Ub/SDS complexes (219, 220).  In the 
future others may discover more small molecules that interact with Ub, but at this 
present point in time ubistatins are the most promising therapeutics and the only small 
molecules shown to directly modulate defined cellular pathways.   
To further advance ubistatins, the greatest obstacle to overcome is the lack of 
any structural information.  The in vivo capabilities of ubistatins are well 
characterized and promising, but for development we will need to know exactly how 
these molecules interact with Ub and polyUb.  On a special note, the original 2004 
ubistatin study incorrectly reported the structure of c59 and it was not until late 2008 
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that this error was formally corrected (215).  As a result those attempting to further 
investigate c59 were actually working with the wrong molecule.  Thus my main goals 
will be to determine the structures of ubistatin/Ub complexes, their stoichiometry, and 
also determine if other ubistatin derivatives directly bind to Ub.  My secondary 
objectives are focused on exploring new properties of ubistatins to determine if they 
have any other potential applications.            
5.2 Physical properties of ubistatins 
5.2.1Structural classification of ubistatins and derivatives  
The original ubistatin molecules (c59 and c92) were highly conjugated 
symmetric ring systems with electronegative sulfonate substituent groups.  Since 
2004 many other ubistatins derivatives have been synthesized in an effort to improve 
affinity for Ub conjugates.  With the recommendation of Prof. David Fushman 
ubistatins were also synthesized as half compounds containing only one of the ring 
systems, which allowed unambiguous NMR studies.  Logically these compounds 
containing just one ring system are termed “half ubistatins” and the original ubistatins 
are referred to as “full ubistatins.”  The chemical structures of full ubistatins are 
presented in (Figure 5.1) and half ubistatins are presented in (Figure 5.2).  All 
ubistatins compounds used for study were designed and synthesized by our 





Figure 5.1 – Chemical structures of full ubistatin compounds. 
(A-H) full ubistatins contain a common ring system and are symmetric.  The main 
differences are in the substituent groups.   





Figure 5.2 – Chemical structures of half ubistatin compounds. 
(A-D)  Chemical structures of half ubistatins maintain the same ring system and lack 
the alkene linker.  (E) Schematic showing how the corresponding half ubistatin of c59 
results in c112.   






Ubistatin compounds although highly conjugated do contain at least one 
single bond which allows for several conformers.  In particular, the terms cis and 
trans are used to describe the relation of substituent groups to each other.  MD 
simulation and energy minimization performed on the PRODRG server suggests that 
the trans conformation is favored in ubistatins with multiple electro negative groups.  
A simple example is the half ubistatin c112, where the ring system containing H6-H9 
can flip resulting in cis and trans conformations, however the larger ring system 
remain rigidly locked (Figure 5.3).     
 
 
Figure 5.3 – cis and trans conformations of c112. 
(A) c112 can take on a cis conformation by rotation of the H6,H7,H8,H9 ring 
positioning the two sulfonate groups (red and yellow sticks) on the same side of the 
compound. (B) The energetically favored trans conformation of c112 has the two 
sulfonate groups on opposite sides.   
 
 
5.2.2 Spectroscopic properties of ubistatins  
Due to the symmetry of full ubistatins, the chemical shifts corresponding to 
their 1H signals are indistinguishable from either ring system in the compound.  
Additionally, full ubistatins appear to have a propensity to aggregate at high 
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concentrations.  This aggregation effect is not surprising and has been reported for 
similar dyes such as Congo Red (221-223).  For NMR purposes half ubistatins are 
much more suitable with distinct resonance frequencies for 1H signals (Figure 5.4).  
 
 
Figure 5.4 – 1D 1H-NMR spectra of c112 and c59 
(A) 1H-NMR spectrum of the half ubistatin c112 (black) shows narrow line shapes.  
(B) 1H-NMR spectrum of full ubistatin c59 shows (red) a broad line shape suggesting 
a larger molecular weight due to aggregation.  (C) Overlay of 1D spectra from c112 
(black) and c59 (red) have a nearly identical pattern (traced by blue lines), however 
there are 9 protons in c112 and 18 in c59 suggesting that protons in c59 have 




 More importantly, the 1H signals from half ubistatins allow for intermolecular 
NOE’s to be assigned to individual protons.  Using analysis from 2D 1H, 1H-TOCSY 
experiments which show three bond 1H J-couplings and 2D 1H, 1H-NOESY, which 
shows NOEs between 1H nuclei within 5Å, all nine protons in c112 can be assigned 
(see Figure 5.5).  Integration of peaks in the 1D spectrum provides an estimate as to 
how many protons each peak contains.  All protons in c112 are isolated except for 
H4, H5, and H9 which overlap.  Nevertheless, useful TOCSY and NOESY signals 
arise from their positions.            
 
Figure 5.5 – Assignment of protons in c112. 
(A) Structure of c112 with individual protons labeled 1 through 9.  (B) Overlay of 2D 
1H,1H -TOCSY (black), 2D 1H,1H -NOESY (blue), and 1D 1H (bottom).  A trace 
showing an NOE cross peak between H1 and H2 is highlighted (blue dashed line) and 
a trace connecting H6 and H8 in TOCSY is shown (black dashed line).   
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To expand the capabilities of ubistatin compounds I also assessed their 
fluorescent properties.  For quantification purposes the maximum absorbance for each 
compound was determined.  All ubistatins showed strong absorbance in the short UV 
range (220-300 nm) and had slightly different emission profiles.  Given that ubistatins 
strongly absorbed at 280 nm, I went to test their fluorescent properties at 345 nm, a 
wave length well above the absorbance of any protein.  These studies were performed 
to assess whether tryptophan emission and FRET assays could be used with 
ubistatins.  Interestingly, the absorbance range of the ubistatin molecules was very 
broad ranging from 220-360nm for the compounds tested.  Conveniently all ubistatins 
gave a detectable emission with excitation at 308 nm and a transilluminator could be 
used to confirm their presence in samples (Figure 5.6).   Furthermore, the wave 
length corresponding to the emission maxima for each compound deviated highly 





Figure 5.6 – Detection of a colorless ubistatin sample with a UV 
transilluminator. 
(A) The 5 mm Shigemi tube containing c112 and Ub1 appears colorless, but when the 
transilluminator is turned on (B) c112 produced a diagnostic emission in the presence 






Figure 5.7 – Emission profiles of ubistatin compounds with excitation at 280 nm 






Figure 5.7 (continued) – Emission profiles of ubistatin compounds with 
excitation at 280 nm and 345 nm. 
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5.3 Screening for Ub binding ubistatin compounds  
5.3.1 1H,15N-HSQC titration of Ub1  
Initially 1H,15N-HSQC titrations were used to determine whether a particular 
ubistatin compound was able to bind to Ub.  The standard in vivo assay used 
previously detected activity, not binding and it is possible that some ubistatins could 
weakly bind Ub, but fail to show the expected outcome in the assay.  For future 
development of ubistatins it is also essential to understand how certain derivatives 
bind and the affinity of the interaction.  15N-Ub1 was titrated with ubistatins c59, 
c125, c126, c211, c258, c273, half ubistatin c112, half ubistatin c114, and ANS as a 
control.  Originally DMSO was added to help dissolve the ubistatins, however even at 
low concentrations ~5% (v/v) DMSO appeared to interfere with Ub as evident by 
large global CSPs in 1H,15N-HSQC.  A buffer containing 20 mM sodium phosphate 
pH 7.5 greatly improved the solubility of the ubistatins and there was no detectable 
effect on Ub, which was in 20 mM sodium phosphate pH 6.8 buffer.  Furthermore, 
the ability to dissolve a higher concentration of ubistatins meant a smaller volume 
would need to be added to the 15N-Ub1 sample.  This system was ideal for many 
ubistatins, however c258 and c273 were poorly soluble and precipitated early in the 
titration, while c211 precipitated at a molar ratio of [c211]:[Ub1]=1.0.  The CSP plots 
(Figure 5.8) demonstrate that c59 and its corresponding half ubistatin c112 







Figure 5.8 – End point CSPs for ubistatin/Ub1 titrations. 
Initial screening by 1H,15N-HSQC titration with 15N-Ub1 aimed to characterize 
binding by the appearance of CSPs around Ub’s L8,I44,V70 hydrophobic patch.  (A) 
c211 precipitated at [c211]:[Ub1]=1.0, but did not produce any CSPs on Ub.  (B) c59, 
produced large CSPs consistent with binding to the hydrophobic patch.  The half 
ubistatins, (C) c112 and (F) c114 each create similar CSPs upon binding to Ub.  The 
full ubistatin (E) c126 binds Ub strongly, while a similar molecule (D) c125 does not 
bind to Ub.     
   
 As a control experiment to assess if related molecules could create specific 
interactions with Ub, ANS was also titrated into 15N-Ub1.  ANS was chosen because 
its similar structure to ubistatins and its ability to strongly bind solvent exposed 
hydrophobic residues suggests that Ub could nonspecifically interact with similar 
molecules.  At a molar ratio of [ANS]:[Ub1]=2.0, there where small (less than 0.1 
ppm) CSPs in the hydrophobic patch residues, which supports that ANS forms weak 
transient interactions with Ub (Figure 5.9).  The lack of detectable intermolecular 
NOEs supports the ANS/Ub interaction is very weak, and stems from a primarily 




Figure 5.9 – ANS control titration  
(A) Residue specific CSPs in Ub at a molar ratio of [ANS]:[Ub1]=2.0.  There are 
slight interactions around residues L8 and I44.  (B) 1H,15N-HSQC overlay with no 
ANS (black) and at [ANS]:[Ub1]=2.0 (blue).  A zoomed in section shows small shifts 
in H68, I44 and F45.  The structure of ANS is at the bottom right of the spectrum. 
   
      
 Interestingly the ubistatins that bound Ub all contained at least two sulfonate 
groups per ring system.  Compounds that preserved the ring system, but lacked 
substituents were not soluble, while compounds that contained less electronegative 
groups (e.g. carboxylate groups) failed to bind Ub.  At the same time these 
observations were made, our collaborators also noticed the same trend for their in 
vivo assays, i.e. ubistatin activity was only observed with sulfonate containing 
compounds.  The collaborators also noticed that half ubistatins had a reduced activity.  
Presumably this was due to different binding properties or affinities of Ub between 
half and full ubistatins.  A comparison 1H,15N-HSQC spectra shows that both c112 
and c59 interact with the same residues on Ub and the fact that trajectories for many 
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signals in the spectra are identical further supports similar binding between c112 and 





Figure 5.10 – Spectral comparison of c112 and c59 titration with Ub1. 
Residue specific CSP plots at the end point molar ratio (A) [c112]:[Ub1]=3.10 (blue) 
and (B) [c59]:[Ub1]=3.10 (yellow) are inlayed into their corresponding 1H,15N-HSQC 
overly. (A) Spectral overlay showing starting point [c112]:[Ub1]=0.00 (black) and 




One particular difference between c112 and c59 binding of Ub, was that c59 appeared 
to cause a loss in signal intensity in 1H,15N-HSQC, while c112 did not.  This could be 
due to an increase in size, strong sub-micromolar binding, or both.  Experiments to 
address the size of the c59/Ub1 complex are described in the next section.  The 
residue specific titration curves for c112 and c59 with Ub1 showed a very different 
story, the binding of c59 appeared much stronger than the binding of c112 (Figure 
5.11). 
 
Figure 5.11 – Comparison of residue specific titration curves for c112 and c59. 
The CSPs for select residues in 1H,15N-HSQC titration are plotted vs. the molar ratio 
of c112 and c59 over the course of the titration for residue (A) I13, (B) I44, (C) H68, 
and (D) V70, curves for c59 are in dark-yellow circles and curves for c112 are in blue 
circles.  The line connecting the experimental points is the simulated 1:1 binding 
curve.  Note that the kink in the curves for c59 indicating strong stoichiometric 




With a 1:1 binding model, the Kd for the c112 for Ub1 interaction determined by 
NMR 1H,15N-HSQC titration was calculated to a Kd = 212 ± 44 µM.  Analysis of 
residuals and a simple visual inspection made it obvious that residue specific curves 
for the c59/Ub1 titration exhibited tight stoichiometric binding, preventing me from 
determining a Kd.  To determine the Kd for the c59/Ub1 interaction, a different 
method preferably with the concentration of Ub1 kept in the micromolar range would 
be needed.  Using the F45W mutant of Ub (see section 7.2) the Kd of the c59/Ub1 
interaction was measured by tryptophan emission quenching.  The spectroscopic 
properties of c59 allowed for the tryptophan emission to appear undisturbed in the 
emission spectra, as well as emission from c59 with excitation at 280 nm.  A major 
concern was that overlap from the highly fluorescent c59 compound would disturb 
the tryptophan signal by increasing intensity in that region.  However, this was not the 
case and upon addition of c59, the emission for tryptophan showed a dramatic 
decrease in intensity (Figure 5.12).  The change in intensity at 335 nm was calculated 
between each titration point and fit to a 2:1 binding model resulting in a Kd = 3.4 ± 
2.8 µM for the c59/Ub1 interaction.  If each of the two ring systems of c59 represents 
a separate Ub binding motif, then the difference in Kd between c112 and c59 is 
expected.  It is also possible that weak affinity of c112 for Ub1 could dramatically 
change for polyUb chains, just as the Kd of UBA(2) from hHR23A changes from 






Figure 5.12 – Fluorescence quenching using the Ub F45W mutant to monitor c59 
interaction. 
(A) The tryptophan at reside 45 in Ub1 and c59 both have detectable emission with 
excitation at 280 nm.  In the absence of c59 (black line) the emission of tryptophan 
~340nm is strong, however as c59 is added (blue line) the intensity of tryptophan 
emission decreases while the emission intensity of c59 spikes.  At saturation, there is 
barely any tryptophan emission (red line), however the large intensity of the c59 
signal exceeds the detection limit using these settings.  (B) Curves representing the 
spectra for each titration point focused on wave lengths that capture tryptophan 








5.3.2 Gauging the specificity of ubistatins  
To test if c59, the compound with the highest affinity for Ub could still form 
strong interactions in a cellular environment I performed a titration in whole cell 
lysate.  15N-Ub1 was spiked into freshly lysed MCF-7 cells, then c59 was titrated in 
and the interaction was observed by 1H,15N-HSQC.  Upon addition of Ub1 many 
CSPs were observed without any c59 present along with some decreases in signal 
intensity for certain residues on Ub.  This suggested that in addition to the change in 
solvent and viscosity, changes in Ub were caused by specific interactions with factors 
in the MCF-7 lysate.  Nevertheless, when c59 was added, nearly an identical CSP 
pattern and spectral changes were produced (Figure 5.13).  This result directly proves 
that ubistatin compounds selectively bind Ub, discriminating from all other proteins 
in the cell.  Furthermore, this represents a straight forward method to monitor the 




Figure 5.13 – Selectivity of c59 for Ub1 in MCF-7 lysate. 
(A) 1H,15N-HSQC overlay of 15N-Ub1 in MCF-7 lysate with no c59 (black) and at 
molar ratio [c59]:[Ub1]=0.67 (red).  (B) Residue specific CSPs of from the MCF-7 
sample at [c59]:[Ub1]=0.67 (red) and in standard NMR buffer at molar ratio 
[c59]:[Ub1]=0.40 (blue).  The MCF-7 sample has smaller CSPs due to the additional 
factors c59 must overcome to bind Ub.         
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 To determine if ubistatins could discriminate between UBLs and Ub, I 
titrated Rub1, the closest related UBL to Ub with c112.  Interestingly, Rub1 is also 76 
residues in length and contains the same L8,I44,V70 hydrophobic patch in the exact 
same location as Ub.  However, some of the residues in Rub1 surrounding the 
hydrophobic patch differ from those in Ub.  If c112 does bind Rub1 there should be 
some detectable binding interaction at a moderate molar ratio.  When 15N-Rub1 was 
titrated with c112, very small CSPs were observed in 1H,15N-HSQC early in the 
titration.  Still at molar ratio [c112]:[Rub1]=1.45 there were hardly any noticeable 
CSPs, however the small CSPs that were quantifiable resulted from residues I44, 
H68, and V70 (see Figure 5.14).  This suggested that c112 formed weak transient 
interactions with Rub1, analogous to those attributed to the ANS/Ub interaction.  In 
addition to the titration data for c112 with Rub1 (Figure 5.14), the absence of 
intermolecular NOEs and 15N T1 measurements also supported that there was hardly 




Figure 5.14 – The UBL Rub1 forms weak interactions with c112. 
(A) Titration of 15N-Rub1 with c112 produces small CSPs in 1H,15N-HSQC.  Signals 
corresponding to [c112]:[Rub1]=0.00 (black) show little deviation from 
[c112]:[Rub1]=1.45 (green), with slight shifts in I44, H68, and V70.  (B) Residue 
specific CSPs for [c112]:[Rub1]=1.45 (green) and for comparison [c112]:[Ub1]=1.44 
(blue).  The large difference in magnitude supports that c112 binds Ub1 with a much 





5.3.3 Proteasomal DUBs are inhibited by c112 and c59 
Given that it is established ubistatins bind the polyUb chain, I wanted to 
determine if this interaction would interfere with the activity of DUBs.  In the 2004 
study they reported polyUb conjugates increased or stabilized in the cell, however the 
proteasomal DUB Rpn11 still retained some activity (215).  Another observation was 
that ubistatins had a greater affinity for K48 linkages compared to K63 linkages.  
Therefore it is possible that Rpn11 was active because it was cleaving linkages other 
than K48 that reached the proteasome or since Rpn11 is reported to cleave the Ub-
substrate bond, the ubistatins bound to the polyUb signal did not affect Rpn11 activity 
(51, 212).  The effects of ubistatins on DUB activity has yet to be tested and I found it 
necessary to investigate this question. Ubp6, a proteasome associated USP DUB is 
accepted as the second major DUB associated with the proteasome and prefers to 
cleave Ub-Ub bonds from the distal end.  This is in contrast to Rpn11 which can 
cleave the Ub-substrate bond and also endo Ub-Ub bonds (213).  Similar to other 
USP DUBs, Ubp6 can cleave several different Ub-Ub linkages, but preferentially 
cleaves K48 over K63 (31). Using a simple gel assay, I set to answer if (i) ubistatins 
generally inhibit DUB activity and (ii) if ubistatins do inhibit DUBs, is this only for 
certain Ub-Ub linkages.  The molar ratio of Ubp6 to K48 or K63 linked Ub2 was 
always kept at 0.2.  The molar ratio of c112 and c59 were varied in respect to the Ub2, 
testing ratios of 0.2, 0.5, 1.0, and 3.0.   
The data for K48-Ub2 with c112 and c59 presented in (Figure 5.15) show that 
both compounds are capable of shielding the polyUb chain from Ubp6.  Even at 
concentrations bellow a 1:1 molar ratio (ubistatin:K48-Ub2) there is still a noticeable 
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inhibitory effect.  Quantitatively we see that c59 is a more potent inhibitor of Ubp6 
than c112, as 80% of K48-Ub2 remains after 3 hours, while only 40% remains for 
c112 at the same molar ratio, [ubistatin]:[K48-Ub2]=3.0.  This observation is 
consistent with the previously reported data.   
 
Figure 5.15 – c112 and c59 shield K48 linked polyUb from Ubp6. 
(A) The mono- and di-Ub regions of 15% SDS-PAGE gels with time points of 0, 0.5, 
1.0, 1.5, 2.0, 2.5, and 3.0 hrs.  In the control (top gels) K48-Ub2 is reduced to mono-
Ub quickly, however at sufficient concentrations of c112 (left panel) or c59 (right 
panel) K48-Ub2 is preserved.  (B, C) For each time point, the band corresponding to 
K48-Ub2 was integrated and then normalized.  (B) Inside of the 3 hr time window all 
concentrations of c112 retain a greater amount of K48-Ub2 than the control (C) For 
c59 and there is as similar effect and at a molar ratio [c59]:[K48-Ub2]=3.0 a 
staggering 80% of the K48-Ub2 remains. 
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 With a noticeable inhibitory effect on K48 linkages, I tested K63-Ub2 using 
the same assay.  The results (Figure 5.16) show a slightly different story.  K63 
linkages are cleaved at slower rate than K48 linkages by Ubp6 without the ubistatin, 
however it does not appear that moderate concentrations of either c112 or c59 were 
helpful in shielding K63-Ub2 from Ubp6.  For K48-Ub2 Ubp6 inhibition was 
observed even at low molar ratio [ubistatin]:[Ub2]=0.5 (Figure 5.15 B,C), however 
for K63-Ub2 inhibition of Ubp6 does not occur until the relatively high ratio, 
[ubistatin]:[Ub2]=3.0.  Furthermore, ubistatins appear to facilitate the cleavage of 
K63-Ub2 by Ubp6.  Neither with K48 nor K63 linked polyUb chains is the half 
ubistatin c112 more effective than its corresponding full ubistatin c59.  Taken 
together, this result suggests that when ubistatins are introduced to the cell they also 
prevent K48 polyUb signals from being cleaved by DUBs, in addition to blocking 
their interactions with receptors.  If the polyUb signal must be removed by the 
proteasome this observation provides an additional mechanism as to how ubistatins 





Figure 5.16 – Minimal effect of c112 and c59 on Ubp6 activity for K63 linkages. 
(A) The mono- and di-Ub regions of 15% SDS-PAGE gels with time points of 0, 0.5, 
1.0, 1.5, 2.0, 2.5, and 3.0 hrs.  The control (top gels) show that K63-Ub2 begins being 
cleaved after about 1.5 hrs.  Several concentrations of c112 (left panel) and c59 (right 
panel) show ubistatins can inhibit Ubp6 from cleaving K63-Ub2.  (B, C) For each 
time point, the band corresponding to K63-Ub2 was integrated and then normalized.  
(B) Very little deviation from the control is seen for c112 inside of the 3 hr time 
window (C) For c59 all other conditions besides [c59]:[K63-Ub2]=3.0 shows little to 




5.4 Comparison of c112 and c59 interactions  
5.4.1 Molecular weight by translational diffusion and 15N-T1 relaxation  
The strong signal attenuations in 1H,15N-HSQC titration experiments 
described in (section 5.3) indicated that c59 bound Ub1 tightly, but this alone could 
not be used to determine if the c59/Ub1 complex oligomerized multiple Ubs.  To 
determine the average molecular weight of the c112/Ub1 and c59/Ub1 complexes 
DOSY experiments which measure translational diffusion, and 15N T1 relaxation 
experiments which are sensitive to both the size and shape of the molecule under 
observation were performed for each complex.  Over the course of the titration it was 
possible to measure the translational diffusion properties of both the ubistatin and 
15N-Ub1, however due to practical reasons 15N-T1 relaxation was only measured for 
the beginning and endpoints of each titration for Ub.   
Translational diffusion is a less sensitive method for measuring molecular 
weight compared to rotational diffusion experiments (T1 and T2 relaxation), however 
it is one of the surest NMR experiments to gauge the oligomeric state of ubistatin/Ub 
complexes in a relatively short acquisition time.  For select points along each titration 
the translational diffusion coefficient was measured using a series of 1D experiments 
that differed in z-gradient strengths and also had 15N filtering.  The 15N filter was used 
to segregate signals from the ubistatin and those from Ub.  Conveniently the proton 
signals from c59 and c112 fall in the amide region of Ub, but do not overlap with 
aromatic protons (12C-1H) in Ub.  The translational diffusion coefficient was 
calculated using 1H signals from the methyl containing 3-0 ppm region of 1H spectra.  
The data over each titration (Figure 5.17) show that the translational diffusion 
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coefficient of Ub in the presence of c59 decreases, while c112 causes hardly any 
change in Ub.     
 
Figure 5.17 – Translational diffusion measurements of Ub with c59 and c112. 
(A) A series of 1D 1H spectra collected under varying z-gradient strengths produce 
different intensities that can be used to calculate the translational diffusion 
coefficient.  Signals from ubistatin only appear between 7-9ppm, while the whole 
right side of the spectrum contains signals from Ub.  With no ubistatin, signals from 
Ub1 have a translational diffusion coefficient between 280-300 (black squares). (B) 
As c59 is titrated in, the translational diffusion efficient decreases early 
[c59]:[Ub1]=0.60 (blue triangles), but does not change significantly when c59 reaches 
[c59]:[Ub1]=3.4 (red circles).  (C)  For Ub1 with c112 there is no significant change 
between free Ub1 (black squares) or when [c112]:[Ub1]=3.0 (red circles).  This 
suggests that c59 creates a complex with more than one Ub.       
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The findings from translational diffusion measurements painted a stark contrast 
between c112 and c59, even though each bound the same surface of Ub, c59 appeared 
to form at least a 1:2 (c59:Ub1) complex with Ub while c112 formed a well behaved 
1:1 complex. 
 To understand each complex better, I also measured 15N T1 for each titration 
end point and used existing T1 data for monomeric Ub, K48-Ub2, and K63-Ub2 to 
estimate how large the complex was.  The results (Figure 5.18) certainly show an 
increase in size for c59, but also a small ~80 ms increase in 15N T1 for c112 that was 
not as pronounced in the translational diffusion data.  K63-Ub2 lacking any 
interdomain contacts has a shorter T1 compared to K48-Ub2, yet the T1 for the 
c112/Ub1 complex still has a shorter T1 compared to both di-Ubs suggesting that it 
does not oligomerize Ub.  T1 data for the c59/Ub1 complex gives a much clearer 
picture about the size, which fall just below T1 values of K48-Ub2.  This assertion 
agrees well with the translation diffusion data and supports a 1:2 c59/Ub1 binding 
interaction.  Interestingly, the c59/Ub1 complex (more accurately c59/2Ub1) does not 
appear to reach a larger size at any point in the titration.  The T1 data would support a 
model in which two Ubs tightly enclose one molecule of c59, given that the T1 values 





Figure 5.18 – 15N T1 relaxation reveals the stoichiometry of ubistatin/Ub 
complexes. 
(A) At the end of the c112 and c59 titrations, the T1 was measured.  In respect to free 
monomeric Ub (black line), the c112/Ub complex (magenta line) shows a slight 
increase in T1 for Ub, however, the c59/Ub1 complex (orange line) has the largest 
increase in T1.  (B) To estimate the size of each complex, the T1 from (A) was plotted 
against monomeric Ub (black), K63-Ub2 (blue), and K48-Ub2 (red).  For c112 
(magenta), the T1 values do not reach those of K63-Ub2, however the T1 values for 
c59 (orange) essentially fall right between K63-Ub2 and K48-Ub2 indicating the 
c59/Ub1 complex behaves as a dimer. (C) Corresponding structures of the Ub species 
used for comparison color coded as in the T1 data.   
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5.4.2 Detection of intermolecular NOEs  
To confirm the close proximity of c112 and c59 to Ub, a 2D  1H,1H-NOESY 
with 15N filtering was acquired at each titration endpoint as well.  NOE’s are 
detectable when two nuclei are within a distance of 5Å and since the 1H signals of 
both ubistatins fall within the amide range (see Figure 5.4), the 15N filter would 
suppress intermolecular NOEs in Ub and only allow for NOE’s between the ubistatin 
and Ub to be isolated.  Each ubistatin compound would be expected to show some 
intramolecular NOEs, however if the compound is in close proximity to the 
L8,I44,V70 hydrophobic patch there should be some NOEs to the methyl region as 
well.  The c59/Ub1 complex is essentially twice the size of the c112/Ub1 complex and 
this increases the line shape for all signals, even NOEs.  When the 2D 1H,1H-NOESY 
was performed on a 600 MHz instrument NOEs were not detected for c59/Ub1.  This 
is attributed to both the size of the complex and also the tight binding of c59 at 
residues that would produce NOEs.  As shown in 1H,15N-HSQC, the tight binding of 
c59 can broaden signals beyond detection.  Many NOEs were observed between 
protons in c112 and side chains of Ub (Figure 5.19).  These NOEs are consistent with 
binding to the methyl side chains of the L8,I44,V70 hydrophobic patch and there also 





Figure 5.19 – Detection of intermolecular NOEs between c112 and Ub. 
In this spectrum all NOEs are cross peaks formed off of the diagonal line.  1H,1H-
NOESY with 15N filtering shows that the protons in c112 (blue region) have NOEs to 
residues in Ub (magenta region).  Many of the NOEs between c112 and Ub fall 
within the methyl range.  Aromatic protons in Ub (black region) also show many 












5.4.3 Interactions with K48 and K63 polyUb chains  
To address how both ubistatins interacted with different linkages, K48-Ub2 
and K63-Ub2 were titrated with each ubistatin.  It has been reported that c59 is K48 
selective, but this conclusion was determined in a relatively crude gel shift assay.  
Using 1H,15N-HSQC titration in combination with 15N T1 relaxation, I show that both 
c59 and c112 form essentially the same interactions as they do with monomeric Ub.  
Again, c112 and c59 both utilize the same binding surface on Ub, however the 
characteristics of binding are very different.  From just a simple overlay of the 1H, 
15N-HSQC spectra it is apparent from the pattern of signal attenuations that c59 
strongly binds both K48 and K63 linkages (Figure 5.20 and 5.21).  Spectra for c112 
demonstrate that it also interacts with both linkages, but does not produce the 






Figure 5.20 – 1H,15N-HSQC titration of K48-Ub2 
Titration of K48-Ub2 with both c59 and c112 produces residue specific shifts from 
binding.  (A) Overlay of unbound K48-Ub2 (black) with titration point [c112]:[K48-
Ub2]=4.8 (magenta) shows that signals retain sharp line shapes at saturation (B) The 
overlay of unbound K48-Ub2 (black) with titration point [c59]:[K48-Ub2]=4.00 




Figure 5.21 – 1H,15N-HSQC titration of K63-Ub2 
Titration of K63-Ub2 with both c59 and c112 produces residue specific shifts from 
binding.  (A) Overlay of unbound K63-Ub2 (black) with titration point [c112]:[K63-
Ub2]=4.8 (magenta) shows that signals retain sharp line shapes at saturation (B) The 
overlay of unbound K63-Ub2 (black) with titration point [c59]:[K63-Ub2]=4.00 





To investigate the size of each complex 15N T1 was measured at the end point for each 
titration.  The results (Figure 5.22) show trends similar to monomeric Ub.  
Interestingly, the complexes for K48-Ub2 and K63-Ub2 appear to be dramatically 
different for c59, but not with c112 or in the unbound form.  This large difference 
could be due to c59 oligomerizing K63-Ub2 such that one molecule creates an 
essentially tetrameric Ub (2 x K63-Ub2) complex.  This is interesting considering that 
c59 was reported to bind K48 linkages with a great affinity. The observation of the 
apparent difference in stoichiometry for the K48 vs. K63 linked di-Ub complexes, 
suggests a different binding mechanism for each linkage.  This may explain how 
ubistatins discriminate between K48 and K63 linkages.  I attribute this difference to 
the conformations each linkage presents for binding.  As the CSPs show (Figure 
5.22) ubistatins will bind the L8,I44,V70 hydrophobic patch, but the resulting 





















Figure 5.22 – Analysis of K48 and K63 interactions with ubistatins 
(A) 15N T1 data measured at the endpoint of each titration is reported for the K48 
linkage (left) and K63 linkage (right).  T1 values for unbound di-Ubs are in black, 
c112/di-Ub complexes are magenta, and c59/di-Ub complexes are in orange.  (B-E) 
Reside specific CSPs for c112 (magenta) and c59 (orange) titration with K48-Ub2 
(top row), and K63-Ub2 (bottom row).  Signal attenuations are designated by gray 
bars.    
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5.4.4 Anionic Ub mutants disrupt ubistatin binding 
Based on the CSP, NOESY, and T1 relaxation data, there was no question that 
the L8,I44,V70 hydrophobic patch in Ub was necessary for the binding of ubistatins.   
However, the Rub1 titration which essentially showed no interaction, even though 
Rub1 contained the same L8,I44,V70 hydrophobic patch led me to search for other 
factors essential for ubistatin interactions.  Neighboring residues were a logical place 
to search in addition to considering the properties of the ubistatins themselves.  In 
c112 and c59, the protons in the ring systems must account for a majority of the 
hydrophobic interaction, however the substituent groups, all electronegative 
sulfonates were also shown to be important (see Figure 5.8).  Understandably, I 
searched for cationic residues surrounding the hydrophobic patch and noticed that 
R42 and R74 are in very close proximity.  Their significantly larger CSPs and 
attenuations compared to other cationic residues also supported their involvement.  
However, there was a pitfall in the detection of this ionic interaction that would 
presumably involve a sulfonate group from the ubistatin and a guanidinium group of 
either R42 or R72.  The nuclei involved are arranged in such a way that they are 
essential invisible my NMR methods and the large size of these groups puts 1H-1H 
pairs outside of the 5Å range of NOE detection.  With limited options, I created 
several Ub mutants to test the importance of R42 and R72 for ubistatin interaction.  
Ub(R42A) and Ub(R72A) were designed to determine if either hydrophobics or 
electrostatics were more important for binding, Ub(R42E) and Ub(R72E) were 
introduced to see if was possible to overcome the electrostatic interaction, and 
Ub(K63D) served as a control to ensure that changing the bulk charge of Ub did not 
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disrupt binding.  Electrostatic potential maps are shown for several mutants (Figure 
5.23).   
 
Figure 5.23 – Electrostatic potentials of Ub R42 and R72 mutants. 
(A) Electrostatic potentials (blue=basic, white =hydrophobic, and red=acidic) shown 
on wild type Ub and cartoon representation with relevant features.  (B)  Alanine 
mutants of Ub used, note the change from basic to hydrophobic in the area indicated 
by the green arrow.  (C) Glutamic acid mutants of Ub.  The green arrows indicates a 
complete reversal in potential from basic to acidic in the double mutant, 
Ub(R42E/R72E).      
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  1H,15N-HSQC titration of several alanine and glutamic acid Ub mutants revealed 
that c112 utilized significant hydrophobic contacts to bind, however electrostatic 
interactions were also important for binding Ub.  The end point CSPs for Ub(R42A) 
and (R72A) are still follow the same profile as wild type Ub although they are smaller 
suggesting weaker binding (Figure 5.24).  The Effect of glutamic acid mutants, 
Ub(R42E) and Ub(R72E) is more pronounced for each mutant, with Ub(R42E) 
showing a more notable impact due to its closer proximity to the L8,I44,V70 
hydrophobic patch.  When a the double mutant, Ub(R42E/R72E) is titrated with c112, 
binding is all but abolished (Figure 5.24).  It appears that R42 and R72 are both in 
close proximity to c112 and that they form important electrostatic interactions as 
demonstrated in these titrations.  This effect is localized and changing the bulk charge 
of Ub as shown with Ub(K63D) does not disrupt binding of c112.  Over the course of 
the titration the effects of each mutant are shown for residue specific titration curves 
(Figure 5.25).  In agreement with the endpoint CSPs, the titration curves show that 
the Ub(K63D) binds just as wild type, the alanine mutant still retains some binding, 






Figure 5.24 – CSPs demonstrate electrostatics interactions from R42 and R72 
facilitate c112 binding. 
(A) End point CSPs for Ub wild type (black) compared to alanine mutants Ub(R42A) 
(cyan), and Ub(R72A) (blue).  (B) The glutamic acid mutants Ub(R42E) (cyan) and 
Ub(R72E) (blue) show diminished CSPs compared to wild type Ub (black).  (C)  The 
double mutant Ub(R42E/R72E) (red) has virtually no CSPs indicating that binding of 
c112 is abolished.  (D)  Ub(K63D) (green) containing the same bulk charge as the 
other glutamic acid mutants still retains the ability to bind c112.   
 
 
    
 





Figure 5.25 – Residue specific titrations curves monitor c112 binding. 
The titration curves for residues T7, I44, F45, and V70 in Ub are plotted for each Ub 






With these results I tested if these same mutants would prohibit binding to c59, the 
full ubistatin.  The results (Figure 5.26) show virtually no CSPs from binding and 
also, the c59/2Ub1 complex does not form as the T1 data shows at saturation shows, 







Figure 5.26 – Glutamic acid mutants abolish c59 binding to monomeric Ub. 
(A) 1H,15N-HSQC overlay of titration endpoint of  [c59]:[Ub(R42E/R72E)]=3.0 in 
orange with unbound Ub(R42/R72E) in black.  There are minimal CSPs and the 
peaks are narrow, unlike titration with wild type Ub1.  (B)  Residue specific CSPs of 
[c59]:[Ub(R42E/R72E)]=3.0 in orange are barely visible compared to the CSPs from 
[c59]:[Ub(WT)]=3.1.  (C) T1 data for unbound Ub1 (blue), 
[c59]:[Ub(R42E/R72E)]=3.0 (orange), and [c59]:[Ub(WT)]=3.1 (black).  Note that 








5.4.5 Failure: crystallization of c59 and c112 Ub complexes  
The extensive solution NMR studies provided much useful information on 
several ubistatins.  However, the nature of the c59 compound with symmetric 
unassignable protons and its ability to form large complexes with Ub resulting in 
broadened NMR line widths made structural determination impossible with NMR 
methods.  In a desperate attempt to determine a structure, crystal screening was 
performed on c112 and c59 in complex with monomeric Ub, K48-Ub2, and K63-Ub2.  
Six different 96-condition screens were attempted for each of the six complexes, 
however none produced the desired crystals.  In the case of K48-Ub2, the dimer often 
crystallized without the ubistatin, which was discovered upon diffraction. 
5.5 Structural determination and validation of the c112/Ub1 complex 
5.5.1 Assignment and analysis of intermolecular NOEs  
 
Using a simple 15N filtered 2D 1H,1H-NOESY, NOEs between c112 and 
mono-Ub were detected.  To assign these intermolecular NOEs between 1H-1H pairs, 
a battery of experiments on 13C/15N-Ub in complex with c112 were performed.  First, 
the individual signals for protons in bound c112 were assigned in an approach similar 
to the assignment of free c112 (see Figure 5.5).  For these experiments, the 1H,1H-
TOCSY and 1H,1H-NOESY experiments filtered any 1H attached to 13C or 15N, 
leaving only signals from c112.  To ensure only NOEs between c112 and Ub were 
detected; a variation of NOESY that only allows for NOEs between 12C-1H and 13C-
1H pairs was used.  This experiment resulted in the 1H and 13C chemical shifts for 




Figure 5.27 – Intermolecular NOEs between c112 and Ub. 
Variation of 3D-NOESY with filter to only allow NOEs between 12C-1H and 13C-1H.  
The 1D 1H spectra for c112 in the bound state are shown to illustrate how the signals 
observed in the NOESY towers for each of the protons in c112 are assigned to 
protons in Ub (A) The 2D 1H,1H plane is shown and (C) 2D 1H,13C plane is shown.  




Using a combination of 3D 1H-CCCONH TOCSY and 2D 13C, 1H-HSQC signals for 
Ub were assigned in the c112 bound state of Ub.  With proper assignment, NOEs 
could be quantified in the 2D 1H, 1H-NOESY.  Intramolecular NOEs in c112 and also 
Ub of known distances served for calibration.  There were some concerns about 
spectral overlap for protons in c112, but with much help from Prof. Olivier Walker 










Table 5.1 – Intermolecular NOEs between Ub and c112.  
NOE distance calculated from internal standards.   
*For each distance an error of ±2.0 Å was assumed for docking.    
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5.5.2 Long range distance constraints from PREs  
The NOE data were encouraging and certainly gave us a starting point for 
structural calculations.  However, in such short distances there could be error and also 
it is possible that c112 can be oriented several different ways on Ub’s hydrophobic 
patch.  To better understand how c112 was oriented we designed several experiments 
for use with MTSL as paramagnetic probe.  With several NOE based structural 
models of the c112/Ub complex, we simulated how different sites of attachment for 
MTSL on Ub would affect individual protons in c112 (Figure 5.28).  We proceeded 
with several Ub cysteine mutants.  The position of the paramagnetic center was fit 
using changes in intensity of Ub signals in 1H,15N-HSQC and distances to individual 
proton in c112 were detected with 1D 1-NOESY with a 15N-filter.  Several positions 
on Ub (T12, I36, K48 and K63) were tested for MSTSL attachment (see Figure 
5.29).  As expected, the control with MTSL at residue 63 did not produce any 
quantifiable attenuations in c112 due to the large distance between the unpaired 
electron in MTSL and nuclei in c112.  The data for MTSL at the other positions was 






Figure 5.28 – Simulation of MTSL attachment at every residue in Ub 
To determine the best position for MTSL attachment, the effect of MTSL positioned 
on every residue of Ub was simulated for every proton in c112.  Sections in blue such 
as at residue number 48 indicate all signals from c112 would be attenuated, while all 






Figure 5.29 – MTSL positions on Ub used 
(A) The attachment of MTSL to Ub mutants T12C, I36C, K48C, and K63C is shown 
on the surface of Ub with c112 modeled using NOEs from I44 and V70.  (B)  The Ub 
is removed and just the position of MTSL and c112 are shown.  These positions were 
chosen deliberately to probe c112 from different angles.  K63, far removed is the 
negative control and did not produce a detectable effect on protons in c112.   
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The details of the PRE experiments are described in (section 3.4.5).  After evaluating 
the MTSL data, the following distances were taken for docking (Table 5.2)  
 
Table 5.2 – PRE derived distances to protons in c112 
*For docking an error of ±4.0 Å was assumed to account for flexibility in MTSL and 




5.5.3 Structural calculation of c112  
With the NOE and PRE derived distances, we initiated structural calculations 
for the c112/Ub1 complex.  The additional knowledge of the stoichiometry and along 
with the importance of cationic residues R42 and R72 also help to guide docking.  For 
this docking step and many of the previous steps in distance calculation, Prof. Olivier 
Walker’s expertise was invaluable.  After performing many runs with HADDOCK 
(see section 3.5.2 for details), the results were evaluated and for the first time a high 
resolution structure of an ubistatin/Ub complex was determined (Figure 5.30).  Our 
structure satisfied all of the distances that were calculated from NOEs and PREs, in 
addition to including the electrostatic interaction between R42 and a sulfonate of 
c112.  With this structure as a template we were also able to model how the full 
ubistatin, c59 would look if superimposed on the c112/Ub1 complex.  We find that if 
just bound to one Ub, one half of c59 is left hanging off the binding surface, allowing 
a second Ub to bind.  This explains how c59 forms a c59/2Ub1 complex with 








Figure 5.30 – Solution NMR structure of c112/Ub1  
Cartoon and electrostatic representations of Ub with c112 (black sticks).  Cationic 
R42 and R72 are in close proximity to a sulfonate of c112.  As the NOEs show, the 
main ring of c112 is positioned directly over I44 and V70 of the hydrophobic patch in 
Ub.  The bottom view shows c112 fits in nicely to a cleft on the surface of Ub.  
















Figure 5.31 – Structural model of the c59/Ub1 complex 
Using what was learned from the titration data and c112/Ub1 structure, the proposed 
model for the c59/Ub1 complex is shown with at c59:Ub1 stoichiometry, 1:2.  The 
size of c59 allows two Ubs to simultaneously bind.     
* Structure calculated in collaboration with Prof. Olivier Walker 
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5.6 Discussion and summary  
The idea of designing small molecules to bind to Ub is an exciting concept.  
Targeting the surface of a non-catalytic protein is also an interesting strategy and the 
in vivo data supports that ubistatin compounds are already highly effective, thus 
validating the strategy.  Until this work virtually nothing was known about how 
ubistatins bound Ub.  Through extensive NMR experiments, I have demonstrated that 
ubistatins always bind the L8,I44,V70 hydrophobic patch of Ub, regardless of the 
linkage type.  In collaboration with others we conclude that the sulfonate groups are 
necessary for proper Ub binding.  The observations that c112 can discriminate 
between Rub1 and Ub, while ANS does not bind Ub are particularly encouraging and 
highlights the specificity ubistatins have achieved.  The solution structure obtained 
for the c112/Ub1 complex gives many paths for further development of these 
molecules.  Even if c59 is an already potent drug, it does have an inherent problem of 
membrane permeability (224).  However, our structural models would allow for the 
chemical addition of specialized groups to c59 and c112 to overcome the limitation.  
This study represents a first step into the structural investigation of ubistatins, yet it 
was disappointing that neither a solution or crystal structure could be solved for any 
c59 or polyUb complexes.  It may be that the nature of ubistatin/Ub complexes 
simply do not favor crystallization.  Nevertheless much was learned from ubistatin 
titrations of polyUb chains using solution NMR.  The finding that ubistatins also 
inhibit DUBs provides a new explanation of how these molecules interfere with 
cellular machinery.  There is much more work to be done on ubistatin compounds and 
also for my study to be expanded on, especially the structural aspects.  Perhaps others 
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will design different molecules (e.g. gold nanoparticles) to bind Ub, but at the present 
time ubistatins are the best characterized Ub binding small molecules and certainly 
the most proven.  With the proper structural information, the same concept of 
ubistatins targeting Ub could be attempted for small molecules targeting UBLs.  From 
a drug design point of view, ubistatins may produce an unacceptable number of off 
target effects, considering they inhibit all polyUb signaling.  However, proteasome 
inhibitors arrest the UPP and also disrupt a large number of cellular pathways.  Given 
that ubistatins have been shown to arrest the cell cycle, producing effects similar to 
proteasome inhibitors they are certainly worth pursuing.  If ubistatins do fail as drugs 
then they could simply be used as reagents for in vitro studies as they have been used 
before (216).  With the proper design, it is not likely that ubistatins will fail as drugs 
and the lessons learned from our structural studies with ubistatins could be applied to 




















Chapter 6: A breakthrough: proteomic methods for the analysis 
of K63-linked polyubiquitin conjugates 
 
6.1 Background and research aims 
Tryptic digestion of Ub conjugates followed by mass spectrometry (MS) 
analysis has been the traditional approach to Ub proteomics for the past few decades 
(225).  The hallmark of this approach is that cleavage at R74, leaves a very distinct 
di-glycine (GG) motif attached to Ub modified proteins.  Conveniently, tryptic 
cleavage isolates all Ub-Ub linkage sites on Ub, which has enabled researchers to 
quantify the abundance of individual Ub-Ub linkages from whole cell extracts and 
also pinpoint ubiquitination sites in the proteome (226).  However, even with the 
success of the tryptic cleavage approach, critical information is still unattainable with 
the method.   
Traditional tryptic analysis of the Ub modification can be rather ambiguous 
due to the fact that the GG tag on a lysine is not definitive evidence of ubiquitination. 
This modification could easily be the result of UBL proteins e.g. Rub1 (Nedd8 in 
humans) and ISG15 that would also leave the same GG tag following tryptic 
cleavage.  Thus, it is never possible to state with certainty if the GG tag originated 
from Ub or a number of UBL proteins.  Furthermore, trypsin cleaves Ub in many 
different places producing many small fragments, which could be unfavorable for 
some MS applications.  When other methods such as, Ub-Ub linkage specific 
antibodies are used in collaboration with tryptic cleavage it is possible to 
unambiguously determine sites of ubiquitination and identify the Ub-Ub linkages 
(e.g. K48 and K33) present.  Without extensive supporting experiments, tryptic 
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cleavage alone cannot prove polyubiquitination at a given site or differentiate 
between mixed and branched Ub-Ub linkages.  However, using an alternate cleavage 
method specific for aspartic acid residues, I have demonstrated that it is possible to 
measure the number of consecutive K63-linkages in free or substrate attached polyUb 
conjugates (227).  Notably, my method is the first MS base approach, which is 
feasible for proteomic analysis.  In addition it is also the first instance where a polyUb 
chain greater than two Ubs has been “measured.”  We have demonstrated this 
approach on both unanchored (free) K63 linked polyUb chains and K63 modified 
substrates (228).  The main aim of this alternate cleavage method is to overcome the 
limitations of tryptic cleavage and advance what we can learn about Ub signaling 
using proteomics.  This method does indeed give us an unprecedented view of K63-
linked Ub conjugates.  All MS experiments and analysis presented in this chapter 
were carried out by Joseph R. Cannon in the lab of Prof. Catherine Fenselau.                
6.2 Residue specific cleavage of ubiquitin 
6.2.1 Cleavage of Ub by known proteases 
The serine protease trypsin will selectively cleave bulky cationic residues, 
lysine and arginine at eleven cleavage sites approximately evenly distributed across 
the sequence of monomeric Ub (K6, K11, K27, K29, K33, R42, K48, R54, K63, R72, 
and R74).  A more selective serine protease, Lys-C is highly specific for lysine 
residues will only cleave seven times at each of the seven lysines in Ub.  However, 
both trypsin and Lys-C have virtually no activity for modified lysines, whether the 
modification is acetylation, glycosylation, or ubiquitination.  The arginine specific 
protease, Arg-C produces cleavage products of little interest in Ub which are mainly 
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located near the end of the sequence.  Tryptic and Lys-C cleavage are very effective 
in that they both help separate the lysine residues in Ub’s sequence.  However, lysine 
residues are prone to modification and this will more than likely reduce the usefulness 
of both trypsin and Lys-C.  Alternate cleavage at residues, which are generally never 
modified can help get around this obstacle.  Aspartic acid specific cleavage with Asp-
N cleaves the five Asp residues in the sequence of Ub, which aids in separating the 
eight linkage sites on Ub regardless of how they are modified.  The Asp-N digestion 
fragments of Ub will contain between one and three linkage sites making downstream 
analysis more manageable.  As an alternative to Asp-N, chemical methods such as 
microwave assisted acid hydrolysis (MAAH) provide another means to achieve 
aspartic acid specific cleavage.  In MAAH, an acid such as acetic acid or citric acid is 
placed in solution with the protein (~12% v/v), then heating in a specialized 
microwave catalyzes the selective cleavage of Asp residues resulting in the desired 
cleavage products.  The resulting cleavage products of Ub with common proteases are 
shown (Table 6.1). 
 
Table 6.1 – Cleavage products of Ub by known proteases. 
Note the number of cleave sites and their position in Ub.  This initial analysis allowed 




6.2.2 Making the proper cuts in Ub  
One of the greatest disadvantages of proteolysis of polyUb chains is that the 
exact sequence of the chain is destroyed such that it yields little information.  The two 
Asp specific cleavage methods above present a special case for the K63 linkage.  In 
principle, since Ub is always liked via the C-terminus to any of eight linkage sites on 
another Ub, cleaving such that the C-terminal residues and linkage site are connected 
will preserve the chain.  Conveniently, D58 is the last residue in Ub's sequence to be 
cleaved by Asp specific methods.  This cleavage product contains the K63 linkage 
site as well as the C-terminus of Ub.  With this cleavage method any K63 linked 
polyUb conjugate (unanchored or substrate attached) will retain every consecutive 
K63 linkage.  If a chain is anchored to a substrate, the proximal Ub will also include a 
fragment of the substrate.  Another notable outcome from Asp specific cleavage is 
that other linkage sites are isolated; M1, K6, K11 are on the first fragment, K27 and 
K29 are on the second, K33 is isolated on the third, K48 is isolated on the fourth, and 
K63 is isolated on the sixth (the fifth fragment contains no linkage site).  See (Figure 
6.1).  In addition to the applications with K63 linkages this also allows Asp cleavage 
to reveal the nature of K33 modifications.  For Asp fragments that contain more than 





Figure 6.1 - Asp cleavage of K63-Ub2 creates a signature fragment.   
(A) Primary sequence of mono Ub shown with six fragments after Asp digestion 
bottom.  Linkage sites are show in blue, Asp residues are shown in red, and G76 is 
yellow  (B) The six Asp fragments of mono Ub are shown with their mass (in Da) and 
linkage sites in bold.  (C) Structure of K63-Ub2 with diagnostic Asp cleavage 
fragment in blue and linkage sites K63 and G76 show in magenta sticks.  Bottom 
shows only the diagnostic peptide from K63-Ub2 in blue.  (D) Sequence of K63-Ub2 
with an enlarged view of the diagnostic peptide, note that K63 and G76 are perfectly 
contained in the Asp cleavage fragment.     
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6.3 Validation of the Asp specific cleavage method  
6.3.1 Optimization of cleavage  
 Although Asp-N had previously been used by Goldberg to cleave Ub chains 
for a different purpose, the chemical MAAH method was never tested.  This 
prompted us to perform both Asp-N and MAAH digestion on mono Ub.  Conditions 
such as exposure time to Asp-N and microwave times for MAAH were optimized.  
With both methods the expected cleavage products were observed using MALDI-
TOF.  We were able to produce nearly identical spectra from both stock solutions and 
15% SDS-PAGE gels, demonstrating that both digest methods would be highly 
effective in proteomics.   Interestingly, there was a very pronounced missed cleavage 
product at D58 of Ub with MAAH digestion (Figure 6.2).  Initially we overlooked 
this since it is generally assumed that the conditions for MAAH, (12.5% (v/v) acetic 
acid, pH 2.24) fully denature proteins, however Ub is extremely stable with a 
Tm~90oC and Ub is also purified in ~2% (v/v) perchloric acid reaching a pH 1.5 (229, 
230).  To determine how folded Ub was under MAAH conditions we used 1H,15N-
TROSY (variation of HSQC) to observe Ub in varying concentrations of acetic acid 
(Figure 6.2 D-F).  The 1H,15N-TROSY spectra clearly indicate that Ub is well folded 
in 12.5% (v/v) acetic acid.  There are extra peaks corresponding to alternate 
conformations, which also may indicate small percentage of the Ub is beginning to 
unfold, but the residue specific signals indicate that most Ub retains its overall native 
structure.  D52 which is located in a flexible loop of Ub with virtually no 
intramolecular contacts is readily cleaved by MAAH.  The 310-helix containing D58 
allows for D58 to be involved in an extensive hydrogen bonding network, making it 
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highly resistant to MAAH which requires both the Asp side chain and backbone for 









Figure 6.2 – Asp specific digestion of monomeric Ub. 
(A) Structure of Ub with red sticks show the position of D52 (black star) and D58 
(red star) on the surface of Ub.  D52 is located in an unstructured loop, while D58 is 
in a 310 helix.  (B) PyMol assigned close polar contacts of D58 and T55 are shown as 
dashed lines. (C) MALDI-TOF spectrum of MAAH digested monomeric Ub.  The 
peak corresponding to cleavage at D52, but a missed cleavage at D58 is designated 
with a black star.  The peak representing cleavage at D58 is indicated with a red star.  
(D-F) 1H,15N-TROSY spectra of 15N-Ub1 in different concentrations of acetic acid: 
(D) in pure water, (E) in 12.5% (v/v) acetic acid, and (F) in 45% (v/v) acetic acid.  
The residue-specific NMR signals corresponding to backbone amides are well spread 
in water (blue) and still retain the spread in 12.5% acetic acid, pH 2.24 (red), 
indicating that ubiquitin remains well folded under both conditions.  The spectrum of 
45% acetic acid, pH 1.85 (orange), is characteristic of a nearly unfolded protein.  
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We attribute the near-native structure of Ub to be responsible for partially inhibiting 
MAAH cleavage.  With properly optimized conditions we found there was cleavage 
of a significant portion of D58.  Asp-N cleavage proved to be very efficient, but 
required significant time periods for the digest ranging from 18-24 hours.  In many 
cases we still observed some missed cleavages in MALDI-TOF.          
 
6.3.2 The benefits of a missed cleavage for the analysis of unanchored K63-
linked polyubiquitin chains  
 
As shown in (Figure 6.2) a missed cleavage frequently happens at D58 during 
MAAH, but D58 is also cleaved.  For the analysis of K63 Ub conjugates this would 
produce multiple diagnostic peptides for identification, in addition to the theoretical 
peptides in (Figure 6.1).  After careful consideration we determined that these 
alternate cleavage products resulting from a missed cleavage at D58 would actually 
be beneficial and allow us to analyze MS data with greater confidence.  The reason 
being is that the D58 and D52 cleavage products resulted in two distinct fragments 
that would always be separated by MW=629.7 Da using this cleavage method.    This 




Figure 6.3 – MAAH digestion of K63-Ub2 with Δ629Da diagnostic peptides 
(A) D52 fragment of Ub with missed cleavage at D58 (top) and D58 fragment 
(bottom).  (B) Structure of K63-Ub2 analyzed showing diagnostic peptide (blue) and 
missed cleavage at D52 (red) on distal domain.  (C)  MALDI-TOF spectrum shows 
two distinct diagnostic MAAH peptides form K63-Ub2.  The missed cleavage at D52 




After we established that both Asp-N and MAAH cleavage were effective for 
detecting unanchored K63-Ub2 we set to extend this methodology to longer K63 
linked Ub chains.  If there is 100% cleavage, the mass of the Asp cleavage fragments 
will be the same except for the last, which contains K63.  As the number of 
consecutive K63 linkages increases the mass of the K63 fragment will increase in 
increments of 2,194.49 Da with no missed cleavages and 2,824.08 Da if D52 is 
missed.  The next heaviest fragment in Ub is the first Asp cleavage fragment 
containing M1, K6 and K11 at 2,235.6 Da.  Since all of the Asp fragments except the 
one containing K63 maintain the same mass, the K63 fragment will easily be the 
largest as the number of consecutive K63 linkages increases.  As a practical matter, 
the presence of excess non-K63 containing fragments severely complicates MS 
analysis and for most K63 linked chains the number of fragments containing K63 are 
greatly outnumbered by those not containing K63.  To separate the K63 containing 
fragment, we used LC-MS/MS to isolate a K63-Ub2 fragment and then assigned 
many diagnostic b ions from collision-induced dissociation (CID).  Although LC-
MS/MS analysis was successful for K63-Ub2 the method would prove impractical for 
longer K63 linked chains that have fragments with different elution profiles and 
produce many more diagnostic b ions.  A detailed search of existing reagents led us to 
the K63 linkage specific mouse monoclonal antibody (clone HWA4C4).  Most 
commercially available K63 specific antibodies do not recognize monomeric Ub, but 
instead the K63 linkage.  In the case of the HWA4C4 clone, it was created with a 
very small antigen containing residues 71-76 (RLRGG) of the distal Ub, linked to 
residues 58-63 (DYNIQKEST) of the proximal Ub.  This suggested that this antibody 
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would be highly effective in capturing the Asp fragment whose sequence overlaps the 
antigen (Figure 6.4 A-C).  Structures of similar K63 antibodies (Apu.3A8 and 
Apu2.16) bound to K63-Ub2 (PDB-3DVG and 3DVN) supported this assertion (201).  
After we successfully immunoprecipitated the K63 containing fragment from the 
digest of an octameric K63 chain we set to test if this could be applied to a mixture of 
chain lengths.  In the cell, K63 linkages do not have defined lengths, and can range 
from range from 2-9 linkages for certain substrates (201).  Following MAAH 
immunoprecipitation by the K63 antibody allowed us to successfully isolate the K63 
fragment for each chain length in the K63-Ub2-5 mixture.  Each chain was assigned 
based on pairs of peaks spaced 629 Da apart (Figure 6.4).  This was a clear 
demonstration that Ub chain length could be measured and also is the longest Ub 















Figure 6.4 – Asp digestion followed by immunoprecipitation measures linkages 
in K63-Ub2-5  
(A) PDB-3DVN shows the K63 linkage specific antibody (gray) interacts with the 
linkage (magenta) on K63-Ub2. (B)  The K63 containing Asp fragment (blue) mainly 
interacts with the antibody and does not form contacts with the rest of the K63-Ub2 
molecule (green). (C) Showing only the K63 containing Asp fragment with one 
missed cleavage (blue sticks). (D) MALDI-TOF following immunoprecipitation of 
the K63-Ub2-5 mixture (gel insert).  Open arrows [59-76]n indicates peak representing 
no missed cleavages.  Red arrows show the pair of Δ629 peaks expected for each 




6.3.1 Measuring the K63 Ub modification of a model substrate  
After we were convinced that we could apply our newly devised method to 
unanchored K63 linked Ub chains, we wanted to bring the method to the next step 
and analyze a substrate modified with K63 linkages.  One of the major problems was 
that ubiquitinated substrates are not easily obtainable.  Furthermore, many 
ubiquitinated proteins from in vivo sources or enzymatic reactions produce a large 
amount of heterogeneous chains, have low yields, and were beyond our means.  From 
the literature it was shown that autoubiquitinating E2 and E3 enzymes, such as 
TRAF6 for K63 linkages and Ube2S for K11 linkages have been used to create 
homogeneous linkages of varying chain lengths.  From my studies with DUBs, I 
knew that Ubch5b, an E2 conjugating enzyme could autoubiquitinate, however it also 
promiscuously created other linkages.  For our purposes of obtaining a K63 modified 
substrate, the autoubiquitination E2 or E3 system was ideal since it was both practical 
and yielded the most material.  To create our substrate I reacted Ub(K63), a Ub 
mutant only containing K63 with all other Ks mutated to R, with E1 and Ubch5b.  
This yield only mono, multiple-mono, or K63 ubiquitinated Ubch5b.  After Asp 
digestion and immunoprecipitation, the K63 fragments would be significantly 
enriched and all other fragments from Ub, Ubch5b, or monoubiquitinated Ubch5b 
would not be selected by the antibody.  To ensure that the K63 chain would have a 
defined length, we analyzed samples from a 15% SDS-PAGE gel band corresponding 
to the mass of Ubch5b + 2Ubs.  The results in (Figure 6.5) show we identified one 
K63 Ub linkage at K128 of Ubch5b in the 117-130 Asp fragment, in a system we 




Figure 6.5 – Asp digestion of a K63 modified substrate. 
(A) Model of Ubch5b (gray) modified with K63-Ub2 (green) at K128.  Linkages are 
shown as magenta sticks, the K128 Asp fragment of Ubch5b is colored red, which 
continues to Ub (colored blue).  (B) Asp digest followed by immunoprecipitation 
with the K63 linkage specific antibody isolates an Asp fragment with a K63 Ub 
linkage (blue) and corresponding linkage site on Ubch5b (red).  (C) Gel inlay shows 
the Ubch5b-Ub2 band analyzed.  MALDI contains the expected the signature doublet 
with the expected Δ629 Da split from a missed cleavage on Ub (top spectrum).  The 
same signature fragment is observed with ESI (bottom spectrum).  Sequences from 
Ubch5b are in red and the K63 linkage from Ub is boxed with blue.      
211 
 
6.3.4 Expanding to future applications  
Our initial work clearly only focused on unanchored and substrate attached 
consecutive K63 linkages, however Asp digestion can also be used to detect other 
forms of ubiquitination.  The possibility to isolate K33 linkages, as well as the 
detection of branching on any of the other Asp fragments was discussed in (section 
6.2.2).  A new application of Asp digestion is also to unambiguously reveal linkage 
mixing in Ub chains that contain a K63 linkage distal to another linkage.  No 
technique to sequence mixed linkage chains has been discovered and our Asp digest 
method could greatly aid in the characterization of specific systems containing mixed 
linkages.  Linkage specific antibodies and tryptic digest would detect mixed linkage 
chains by identifying more than one linkage type, but neither method would be able 
to establish the exact sequence of the linkages.  Diagnostic Asp fragments for Ub–
63Ub–nUb that are produced by Asp cleavage of mixed linkage tri-Ubs are shown in 
(Figure 6.6).  Since the K63 linkage is retained any mixed linkage with a distal K63 
linkage could also be analyzed with Asp digest and immunoprecipitation as done with 
the homogeneously linked K63 chains.  A non-K63 linkage proximal or distal to the 
K63 linkage will break the chain during Asp cleavage leaving only units of two Ub-
Ub bonds.  If there is longer sequence of K63 linkages distally attached to a non-K63 
linkage, the sequence of K63 linkages will remain intact during Asp cleavage and the 
proximal non-K63 linkage will be detected essentially as a substrate.  If however a 
non-K63 linkage is distally attached to a sequence of K63 linkages it will not be 






Figure 6.6 – Asp digestion of mixed linkage Ub–63Ub–nUb chains. 
Following Asp digestion these peptides would result from a K63 linkage distally 
attached to any other linkage site besides K63 on Ub.  (A) Ub–63Ub–1Ub, (B) Ub–
63Ub–27Ub, (C) Ub–63Ub–6Ub, (D) Ub–63Ub–29Ub, (E) Ub–63Ub–11Ub, (F) Ub–63Ub–
33Ub, (G) Ub–63Ub–48Ub   
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With the ability of the K63 linkage specific antibody to capture the desired 
Asp digest fragments our methodology should allow for easy analysis of in vivo 
extracts.  We have yet to attempt a bottom up proteomics approach, but we have laid 
the ground work to do so and are developing software for the analysis of such data.  
An equation to predict he mass of K63 linked Ub conjugates is a core feature of the 
software, show in (Figure 6.7).  To account for missed cleavages the term “Ub” 
representing the mass of the Ub fragment can be 2,842.18 Da for one missed cleavage 
or 2,21.21 Da for no missed cleavages.  Calculating the highest expected mass and 
subtracting 629 Da proved to be a straight forward way to search for Asp fragments.  
The equation can also be applied to unanchored K63 chains by setting the parameter 
designating the substrate fragment z equal to 0 Da.   
It is unclear if polyUBL chains or heterologous Ub/UBL chains can be 
effectively approached with the Asp cleavage method.  However, the tryptic method 
has been used for SUMO2/Ub chains and other cleavage methods could presumably 












Figure 6.7 – Accurate prediction of Asp cleavage masses. 
(A) Equation with description of parameters to predict search masses for K63 
modified Asp fragments (B) Demonstration of the equation with Ubch5b and one 
K63 Ub linkage.  The predicted mass of 7,278.19 Da and corresponding peak 629 Da 




6.4 Discussion and summary 
 
Our method which utilizes Asp specific cleavage followed by 
immunoprecipitation clearly can measure the number of consecutive K63 Ub linkages 
in unanchored or substrate attached Ub chains.  The alternate cleavage methods of 
Asp-N and MAAH work equally well, but with their distinct advantages and 
disadvantages (mostly experimental details).  In the larger picture, this simple 
approach can easily be extended to characterize K63 linkages in other systems with a 
more traditional proteomics approach.  However, expanding on our approach by 
employing alternate cleavage methods and specialized antibodies should allow us to 
gain much more information in future studies.  A future aim will undoubtedly be to 
expand this method for use with mixed linkage polyUb chains and also to UBLs that 
form similar polymers.    
The approach outlined in this chapter is by far the most versatile approach to 
date and can be used for both proteomics applications and the analysis of Ub 
conjugates in a controlled setting.  Using customized instrumentation and ion 
mobility MS, David Clemmer and co-workers were able to differentiate between 
unanchored polyUb chains of K48 or K63 linkages due to their ability to retain 
distinct structural characteristics in the gas phase (233).  Another top down method 
was used by Layfield and co-workers to show connectivity between a K48 linked Ub 
dimer from an in vivo sample, however the MS technique requires extensive 
optimization and is most likely impractical for longer Ub chains (234).  Nevertheless, 
the success of these methods and other non-tryptic approaches have certainly gave the 
field an unprecedented view of Ub signaling.      
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 Chapter 7:  Short research projects  
7.1 Background and research aims 
The projects contained in this section represent experiments I performed as 
part of larger collaborations, which were not of my own design or techniques I 
developed.       
7.2 Applications of the F45W ubiquitin mutant 
7.2.1 Advantages of fluorescent Ub variants 
The Ub(F45W) mutant was the first fluorescently labeled Ub species and 
originally used to prove the controversial “late two-state” folding pathway of Ub 
(235-237).  Many other fluorescently labeled Ub variants have been used for a range 
of applications, but mainly for detecting DUB inhibition in high throughput formats 
(238, 239).  Although sound, most of the current fluorescence assays for study of Ub 
have several draw backs including the concerns over the introduction of extrinsic 
fluorophores, the shelf life of reagents, and costs of materials.  To improve upon 
existing methods I demonstrate several novel applications of the Ub(F45W) mutant 
and also devote much effort to studying the effects of the mutation.  The substitution 
of a tryptophan at position 45 in Ub results in an almost native probe, which is in 
close proximity to the L8,I44,V70 hydrophobic patch.  This makes the mutant ideal 
for monitoring Ub/receptor interactions.  Furthermore, addition of the fluorescence 
capability also makes this Ub mutant useful for FRET applications as well.     
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7.2.2 Ub(F45W) retains a native Ub structure 
Given that many studies have used the F45W Ub mutant in some form, but 
neglected to strictly assess if: (i) the native structure of monomeric Ub was preserved, 
(ii) the F45W mutation effected the conformation of polyUb chains, and (iii) the 
affinity of Ub(F45W) variants for receptors changed, I first attempted to determine if 
any structural changes arose from the mutation.  I immediately had a concern about 
the stability of Ub(F45W) when I observed that it precipitated with the perchloric 
acid used during standard Ub purification.  However, when using the heating method 
(see section 3.1.4) the F45W mutant was very stable even at temperatures nearing the 
Tm of Ub, which demonstrated that the mutant retained its characteristic thermal 
stability.  After purification, the residue specific CSPs between wild type and 
Ub(F45W) were calculated from their 15N-HSQC spectra.  CSPs where observed 
where expected, i.e. residues in close proximity to the mutation (see Figure 7.1).  
Aside from these especially large CSPs near the mutation site, CSPs for other 
residues are extremely small in Ub(F45W), supporting that the mutation does not 






Figure 7.1 – Solution properties of monomeric Ub(F45W). 
(A) 1H,15N-HSQC overlay of wild type Ub (blue) and Ub(F45W) (red) shows an 
overlap for many peaks, but large changes in those around the mutation site.  Note the 
presence of and extra speak (far left) corresponding to the side chain of tryptophan.  
(B) Residue specific CSPs are plotted between wild type and Ub(F45W), showing 
that the effect of the mutation is localized. (C) F45W modeled into (PDB-1D3Z) 
shows its close proximity to the L8, I44,V70 hydrophobic patch (yellow spheres), 
residues with in 4Å are colored in gray.  
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 After determining that the overall structure of Ub(F45W) was essentially that 
of wild type, the viability of the F45W mutation was tested in vivo.  Collaborators 
Dan Bolon and Ryan Hietpas used a yeast system with a rescue plasmid containing 
either wild type Ub or Ub(F45W) as the sole source of Ub.  Ub(F45W) was shown to 
be just as viable as wild type (Figure 7.2).  This results leads to several important 
conclusions regarding the F45W mutant.  Most importantly, the F45W mutant does 
not interfere with Ub signaling in the cell and all pathways continue uninterrupted.  
Following the current dogma this implies that the structure of Ub must be well 
retained in the mutant.  In addition, other properties such as the conjugation of 
Ub(F45W) into polymeric chains and their deconjugation must also be retained.  
 
 
Figure 7.2 – Ub(F45W) is viable in yeast 
 (A) Ub from any source can be used in the Raf/Gal non-selective media.  (B) In the 
dextrose media only Ub form the rescue plasmid is expressed.  Where there is no Ub, 
the cells die from the lack of this essential protein.  With wild type Ub and 
Ub(F45W), the cells flourish.  This demonstrates that both forms of Ub are 
indistinguishable from the cell’s point of view. 







These results were encouraging and justified treating the F45W mutant essentially as 
wild type Ub.  Since there were no major structural changes I proceeded to the next 
step and formed polyUb conjugates with the F45W mutation incorporated at several 
different positions (distal, proximal, and higher conjugates with F45W at every 
position) for both K48 and K63 linkage types.  Solution NMR data collected for 
Ub(15N)–48Ub(F45W) showed that signals in the distal domain in the K48 linkage did 
not have any significant deviation from signals in the wild type conformation and 
supports that the polyUb chain must also retain the same structural conformations.  
As a final check, crystallization was attempted with both monomeric F45W and a 
K48 linked dimer containing F45W in the proximal domain, Ub–48Ub(F45W).  In the 
absence of a structure at atomic resolution, this approach would provide one and in 
the process also reveal if there are similar crystallization properties between wild type 
and F45W Ub.  After screening, a crystallization condition for monomeric F45W 
(25% PEG-3,350, 40 mM zinc acetate) very similar to PDB-1UBQ and other reported 
crystal structures for monomeric Ub was found (240).  For Ub–48Ub(F45W) no 
screening was attempted and it was simply placed in conditions identical to those 
used for PDB-3M3J (0.2 M lithium sulfate, 50 mM Tris pH8.0, and 25% (v/v) PEG-
3,350), which resulted in the reported plate like crystals (241).  These crystals 
diffracted at 2.7 Å in the same space group, again showing very similar properties 





Figure 7.3 – Crystallization of F45W in monomeric and K48-Ub2 forms. 
(A) Cubic crystals of monomeric F45W in 25% PEG-3,350, 40 mM zinc acetate after 
9 days of growth at 22oC.  (B) Plate crystals of Ub–48Ub(F45W) grown in 0.2 M 
lithium sulfate, 50 mM Tris pH8.0, and 25% (v/v) PEG-3,350 at 22oC for 6 days.    
 
7.2.3 Binding interactions of F45W 
After establishing that the F45W mutation was essentially identical to wild 
type Ub structurally, I set to determine if the mutant would form the same binding 
interactions with receptors.  The yeast data suggested F45W Ub interacted, but 
provided no means for quantifying isolated Ub/receptor interactions.  A concern was 
that subtle changes around the F45W mutation could alter the binding surface 
resulting in different affinities for receptors, but still be viable.  To determine the 
binding properties of F45W, titrations of the globular UBA domain from the 
UBL/UBA shuttle ubiquilin-1 (UBQ-1) and the α-helical UIM domain from 
proteasome subunit Rpn10 were performed using both NMR and tryptophan 
emission.  Data from 1H,15N-HSQC titration of either 15N-wild type Ub1 or F45W 
Ub1 shows similar residue specific CSPs on the L8,I44,V70 hydrophobic patch, and 
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also nearly identical titrations curves for select residues with UBA from UBQ-1 
(Figure 7.4).      
 
 
Figure 7.4 – F45W Ub1 natively interacts with UBA from UBQ-1. 
(A) Residues specific CSPs for wild type Ub1 (black) and (B) F45W-Ub1 (red) with 
the UBA domain of UBQ-1 show a similar pattern consistent with binding the 
L8,I44,V70 hydrophobic patch.  (C) Titration curves for residues T7, R42 and L67 of 
wild type (black) and F45W (red) show a near identical affinity for each.  (D) 
Solution structure of complex (PDB-2JY6) between monomeric Ub (green) and 
UBQ-1 UBA (gray), shows F45W (red) is very close to the interaction site, 
hydrophobic patch (yellow spheres).    
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NMR titration data with the UIM of Rpn10 also revealed a similar binding interaction 
(Figure 7.5).   
 
 
Figure 7.5 – Rpn10 UIM recognition of F45W Ub1. 
(A) Residues specific CSPs for wild type Ub1 (black) and (B) F45W-Ub1 (red) with 
the UIM domain of Rpn10 show a similar pattern in agreement with the binding 
mechanism.  (C) Titration curves for residues K27, F(W)45, and V70 of wild type 
(black) and F45W (red) have identical profiles, but differ in magnitude.  (D) Solution 
structure of complex (PDB-1YX5) between monomeric Ub (green) and Rpn10 UIUM 





With NMR data in good agreement, the ability of F45W to serve as a probe for the 
quantification of binding was tested by tryptophan fluorescence.  Generally, 
tryptophan emission is very sensitive to many factors including binding interactions 
which change the solvent exposed surface area of Ub.  Data for UBQ-1 UBA are 
shown as an example (Figure 7.6).  Upon receptor binding, there is a large increase in 
tryptophan emission for both monomeric F45W and Ub–48Ub(F45W) with the same 
ligand.  The profile of the curves also supports the binding model in that monomeric 
F45W saturates at exactly 1:1 and Ub–48Ub(F45W), which can bind two UBAs, 
saturates much later.  When saturation is reached there is no more increase in 
emission and F45W appears to function ideally as a probe.        
 
Figure 7.6 – Tryptophan emission of Ub(F45W) increases with UBA binding.   
(A)  Overlay of emission spectra over the course of monomeric F45W Ub with UBA 
from UBQ-1.  As UBA is added there is an increase in fluorescence intensity.  (B) 
One wave length, 340 nm was used to calculate the Kd for monomeric and K48 linked 
F45W variants.  Due to the difference in stoichiometry between monomeric F45W 
and Ub–48Ub(F45W) saturation is reached at different molar ratios in the titration, 
which is consistent with the literature.  For the titrations Ub(F45W) was 45 µM and  
Ub–48Ub(F45W) was 43 µM.  Both curves correspond to a 1:1 binding model.       




After performing several titrations by both 1H,15N-HSQC and tryptophan emission, 
the determined Kd values were evaluated between each.  The NMR and fluorescence 





Table 7.1 – Similar recognition of F45W Ub to know receptors. 
* denotes Kd values from published studies (95, 242)    
The Kd values from NMR are very similar for both wild type and F45W Ub variants.  
Obtained under different conditions, the Kd values from fluorescence fall within an 
acceptable range of those determined by NMR.  All fluorescence curves were fit to a 
1:1 binding model.    
 
Combined with the existing data, this provides quantitative evidence that the F45W 
mutation is appropriate for a range of in vitro studies.  The fact that Ub–48Ub(F45W) 
interacts essentially natively with a UBL/UBA shuttle and a polyUb receptor on the 
proteasome supports that the mutant will not interfere with the UPP.   No other 
linkage selective receptors (e.g. tUIM for K63 linkages) were tested, nor were DUBs.  
These experiments were omitted based on the assumption that F45W would produce 
the same result as wild type.  One interesting point is that the Kd and other parameters 
can vary between methods and are hard to reproduce.  In this case with moderate 
(µM) Kd values, the data being similar between wild type Ub and Ub(F45W) was also 
consistent between solution NMR and fluorescence.  This is interesting in that the 
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micro Kd values obtained from solution NMR appear to be very agreeable with a 
fluorescence approach that senses a macroscopic Kd.    
7.2.4 Applications of the F45W-AEDANS FRET pair in polyUb 
The use of fluorescently labeled and FRET capable Ub systems has increased 
and commercially available fluorophores have improved, however these relatively 
large (~1 kDa) in respect to Ub (8.65 kDa) extrinsic probes are stable for short 
periods of time, and also can be difficult to attach.  Since F45W is the most natural 
fluorescent label that can be carried by Ub and is also stable for years, I set to expand 
its use for FRET applications.  As a FRET acceptor for tryptophan, the ANS 
derivative IAEDANS which absorbs at 336 nm and emits at 485 nm was selected 
(243).  IAEDANS is small, inexpensive, highly thiol-reactive, and has been used in 
many other systems aside from Ub to obtain meaningful data (244).  With a well 
established precedent for the use of Ub cysteine mutants with MTSL to solve 
Ub/receptor complexes, (208, 242) IAEDANS was perfect since it could be used with 
our existing NMR Ub constructs.  The Förster distance of AEDANS (the Iodine is a 
leaving group after the IAEDANS attaches to a cysteine residue) is ~22 Å which 
makes the tryptophan-AEDANS pair ideal for monitoring interactions in polyUb 
systems (243, 245).  
An external fluorophore on Ub can be very useful for detecting different 
interactions (135, 156).  To explore this with Ub T12CAEDANS I performed a simple 
gel assay with Ub T12CAEDANS  in an enzymatic K48 chain reaction.  The results 
(Figure 7.7) show AEDANS does not interfere with chain synthesis and it alone has 
some useful fluorescence applications, in this case detecting Ub conjugates.  This 
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result was encouraging and implied that T12CAEDANS could form conjugates with 
many other Ub variants aside from itself.   
 
Figure 7.7 – Ub T12CAEDANS as a fluorescent probe for K48-linked polyUb 
synthesis. 
Ub T12C monomers labeled with AEDANS are reacted in a standard enzymatic K48 
reaction containing E2-25K.  The same exact gel demonstrating that Ub T12CAEDANS 
K48 linked polyUb chains are formed is shown in (A) with Coomassie staining and 
before staining (B) on a UV transilluminator with a 308 nm lamp.  All Ub species are 
highly fluorescent and a distribution of chains is visible.  A schematic showing 




 To create the FRET system, AEDANS labeled Ub monomers and F45W 
monomers were combined to form a K48 dimer with AEDANS on the distal Ub and 
F45W on the proximal Ub, formal name Ub(T12CAEDANS) –48Ub(F45W).  This 
system provides a unique method to uncover more details from the interactions of 
K48 linked chains.  To date most FRET applications of Ub have been used for crude 
methods such as gel assays or to determine DUB kinetics, but never for true distance 
measurements.  A recent study has used single molecule FRET to determine the 
relative distribution of polyUb conformations (e.g. open and close in K48-Ub2), but 
failed to produce any information on distances (156).  With the F45W-AEDANS 
system it should be possible to accurately measure distances and obtain insightful 
structural information.  To test this I titrated Ub(T12CAEDANS) –48Ub(F45W) with the 
K48 selective ligand UBA(2) from hHR23A.  Upon binding, UBA(2)  inserts 
between the K48 interface in the classic “sandwich mode,” which should cause the 
distance between AEDANS and F45W to increase (208).  Indeed the emission of 
AEDANS at 485 nm clearly shows this effect for titration of Ub(T12CAEDANS) –
48Ub(F45W) with UBA(2) (Figure 7.8).  As UBA(2) is added, the intensity of 
tryptophan emission at 340 nm increases, however intensity for AEDANS emission at 
485 nm decreases.  When Ub(T12CAEDANS) –48Ub(F45W) is fully saturated the 
decrease in AEDANS emission begins to level off.  This trend is consistent with the 
binding mechanism and supports that the two Ubs must open to bind UBA(2), 
increasing their distance between each other.  The assumed distance between 
AEDANS and F45W is 21 Å in the free form and 35 Å for the UBA(2) bound form.  




Figure 7.8 – FRET application of K48-Ub2 and UBA(2). 
(A) Emission spectra overlay for titration of Ub(T12CAEDANS) –48Ub(F45W) with 
UBA(2).  With no UBA(2), the FRET emission signal from AEDANS at 485 nm is 
maximal, but as UBA(2) is added in the signal decreases due to UBA(2) separating 
the two Ubs.  (B) Schematic showing the Förster resonance energy transfer of the 
excitation light through F45W and then through AEDANS.  (C) Plot of the intensity 
of AEDANS emission shows a decrease that levels off as saturation is approached.  
(D) Model of Ub(T12CAEDANS) –48Ub(F45W) in the free state with proximal Ub 
(green) and distal Ub (red).  The tryptophan (red sticks) is measured to be 21 Å away 
from the AEDANS (black sticks).  (D) Model of the bound state with UBA(2) (gray) 
opening the proximal Ub (green) and distal Ub (red), increasing the distance between 
F45W and AEDANS to 35 Å.      
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7.3 Pathology of Ubb(+1) accumulation 
7.3.1 Background and research aims 
Abnormal ubiquitination patterns have been detected in Alzheimer’s and other 
neurodegenerative polyglutamate diseases, Parkinson’s and Huntington’s (246-249).  
Given that the UPP is inhibited in these diseases, many suspect that a root cause 
results from the cytotoxicity of elevated levels of pathological proteins, which would 
normally be destroyed by the UPP (250).  However, there is a debate as to whether 
these proteins are cytotoxic or merely a symptom brought on by other factors.  Aside 
from the classic disease causing protein (e.g. alpha-synuclein, Parkin, or the 
Huntington’s protein) there is frequently a disruption in the Ub gene itself.  
Specifically a frame shift mutation near the end of the Ub sequence causes a G76Y 
point mutation and a long 25 residue extension after G76Y of Ub, resulting in a new 
gene product termed Ubb(+1) (251-253).  Recent work has uncovered that Ubb(+1) 
may in fact be more pathological than an aggregated protein such as alpha-synuclein 
(254).  Physiologically this is a reasonable assumption given the concentration of Ub 
is relatively high (10µM) in the cell compared to other proteins.  A great deal of in 
vitro work provides many hints as to how Ubb(+1) can be detrimental to cell 
function, specifically its ability to inhibit proteasomal degradation (255, 256).  For 
our study we set to investigate how the Ubb(+1) gene product effected the UPP in 
yeast, investigate structural properties of  Ubb(+1), and characterize how the mutant 




7.3.2 Synthesis and analysis of Ub–48Ubb(+1) 
 
Several variations of Ubb(+1) that differ in lengths of C-terminal extensions 
and also the residue at position 76 have been studied in vitro (254, 255, 257, 258). 
Data from these studies suggests that the length of the C-terminal extension impacts 
how Ubb(+1) inhibits the proteasome and the residue at position 76 determines how 
efficiently DUBs can process Ubb(+1) conjugates.  The main outcome of Ubb(+1) 
and other variants expressed for in vivo systems (mouse and drosophila) is marked by 
the accumulation of polyUb conjugates (250, 252, 259).  The first solution studies of 
the Ubb(+1) structure by Cheryl Arrowsmith proved that the mutant Ub could bind 
natural partners such as E2-25K and the C-terminal extension was extremely flexible.  
Given that the Ubb(+1) mutant inhibited the proteasome I set to explore if the 
structural conformation of K48 linked Ubb(+1) conjugates deviated from those of the 
wild type.  I used E2-25K to synthesize conjugates for study and found that Ubb(+1) 
was efficiently ligated (Figure 7.9).  Intrigued by this I also explored if Ubb(+1) 
could be linked at other sites using Ubc13:Mms2 to make K63 linkages.  Both E2s 
efficiently ligated K48 and K63 of Ubb(+1) suggesting that any problems caused by 










Figure 7.9 – Ubb(+1) is ligated in enzymatic K48 and K63 reactions.  
The ability of Ubb(+1) to form conjugates was tested in enzymatic reactions.  To 
assess the conjugates only K48R/K63R-Ub and an N-terminal 6xHis Ubb(+1) are 
used.  The products are isolated with a His-Trap step.  The 15% SDS-PAGE gel 
shows the K48 reaction with E2-25K, Ubb(+1) reacts very efficiently to form Ub–
48Ubb(+1) and the product is easily isolated. The right three lanes show Ubc13:Mms2 
forms Ub–63Ubb(+1) with some residual Ubb(+1) monomer and both Ubb(+1) 
species are isolated in the His-Trap step.      
 
 
The specific K48 linked Ubb(+1) conjugate I chose to study by NMR was 
Ub(15N)–48Ubb(+1).  By default, Ubb(+1) must be the proximal domain and the distal 
domain was 15N enriched since its 1H,15N-HSQC spectrum would not be complicated 
by signals from residues in the C-terminal extension.  In addition, this approach 
makes it much more feasible to test other Ubb(+1) variants with the same experiment.  
Since the structural properties of Ubb(+1) conjugates have not been studied in detail 
it was reasonable to start with the dimeric chain.  Overlay of the 1H,15N-HSQC 
spectra for Ub(15N)–48Ubb(+1) and the monomeric Ub show many CSPs.  The pattern 
of these CSPs suggests the distal Ub in Ub(15N)–48Ubb(+1) does indeed form the 
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classic hydrophobic interface (Figure 7.10).  There are some subtle changes 
compared to wild type Ub(15N)–48Ub, but Ubb(+1) as a proximal Ub does not 
dramatically shift the overall conformation of Ub(15N)–48Ubb(+1) from that of the 
wild type. To gauge the nature of the hydrophobic interface 15N T1 relaxation was 
measured for the distal Ub in Ub(15N)–48Ubb(+1).  If the interface is weakened there 
should be a decrease in T1 and an increase if the interface is strengthened.  The T1 
does appear to drop slightly (~100ms) suggesting the conformation is slightly shifted 
to the open form, however the classic K48 interface is still retained to some degree 
(Figure 7.10).  Determining the actual structure of Ub(15N)–48Ubb(+1) will require a 






























Figure 7.10 – Conformational properties of K48 linked Ubb(+1) conjugates. 
The ability of Ub(15N)–48Ubb(+1) to retain the classic K48 interface was tested with 
several NMR methods.  (A) CSPs between 1H,15N-HSQC spectra of monomeric Ub 
and Ub(15N)–48Ubb(+1) were calculated showing distinct differences in the 
L8,I44,V70 residues of the hydrophobic patch.  (B)  15N T1 between wild type 
Ub(15N)–48Ub (black circles) and Ub(15N)–48Ubb(+1)  (red squares) show a similar 
profile in Ub, however Ub(15N)–48Ubb(+1) has a slightly shorter T1 suggesting small 
conformational differences between the two forms of K48-Ub2.      
 
 
After determining that the overall conformation of K48 linked Ubb(+1) 
conjugates were similar to that of wild type, I then moved to investigate how DUBs 
would process these conjugates.  Others have already demonstrated that UBDs and 
other binding partners could efficiently recognize Ubb(+1).  Since Ubb(+1) inhibits 
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the proteasome I tested if the activity of Ubp6 would differ for Ub–48Ubb(+1).  If 
there is inhibition this can result for the Ubb(+1) conjugates changing the 
conformation of the polyUb chain, which impacts Ubp6 recognition.  This effect has 
already been demonstrated for other Ub mutants that shift the conformational 
equilibrium of K48-Ub2.  Also, the tail of Ubb(+1) could be inhibitory as well.  The 
results in (Figure 7.11) show that Ubp6 has absolutely no problem cleaving the K48 
linkage in Ub–48Ubb(+1) and it is removed essentially at the wild type Ub–48Ub.     
         
 
Figure 7.11 – Ub–48Ubb(+1) does not interfere with Ubp6 activity. 
15% SDS-PAGE gel showing cleavage of Ub–48Ub and Ub–48Ubb(+1) under 
identical conditions.  After 1 hour essentially all of the dimeric Ub is converted to its 





For the first time Ubb(+1) conjugates have been isolated and analyzed 
structurally.  My data shows that Ub–48Ubb(+1) retains the classic K48 interface, but 
with a conformational equilibrium slightly favoring the open form.  However, this 
does not appear to effect conjugation by E1,E2 enzymes or deconjugation by 
proteasomal DUBs.  This does not mean that Ubb(+1) is harmless to the cell.  
Ubb(+1) conjugates could actually be pathological via several other mechanisms.  
Data from collaborators on this study also supports this.  That fact that Ubb(+1) 
conjugates accumulate suggests other parts of cellular machinery fail to function 
properly.  For example, the high number of Ubb(+1) conjugates may reach the 
proteasome and other pathways where the downstream machinery is inhibited by 
these atypical substrates.  Ubp6 has been shown to recognize the distal Ub, however 
other DUBs which recognize the C-terminus of Ub have been shown to be inhibited 
by the atypical extension on Ubb(+1).  This would certainly explain how the 
conjugates accumulate in the cell and it is likely that they also keep certain DUBs 
from functioning optimally.  It is interesting that the rest of the polyUb chain attached 
to Ubb(+1) appears normal, thus the pathology of Ubb(+1) lies within the Ubb(+1) 
molecule itself and not its conjugates.  The ability of Ubb(+1) to be formed into 
conjugates likely contributes to its pathology since once a regular polyUb signal is 
formed on Ubb(+1), the conjugate could be targeted to specific parts of the cell 







7.4 Monoubiquitin modification of histones 
7.4.1 Background and research aims 
The histone code refers to the hypothesis that many different post-translational 
modifications carried by histones serve to regulate gene expression and chromatin 
structure (260).  Ubiquitination of histones has been well studied (261-263), however 
the structural properties of ubiquitinated histones have never been investigated.  One 
of the most pressing issues is addressing how a post-translational modification affects 
both chromatin structure and transcription.  In the case of Ub, a controversial 
hypothesis is that when attached to the tail of either H2A or H2B, the Ub 
modification can form specific interactions with individual histones in the 
nucleosome.  If this is true Ub could potentially regulate specific DNA sequences in 
the genome.  The structure of a nucleosome, containing eight histones, two of each 
H2A, H2B, H3, and H4 along with a 146 bp DNA fragment is show in (Figure 7.12).  
This structure is the most fundamental unit of chromatin and has a distinct 




Figure 7.12 – structure of nucleosome with the H2A/H2B heterodimer.   
An X-ray structure of a human nucleosome (PDB-3AFA) shows an arrangement with 
two tetrameric layers of histones and a single strand of DNA wrapped about both.  
(A) histones are shown as cartoons with H2A (red), H2B (blue), H3 (cyan), and H4 
(green).  (B)  Another angle shows that H2A (red) and H2B (blue) are always in close 
proximity inside of the nucleosome.  (C) All other components are removed and the 




Individual histones, H2A and H2B are the best studied and can take on a variety of 
post-translational modifications (130, 131).  The acidic patch on H2A is a structural 
feature that has been demonstrated to participate in a variety of interactions (264).  To 
test the hypothesis regarding the ubiquitination of histones, H2A and H2B would be a 
logical starting point.  Thus the main objective of this study is to determine if Ub 
attached to H2A or H2B creates any detectable interactions.       
7.4.2 Synthesis and analysis of monoubiquitinated H2A and H2B 
The literature states that C-terminal tails of H2A and H2B harbor common 
sites of ubiquitination and are vital for chromatin regulation (131, 260).  Specifically 
K119 in H2A and K120 in H2B, which led us to investigate the properties of mono-
Ub attached to these positions.  Lacking the ability to produce selectively 15N 
enriched Ub-histone conjugates, we opted to use a chemical method relying on simple 
cross linking through cysteine residues.  15N-Ub(G76C) with a 6xHis N-terminal tag 
was reacted with H2A(K119C) or H2B(K120C), then purified using His-Trap, 
followed by size exclusion.  The opposite non-ubiquitinated histone was added and 
the H2A/H2B dimer formed (Figure 7.13).  We wanted to study the Ub modification 
in this context since this is a more accurate representation of the nucleosome.  This 
procedure resulted in the following two complexes for solution NMR studies, 





Figure 7.13 – 15N-Ub is efficiently ligated to desired positions of H2A and H2B 
with simple cross-linking chemistry. 
(A) A non-reducing 15% SDS-PAGE gel shows Ub(15N)–K119CH2A and Ub(15N)–
K120CH2B are formed.  The H2A/H2B complex is disrupted by SDS-PAGE, however 
the 15N Ub remains attached to the respective histone.  (B) Schematic representation 
of the Ub–K119CH2A/H2B and Ub–K120CH2B/H2A complexes with Ub attached.     
 
 
To monitor any potential interactions that Ub could be created, a standard NMR 
approach detecting residue specific CSPs on 15N-Ub in 1H,15N-HSQC was employed.  
CSPs were calculated between free monomeric 6xHis-Ub(G76C) and Ub attached to 
histone dimers, Ub(15N)–K119CH2A/H2B and Ub(15N)–K120CH2B/H2A.  The results in 
(Figure 7.14) show that there are minimal CSPs for both, however slightly higher 
CSPs for Ub(15N)–K119CH2A.  The tail region of Ub (residues 72-76) also appears to 
contain elevated CSPs, but this is most likely due to ligation of the Ub to either 
histone, not a specific interaction of Ub.  These experiments were carried out at two 
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different salt (NaCl) concentrations 150 mM and 250 mM to ensure that we screen 
out any mild electrostatic interactions the acidic patch on H2A could form.  However, 
the same result was observed in 150 mM and 250 mM NaCl.           
 
 
Figure 7.14 – Analysis of Ub modified H2A and H2B by 1H,15N-HSQC. 
If the Ub attached to either H2A or H2B is undergoing a significant interaction, there 
should be noticeable CSPs compared to the 6xHis-Ub(G76C) monomer, which both 
CSP plots use for comparison.  (A) CSPs plot for Ub–K119CH2A/H2B shows small 
CSPs for Ub in the C-terminal region. (B) Ub–K120CH2B/H2A has even less CSPs and 












7.4.3 Conclusions   
Ubiquitination of histones is an extremely important post-translational 
modification to understand.  The exact roles of Ub are currently still unclear, but 
nevertheless Ub must serve some function when it is attached to histones.  A few 
studies have shown that K63 polyUb chains form on histones at sites of DNA 
damage, which initiates DNA repair (130), however Ub appears to serve in many 
other roles than DNA repair for histones (129).  This current investigation did not 
detect any strong interactions between the Ub on either Ub–K119CH2A/H2B or Ub–
K120CH2B/H2A.  But it is important to not rule out the possibility that Ub could still 
serve as a steric block to prevent other factors from interacting with histones.  The 
approach used is sound and certainly should be extended beyond this study to address 
the structural properties Ub modified histones.  There are many fruitful research paths 











 Chapter 8: Summary and concluding remarks   
8.1 Summary of significant results  
The first structural study of mixed linkage polyUb chains presented here is the 
most significant biological concept of my doctoral work.  The existence of mixed 
linkage chains goes against the traditional dogma in the field, but nevertheless is an 
important factor that cannot be ignored.  It appears that an ever increasing number of 
studies are uncovering mixed linkage polyUb chains form in vivo systems and to 
understand the functions of these chains we will ultimately have to understand their 
structural properties.  My theoretical study of branched chains explored at total of 28 
out of an almost infinite number that can exist.  In no way do my conclusions go as 
far as to say that each of these theoretical chains represents a new signal.  In fact my 
findings, both theoretical and experimental support that even though many chains are 
possible, there is much degeneracy in their signaling properties.  Analysis of the 
theoretical branched tri-Ub chains suggested that linkage mixing could lead to new 
polyUb signals, which I grouped into four distinct structural conformations.  If 
linkage mixing does in fact present new signals, the structural conformations which I 
classified will be important for understanding how this is possible.  The experimental 
study of K48 and K63 mixed linkage branched and unbranched chains: [Ub]2–48,63Ub, 
Ub–63Ub–48Ub, and Ub–48Ub–63Ub uncovered a common theme.  Regardless of how 
the linkages were mixed, their individual properties were preserved.  Structurally the 
K48 linked Ub pair always adopted the classic K48 interface characteristic of the 
homogeneous chain, while the lone K63 linked Ub retained the extended 
conformation of the homogeneous K63 linkage.  After establishing that the native 
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structures were preserved in each mixed linkage chain, the binding properties of each 
linkage were also found to be preserved.  Linkage selective receptors UBA(2) and 
tUIM each recognized the K48 and K63 linkage, respectively in [Ub]2–48,63Ub.  
Individual K48 and K63 linkages were then shown to retain the same properties for 
linkage selective DUBs and antibodies.  After observing the same trend in each 
experiment, the conclusion that distinct K48 and K63 signals could be encoded in the 
same polyUb chain via linkage mixing was more than obvious.  The physiological 
significance of these chains remains to be seen, but nevertheless this establishes an 
important principle in linkage mixing.  
Determining the structure of the c112/Ub1 complex along with the other 
details regarding ubistatin/Ub interactions in the process provides for a complete 
understanding of how ubistatins function.  The concept of targeting Ub with small 
molecules is extremely important for therapeutic applications and the structural work 
presented here will help guide further development.  The data show that half (c112) 
and full (c59) ubistatins bind the same site of Ub, but with differences in 
stoichiometry and affinity.  Hydrophobic patch residues I44 and V70 and also nearby 
cationic residues R42 and R72 were shown to be essential for ubistatin/Ub 
interactions.  This supports that ubistatins employ both a hydrophobic and an 
electrostatic binding mechanism.  Titration data from ubistatin derivatives lacking 
sulfonate groups also supports these binding mechanisms.  The inability of Rub1, 
which contains the same L8,I44,V70 hydrophobic patch as Ub to bind c112 supports 
that the ubistatin binding site on Ub is a unique drug target.  Both half and full 
ubistatins are capable of binding either K48 or K63 linked polyUb chains with the 
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same binding mechanism, however the T1 data suggest that c59 forms different 
complexes with K48-Ub2 and K63-Ub2.  The ability of both c112 and c59 to inhibit 
the proteasomal DUB Ubp6 has implications for other DUBs as well and explains 
how ubistatins induce the accumulation of polyUb conjugates.    
The new Asp cleavage method for the analysis of K63 polyUb conjugates is a 
real breakthrough for Ub proteomics.  Aside from the novelty of measuring 
consecutive K63 linkages in unanchored or substrate attached polyUb chains, there 
are also broad implications for those studying Ub signaling with the traditional 
trypsin cleavage approach.  The Asp method provides a clear path for determining 
how the K63 polyUb signal is presented in the cell, specifically where it is attached 
and the sequence of linkages.  In addition, this method also provides a means for 
detection of mixed linkage polyUb chains, provided they contain a K63 linkage.                 
 
8.2 Outlook for future studies 
Continuing work on mixed linkage chains is absolutely essential for the field, 
however new projects must be carried out logically and either address abstract 
concepts I failed to address or delve further into in vivo systems where mixed 
linkages have been reported.  My study only addressed 2D branched chains and 
unbranched mixed linkage chains.  It is possible that in the cell polyUb chains are 
highly branched, where a single Ub is simultaneously ubiquitinated at more than three 
positions.  The greatest obstacle is deciding where to start and another major hurdle is 
the lack of methods available for the detection of mixed linkage chains.  Given that 
my work represents the first structural study in the field, I am confident that there will 
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be many more routes to travel.  It will be important to note the common trends as they 
are discovered, for example the observation that K48 linkages always retain their 
homogeneous characteristics.  For the communication of future findings on this 
subject, the Cohen-Nakasone-Fushman nomenclature system will limit much 
confusion and facilitate the clear transfer of ideas.  The study of mixed linkage chains 
should transition from an abstract idea to principles rooted in solid experimental data.  
The discovery of UBDs that preferentially bind mixed linkage chains would also go a 
long way in cementing their importance in the field.  At the same time, mixed linkage 
chains representing the structural conformations I described should also be searched 
for with in silico methods or synthesized and assessed experimentally.      
Given the importance of Ub signaling many more will attempt to target Ub 
with small molecules, whether they are ubistatin derivatives, gold nanoparticles, or of 
another design.  The structure representing the c112/Ub1 complex suggests that there 
is room to further derivatize c112 to better interact with the surface of Ub.  Ubistatins 
should be approached from multiple angles for development, but the structural data 
cannot be ignored.  With the structural knowledge, ubistatins can be modified with 
specialized chemistry to make them more favorable drugs without disrupting their 
activity.  This will allow ubistatins to overcome their inherent drawbacks such as 
membrane permeability and solubility.  Ub is the ideal drug target given its high 
conservation and inability to accommodate even subtle changes.  The choice of Ub as 
a drug target is wise in that there is absolutely no mechanism for disease to acquire 
resistance to ubistatins.  My failure to determine any structures for c59 in complex 
with Ub could very well be another researcher’s success and is a worthwhile venture.  
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Furthermore, although ubistatins bind the same surface of Ub, only monomeric Ub 
was investigated.  For chains longer than dimers it is possible that ubistatins could 
also form new complexes and the structures of ubistatins in complex with different 
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